EXHIBIT 10.1

 

CONFIDENTIAL TREATMENT

 

EPIX Medical, Inc. has requested that the marked portions of this document be
accorded confidential treatment pursuant to Rule 24b-2 under the Securities
Exchange Act of 1934.

 

Final Version

 

THROMBUS DEVELOPMENT AGREEMENT

 

between

 

EPIX MEDICAL, INC.

 

and

 

SCHERING AKTIENGESELLSCHAFT

 

--------------------------------------------------------------------------------

 

TABLE OF CONTENTS

 

ARTICLE 1:

DEFINITIONS

 

 

ARTICLE 2:

THE PROOF OF CONCEPT DEVELOPMENT PROGRAM

2.1.

General

2.2.

Conduct of the Proof of Concept Development Program

2.3.

Proof of Concept Plan

2.4.

Development Information

2.5.

Availability to Employees

 

 

ARTICLE 3:

PROOF OF CONCEPT DEVELOPMENT PROGRAM FUNDING

3.1.

Funding Commitment

 

 

ARTICLE 4:

LICENSE OPTION

4.1.

Schering’s Development Option

 

 

ARTICLE 5:

LICENSES

5.1.

License Grants

5.2.

Retained Rights

5.3.

Diligence

5.4.

Labeling and Packaging

5.5.

Reports and Forecasts

 

 

ARTICLE 6:

LICENSE PAYMENTS

6.1.

Schering License Terms

6.2.

EPIX License Terms

 

 

ARTICLE 7:

GENERAL PAYMENT TERMS

7.1.

Payment Dates and Reports

7.2.

Payments; Currency Conversion

7.3.

Records; Audit Rights; Disputes

7.4.

Withholding Taxes

 

 

ARTICLE 8:

INTELLECTUAL PROPERTY

8.1.

Inventorship

8.2.

Ownership

8.3.

Filing, Prosecution, Maintenance, Enforcement and Defense

 

 

ARTICLE 9:

CONFIDENTIALITY

9.1.

Nondisclosure Obligations

9.2.

Terms of this Agreement

9.3.

Publications

9.4.

Injunctive Relief

 

 

ARTICLE 10:

REPRESENTATIONS AND WARRANTIES

10.1.

Representations and Warranties

10.2.

Organization

 

ii

--------------------------------------------------------------------------------

 

 

10.3.

Authorization

 

10.4.

No Inconsistent Obligation

 

10.5.

Warranty Disclaimer

 

 

 

 

ARTICLE 11:

INDEMNITY

 

11.1.

Claim

 

11.2.

Schering Indemnity Obligations

 

11.3.

EPIX Indemnity Obligations

 

11.4.

Procedure

 

11.5.

Limited Liability

 

 

 

 

ARTICLE 12:

EXPIRATION AND TERMINATION

 

12.1.

Term

 

12.2.

Termination without Cause

 

12.3.

Termination for Material Breach

 

12.4.

Termination for Failure of Schering to use Due Diligence

 

12.5.

Effects Termination on Sublicenses

 

12.6.

Termination Upon Insolvency

 

12.7.

Rights in Bankruptcy

 

12.8.

Accrued Rights; Surviving Obligations

 

 

 

 

ARTICLE 13:

MISCELLANEOUS

 

13.1.

Force Majeure

 

13.2.

Assignment

 

13.3.

Severability

 

13.4.

Notices

 

13.5.

Applicable Law

 

13.6.

Dispute Resolution

 

13.7.

Public Announcements

 

13.8.

Entire Agreement; Amendment

 

13.9.

Headings

 

13.10.

Agreement Not to Solicit Employees

 

13.11.

Exports

 

13.11.

Waiver

 

13.12.

Counterparts

 

13.13.

Independent Contractors; Negation of Partnership

 

13.14.

Ambiguities

 

 

 

Exhibit 1.12

 

Structure of EP-2104R

Exhibit 1.14

 

EPIX Patent Rights

Exhibit 1.42

 

Schering Patent Rights

Exhibit 2.1

 

Deliverables

Exhibit 3.1

 

EPIX Budget Plan EP-2104R

 

iii

--------------------------------------------------------------------------------

 

THROMBUS DEVELOPMENT AGREEMENT

 

THIS THROMBUS DEVELOPMENT AGREEMENT dated as of May 26, 2003 (the “Agreement”)
is made by and between EPIX Medical, Inc., a Delaware corporation having its
principal place of business at 71 Rogers Street, Cambridge, Massachusetts
02142-1118 USA (“EPIX”), and Schering Aktiengesellschaft, a German corporation
having its principal place of business at 13342, Berlin, Germany (“Schering”).

 

RECITALS

 

WHEREAS, EPIX has expertise in and owns, or otherwise Controls, certain
technology for the development of enhancers for magnetic resonance imaging of
thrombi;

 

WHEREAS, Schering has expertise in and owns, or otherwise Controls, certain
technology for the development and commercialization of magnetic resonance
imaging and desires to fund EPIX’s next stage efforts to develop the Thrombus
Compound(s) and desires to obtain certain rights to an exclusive license to
pursue late stage development of the Thrombus Compound(s) and to develop and
sell Licensed Products worldwide in accordance with the terms and conditions of
this Agreement; and

 

WHEREAS, EPIX is willing to perform such development work and grant to Schering
such license rights upon the terms and conditions set forth below.

 

NOW THEREFORE, in consideration of the premises and of the covenants contained
herein, the Parties hereto mutually agree as follows:

 

ARTICLE 1:  DEFINITIONS

 

For purposes of this Agreement, the terms defined in this Article shall have the
meanings specified below:

 

1.1                                 “Adverse Event” shall mean any untoward
medical occurrence in a patient or subject who is administered a Licensed
Product, whether or not considered related to the Licensed Product, including,
without limitation, any undesirable sign (including abnormal laboratory findings
of clinical concern), symptom or disease temporally associated with the use of
such Licensed Product.

 

1.2                                 “Affiliate” shall mean any corporation or
other entity that directly or indirectly controls, is controlled by or is under
common control with a Party to this Agreement.  A corporation or other entity
shall be regarded as in control of another corporation or entity if it owns or
directly or indirectly controls more than fifty percent (50%) of the voting
stock or other ownership interest of the other corporation or entity, or if it
possesses, directly or indirectly, the power to direct or cause the direction of
the management and policies of the corporation or other entity or the power to
elect or appoint fifty percent (50%) or more of the members of the governing
body of the corporation or other entity.

 

1

--------------------------------------------------------------------------------

 

1.3                                 “Agreement Date” shall mean the date first
appearing on the first page of this Agreement

 

1.4                                 “Buy-up Option” shall have the meaning as
set forth in Section 6.1.4.

 

1.5                                 “Clinical Proof of Concept Study” shall mean
a Phase I or Phase II clinical trial based on a clinical trial protocol to be
reviewed by Schering with regard to safety and efficacy data to be gained, and
designated by the Parties prior to its commencement as a “Clinical Proof of
Concept Study.”

 

1.6                                 “Control” or “Controlled” means (a) with
respect to Technology (other than Proprietary Materials) and/or Patent Rights,
the possession by a Party of the ability to grant a license or sublicense of
such Technology and/or Patent Rights as provided herein without violating the
terms of any agreement or arrangement between such Party and any Third Party and
without having to pay additional amounts to such Third Party in connection with
such grant of rights and (b) with respect to Proprietary Materials, the
possession by a Party of the ability to supply such Proprietary Materials to the
other Party as provided herein without violating the terms of any agreement or
arrangement between such Party and any Third Party and without having to pay
additional amounts to such Third Party in connection with such supply.

 

1.7                                 “Cost” or “Costs” shall mean expenses
incurred by the Parties, determined in a reasonable manner in accordance with
GAAP in case of EPIX and IAS in case of Schering, and consistent with each
Party’s accounting practice.  The Parties recognize that financial records of
Schering are and shall continue to be maintained in accordance with IAS rather
than GAAP.  Schering agrees to use reasonable commercial efforts to identify for
EPIX material differences in the recognition of expenses under GAAP and IAS and,
in cases where there are material differences, to use the GAAP method of
recognition.  Schering shall not be required to produce financial reports in
accordance with GAAP if Schering does not keep such reports in accordance with
GAAP as part of its normal accounting and financial reporting practices.

 

1.8                                 “Cost of Goods Sold”  shall mean the cost
for manufacturing the Licensed Product, using Schering’s standard accounting
procedures computed in accordance with IAS applied on a consistent basis. Such
cost shall include, but not be limited to, the fully burdened cost of all raw
materials, auxiliaries and other ingredients, labor and overhead, depreciation,
maintenance and repair, destroyed material, production variance, imputed
interest on safety stocks and capacity cost for dedicated equipment, for the
synthesis, formulation, filling, finishing, labeling, packaging, storing,
testing and quality control, and assurance activities, and shall also include
reasonable expenses for services and transportation charges and any royalties
paid to Third Parties in connection with the manufacturing process or materials
used. “Cost of Goods” shall not include general and administrative expenses,
sales and marketing costs or costs associated with meeting the chemistry
manufacturing and control requirements of the FDA or other regulatory
authorities.

 

1.9                                 “Development Costs” shall mean all internal
(direct and indirect) and Third Party Costs incurred  by Schering in connection
with the development of Schering Licensed Product

 

2

--------------------------------------------------------------------------------

 

following the Exercise Date.  Such expenses include, but are not limited to (i)
direct labor (salaries, wages, incentive program Costs, awards and employee
benefits but excluding any employee benefits associated with equity incentive
plans); (ii) materials and supplies; (iii) allocated Costs for building space
directly dedicated to the  development of Schering Licensed Product (including
rent, depreciation, amortization and maintenance) but excluding expenses
relating to unused capacity, development of other products, and amortization of
property, plant and equipment not directly related to the development of
Schering Licensed Product; (iv) Third Party contracts and consulting expenses
incurred for services in connection with the development of Schering Licensed
Product; (v) allocated Costs for information technology directly dedicated to
the development of Schering Licensed Product; (vi) fees, expenses and
disbursements of outside counsel, and payments to Third Parties and internal
costs incurred in connection with the preparation, filing, prosecution and
maintenance of Schering Licensed Patent Rights including the costs of patent
interference and opposition proceedings (“Patent Costs”), and (vii) travel and
entertainment, telephone, recruiting, training (both internal and external),
product liability insurance (including, without limitation, clinical trial
insurance), software, personal computer equipment and support Costs and freight
and delivery expenses. Such Costs shall not include General and Administrative
Expenses or expenses incurred from departments that are not directly engaged in
the development of Schering Licensed Product including, but not limited to,
finance and procurement, corporate administration, human resources, business
development and licensing, sales and marketing except for Costs of investor
relations.

 

Development activities for which Development Costs are incurred include, but are
not limited to, pre-clinical and clinical work and all Costs of the product in
development related to regulatory filings in the Territory.

 

1.10                           “Development Option” shall have the meaning set
forth in Section 4.1 hereof.

 

1.11                           “Effective Date” shall mean March 1, 2003.

 

1.12                           “EP-2104R” shall mean EPIX’s proprietary MRI
enhancing agent having the chemical structure illustrated on Exhibit 1.12
attached hereto.

 

1.13                           “EPIX Licensed Product” shall have the meaning
set forth in Section 4.1.2 hereof.

 

1.14                           “EPIX Patent Rights” shall mean all Patent Rights
claiming EPIX Technology, including without limitation the Patent Rights listed
on Exhibit 1.14 attached hereto.

 

1.15                           “EPIX Royalty Term” shall mean the period
commencing on the date of the First Commercial Sale by EPIX, its Affiliates, or
its Sublicensees, of an EPIX Licensed Product and continuing until the date upon
which the total royalties paid to Schering on Net Sales made anywhere in the
Territory, pursuant to Sections 6.2.1 and 6.2.2 equals [*****] of the Schering
Payment paid by Schering to EPIX during the Proof of Concept Period.

 

3

--------------------------------------------------------------------------------

 

1.16                           “EPIX Technology” shall mean all Technology
necessary or useful in the Field that is (a) Controlled by EPIX immediately
prior to the Effective Date, or (b) developed or conceived by EPIX on or after
the Effective Date. .

 

1.17                           “Exercise Date” shall have the meaning set forth
in Section 4.1.1 hereof.

 

1.18                           “FDA” shall mean the United States Food and Drug
Administration and any successor agency thereto.

 

1.19                           “Field” shall mean thrombus imaging in animals or
humans using magnetic resonance.

 

1.20                           “First Commercial Sale” shall mean the date of
the first sale of a Licensed Product in the ordinary course of business in any
country by either Party, after all required marketing, pricing and reimbursement
approvals of the competent health authority of such country have been obtained
by the selling Party.

 

1.21                           “GAAP” shall mean United States Generally
Accepted Accounting Principles.

 

1.22                           “General and Administrative Expenses” shall mean
all direct and indirect Costs incurred by Schering or EPIX in connection with
departmental units that are not directly engaged in the Proof of Concept
Development Program of the Thrombus Compound(s).  General and Administrative
Expenses shall include, but not be limited to, charges falling within the
following, groups: finance, procurement, order entry, corporate administration,
legal (both external and internal expenses), human resources, business
development and licensing and investor relations.  General and Administrative
Expenses shall exclude the following groups of charges: clinical trial insurance
Costs, facilities and information technology.

 

1.23                           “IAS” shall mean the International Accounting
Standards.

 

1.24                           “IND” shall mean an investigational new drug
application filed with the FDA and necessary for beginning clinical trials in
humans, or any comparable application filed with the regulatory authorities of a
country other than the United States prior to beginning clinical trials in
humans in such country, with respect to Licensed Products.

 

1.25                           “Joint Patent Rights” shall mean all Patent
Rights that claim Joint Technology.

 

1.26                           “Joint Technology” shall mean all Technology or
tangible chemical, biological or physical material invented by employees or
agents of either Schering, EPIX or both in connection with the Proof of Concept
Development Program.

 

1.27                           “Licensed Product” shall mean an EPIX Licensed
Product and/or a Schering Licensed Product as the context indicates.

 

1.28                           “License Term” shall mean, with respect to each
Schering Licensed Product sold by Schering, its Affiliates, or its Sublicensees,
the period commencing with the First Commercial

4

--------------------------------------------------------------------------------

 

Sale of such Schering Licensed Product and continuing on a country-by-country,
and product-by-product basis until the later of (a) the expiration or
termination of the last Valid Claim covering the Schering Licensed Product, or
(b) twelve (12) years from the date of First Commercial Sale in such country.

 

1.29                           “MAA” shall mean a marketing approval application
filed with the appropriate regulatory authority in a country other that the
United States, after completion of human clinical trials to obtain marketing
approval for a Licensed Product in such country.

 

1.30                           “MRI” shall mean magnetic resonance imaging.

 

1.31                           “NDA” shall mean a new drug application (as
defined in Title 21 of the United States Code of Federal Regulations, as amended
from time to time) filed with the FDA seeking Regulatory Approval to market and
sell any Licensed Product in the United States for a particular indication
within the Field.

 

1.32                           “Net Sales” shall mean  the amount invoiced by
the selling Party, its Affiliates or Sublicensees for sales of a Licensed
Product to unaffiliated Third Parties less the following deductions applicable
to the Licensed Product for:

 

(II)                                  TRANSPORTATION CHARGES AND INSURANCE
CHARGES PAID BY THE SELLING PARTY;

 

(III)                               SALES AND EXCISE TAXES OR CUSTOMS DUTIES
PAID BY THE SELLING PARTY OR ANY OTHER GOVERNMENTAL CHARGES IMPOSED UPON THE
SALE OF THE LICENSED PRODUCT AND PAID BY THE SELLING PARTY EXCLUSIVE OF TAXES ON
THE INCOME OF THE SELLING PARTY;

 

(IV)                              FEES PAID TO DISTRIBUTORS, CONSIGNEES OR
AGENTS IN CONNECTION WITH THE SALE OF THE LICENSED PRODUCT;

 

(V)                                 REBATES AND PREMIUMS GRANTED IN CONNECTION
WITH THE SALE OF A LICENSED PRODUCT;

 

(VI)                              CREDITS TO CUSTOMERS ON ACCOUNT OF
GOVERNMENTAL REQUIREMENTS, PRICE DIFFERENCES, REJECTION, OUTDATING, RETURNS OR
RECALLS OF THE LICENSED PRODUCT;

 

(VII)                           QUANTITY DISCOUNTS, CASH DISCOUNTS OR
CHARGEBACKS GRANTED IN CONNECTION WITH THE SALE OF THE LICENSED PRODUCT;

 

(VIII)                        PROVISIONS FOR PRICE REDUCTIONS AND;

 

(IX)                                A SELLING PARTY’S STANDARD ALLOWANCE FOR BAD
DEBTS AS DEMONSTRATED TO THE OTHER PARTY’S REASONABLE SATISFACTION, AND IN NO
CASE IN EXCESS OF [*****]

 

For the purpose of calculating Net Sales, the Parties recognize that (a) the
selling Party’s customers may include persons in the chain of commerce who enter
into agreements with the

 

5

--------------------------------------------------------------------------------

 

selling Party as to price even though title to the Licensed Product does not
pass directly from the selling Party to such customers and even though payment
for such Licensed Product is not made by such customers directly to the selling
Party and (b) in such cases, chargebacks paid by the selling Party to or through
a Third Party (such as a wholesaler) can be deducted by the selling Party from
gross revenue in order to calculate Net Sales. Any deductions above, which
involve a payment by the selling Party, shall be taken as a deduction against
aggregate sales for the period in which the payment or deduction is made.

 

In the event a Licensed Product is sold in the form of a combination product
containing one or more active ingredients in addition to a Licensed Product, Net
Sales for such combination product will be adjusted by multiplying actual Net
Sales of such combination product by the fraction A / (A+B) where A is the
invoice price of the Licensed Product, if sold separately, and B is the invoice
price of any other active ingredient or ingredients in the combination, if sold
separately.  If, on a country-by-country basis, the other active ingredient or
ingredients in the combination are not sold separately in that country, Net
Sales shall be calculated by multiplying actual Net Sales of such combination
product by the fraction A / C where A is the invoice price of the Licensed
Product if sold separately, and C is the invoice price of the combination
product.  If, on a country by country basis, neither the Licensed Product nor
the other active component or components of the combination product is sold
separately in said country, Net Sales shall be determined between the Parties in
good faith.

 

1.33                           “Part or Parts of the Agreement” means either all
terms relating to the Proof of Concept Development Program or all terms relating
to a license granted or optioned under this Agreement, depending on which terms
are involved.

 

1.34                           “Party” shall mean EPIX or Schering.

 

1.35                           “Patent Rights” shall mean all rights and
interests in and to issued patents and pending patent applications, which for
purposes of this Agreement shall be deemed to include certificates of invention
and applications for certificates of invention and priority rights, in any
country, including all provisional applications, substitutions, continuations,
continuations-in-part, divisionals, and renewals, all letters patent granted
thereon, and all reissues, reexaminations and extensions thereof.

 

1.36                           “Proof of Concept Development Program” shall mean
the early development program up to the completion of the Clinical Proof of
Concept Study described generally in the Proof of Concept Plan.

 

1.37                           “Proof of Concept Period” shall mean the period
of time commencing on the start of a Proof of Concept Development Program for a
Thrombus Compound, and ending upon delivery to Schering by EPIX of the Final
Report for such Program pursuant to Section 4.1.1 hereof. The Proof of Concept
Period for EP-2104R shall commence on the Effective Date.

 

1.38                           “Proof of Concept Plan” shall have the meaning
set forth in Section 2.3 hereof.

 

6

--------------------------------------------------------------------------------

 

1.39                           “Proprietary Materials” means any tangible
chemical, biological or physical research materials that are furnished by or on
behalf of one Party to the other Party in connection with this Agreement,
regardless of whether such materials are specifically designated as proprietary
by the transferring Party.

 

1.40                           “Schering Licensed Product” shall have the
meaning set forth in Section 5.1.2 hereof.

 

1.41                           “Schering Option Product” shall have the meaning
set forth in Section 4.1.

 

1.42                           “Schering Patent Rights” shall mean all Patent
Rights claiming Schering Technology, including without limitation the Patent
Rights listed on Exhibit 1.42 attached hereto.

 

1.43                           “Schering Payment” shall have the meaning set
forth in Section 3.1 hereof.

 

1.44                           “Schering Technology” shall mean all Technology
necessary or useful in the Field that is (a) Controlled by Schering immediately
prior to the Effective Date, or (b) developed or conceived by Schering on or
after the Effective Date.

 

1.45                           “Sublicense Income” means all payments received
by EPIX from a sublicensee in connection with the grant of a sublicense under a
development and a commercial license of right under Section 12.4, including
without limitation, royalties, up-fronts, technology access fees, milestones and
fifty percent (50%) of the premium over fair market value paid to EPIX  in
connection with  the issuance of securities of EPIX where fair market value is
based on the number of securities issued multiplied by the average closing price
of the stock as quoted on NASDAQ, such average based on a twenty (20) business
day period, but excluding (a) payments made to support or fund research and
development activities and (c) payments made for other rights or tangible
property to the extent not in excess of the fair market value of such other
rights or tangible property.

 

1.46                           “Sublicensee” shall mean any Third Party to whom
either Schering or EPIX sublicenses all or some of the license rights grant to
it hereunder pursuant to the terms of Section 6.1.3 hereof.

 

1.47                           “Technology” shall mean and include all present
and future inventions, trade secrets, copyrights, know-how, data, regulatory
submissions and other intellectual property rights of any kind Controlled by a
Party, including Proprietary Materials.

 

1.48                           “Term” shall have the meaning set forth in
Section 12.1 hereof.

 

1.49                           “Territory” shall mean worldwide.

 

1.50                           “Third Party” shall mean any entity other than
EPIX or Schering or their respective Affiliates.

 

7

--------------------------------------------------------------------------------

 

1.51                           “Thrombus Compound(s)” shall have the meaning set
forth in Section 2.1 hereof.

 

1.52                           “Valid Claim” shall mean a claim of an issued
patent or a pending patent application within the Patent Rights that has not
expired or been cancelled, revoked or held invalid by a final decision of a
court or other authority having valid jurisdiction, from which no further appeal
can be taken or from which the time for appeal has expired.

 

ARTICLE 2:  THE PROOF OF CONCEPT DEVELOPMENT PROGRAM

 

2.1.                              GENERAL.  EPIX AND SCHERING WISH TO ESTABLISH
A COLLABORATIVE ALLIANCE TO DEVELOP SPECIFIC COMPOUND CANDIDATES IN THE FIELD
(THE “THROMBUS COMPOUND(S)”).  THE COLLABORATION WILL CONSIST OF A PROOF OF
CONCEPT DEVELOPMENT PROGRAM FOR THE THROMBUS COMPOUND(S) THE COMPLETION OF WHICH
WILL TRIGGER CERTAIN OPTIONS FOR BOTH PARTIES REGARDING FURTHER DEVELOPMENT AND
THE COMMERCIALIZATION OF SUCH THROMBUS COMPOUND(S).   THE INITIAL PROOF OF
CONCEPT DEVELOPMENT PROGRAM SHALL BE ESTABLISHED FOR THE THROMBUS COMPOUND
EP-2104R. FURTHER THROMBUS COMPOUND(S) SHALL ONLY BE DEVELOPED UPON AGREEMENT BY
THE PARTIES. THE COLLABORATION WILL CONSIST OF THE PROVISION OF DATA BY EPIX TO
SCHERING, WHICH ALLOW THE ASSESSMENT OF THE CLINICAL AND COMMERCIAL UTILITY OF
THE THROMBUS COMPOUND BY SCHERING. FOR THIS PURPOSE EPIX SHALL DESIGN, PERFORM
AND MANAGE A PROOF OF CONCEPT DEVELOPMENT PROGRAM FOR THE THROMBUS COMPOUND(S)
WITH THE GOAL TO PROVIDE SCHERING WITH THE DEFINED CLINICAL DATA IN VOLUNTEERS
AND PATIENTS AS DEFINED IN EXHIBIT 2.1 (HEREINAFTER “THE DELIVERABLES”).
GENERATED PRECLINICAL AND CHEMICAL DATA WILL BE DISCLOSED TO SCHERING AS WELL.
FOR THE SAKE OF CLARITY, THE PARTIES AGREE THAT THE WORK PERFORMED BY EPIX UNDER
THE PROOF OF CONCEPT PLAN IS NOT SUBJECT TO PRIOR CONSENT BY SCHERING, EXCEPT AS
EXPLICITLY PROVIDED IN THIS AGREEMENT.

 

2.2.                              CONDUCT OF THE PROOF OF CONCEPT DEVELOPMENT
PROGRAM.  THE PROOF OF CONCEPT DEVELOPMENT PROGRAM SHALL CONSIST GENERALLY OF
CHEMICAL AND PRE-CLINICAL DEVELOPMENT WORK NECESSARY TO SUPPORT THE PROPER
CONDUCT OF THE CLINICAL PROOF OF CONCEPT STUDY IN HEALTHY VOLUNTEERS AND
PATIENTS ACCORDING TO THE APPLICABLE INTERNATIONAL REGULATIONS AND QUALITY
STANDARDS (I.E. ICH GCP, GLP ETC.) AND THE APPLICABLE NATIONAL LAWS AND
REGULATIONS. THE GOAL OF THE PROOF OF CONCEPT DEVELOPMENT PROGRAM IS THE
PROVISION OF THE DELIVERABLES. SCHERING WILL BE INFORMED REGULARLY ON THE TIMELY
PROGRESS OF THE PROGRAM AND ON RELEVANT SAFETY AND EFFICACY INFLUENCING
FINDINGS.

 

2.3.                              PROOF OF CONCEPT PLAN.  EPIX IS RESPONSIBLE TO
DEVELOP A PLAN REASONABLY DESCRIBING THE WORK TO BE CONDUCTED BY EPIX RELATED TO
EP-2104R INCLUDING A CLINICAL TRIAL PROTOCOL (HEREINAFTER “PROOF OF CONCEPT
PLAN”) TO FULFILL THE OBJECTIVES OF THIS AGREEMENT. THE PROOF OF CONCEPT PLAN
SHALL BE MADE AVAILABLE TO SCHERING FOR INFORMATION. IT IS NOT SUBJECT TO
CONSENT BY SCHERING; PROVIDED, HOWEVER, THAT THE CLINICAL TRIAL PROTOCOL WHICH
IS PART OF THE PROOF OF CONCEPT PLAN SHALL BE SUBJECT TO REVIEW BY SCHERING WITH
REGARD TO SAFETY AND EFFICACY DATA TO BE GAINED TO ASSURE THAT THE OBJECTIVES OF
THIS AGREEMENT WITH REGARD TO THE DELIVERABLES CAN BE ACHIEVED.

 

8

--------------------------------------------------------------------------------

 

2.4.                              DEVELOPMENT INFORMATION.  IN THE COURSE OF ITS
PERFORMANCE OF THE PROOF OF CONCEPT DEVELOPMENT PROGRAM, EPIX SHALL KEEP
SCHERING REASONABLY INFORMED AS TO ITS PROGRESS UNDER EACH PROOF OF CONCEPT
PLAN.

 

2.5.                              AVAILABILITY TO EMPLOYEES.  SCHERING HEREBY
AGREES TO MAKE ITS EMPLOYEES AND NON-EMPLOYEE CONSULTANTS REASONABLY AVAILABLE,
AT NO COST TO EPIX, TO CONSULT WITH EPIX ON MATTERS RELATING TO THE DEVELOPMENT
OF THE THROMBUS COMPOUND(S), INCLUDING SCIENTIFIC AND TECHNICAL ISSUES ARISING
DURING THE PROOF OF CONCEPT DEVELOPMENT PROGRAM; PROVIDED, HOWEVER, THAT SUCH
ADVICE IS NOT BINDING TO EPIX AND DOES NOT AFFECT EPIX’ RESPONSIBILITIES UNDER
THIS AGREEMENT.

 

ARTICLE 3:  PROOF OF CONCEPT DEVELOPMENT PROGRAM FUNDING

 

3.1.                              FUNDING COMMITMENT.  IN CONSIDERATION OF THE
WORK PERFORMED BY EPIX UNDER THE PROOF OF CONCEPT PLAN, SCHERING SHALL PAY TO
EPIX  AN OVERALL AMOUNT OF US$ 8,972,707 (EIGHT MILLION NINE HUNDRED AND SEVENTY
TWO THOUSAND SEVEN HUNDRED AND SEVEN DOLLARS) CONSISTING OF US$ [*****] FOR THE
CLINICAL WORK AND US$ [*****] FOR THE CHEMICAL AND PRE-CLINICAL WORK
(HEREINAFTER “THE SCHERING PAYMENT”) BASED ON EPIX’ BUDGET PLAN ATTACHED HERETO
AS EXHIBIT 3.1. COSTS INCURRED BY EPIX IN THE COURSE OF ITS PERFORMANCE UNDER
THE PROOF OF CONCEPT PLAN, IN EXCESS OF THE SCHERING PAYMENT, WILL BE THE
RESPONSIBILITY OF EPIX. IN CASE THAT EPIX’ ACTUAL COSTS IN THE COURSE OF ITS
PERFORMANCE UNDER THE PROOF OF CONCEPT PLAN ARE LOWER THAN THE SCHERING PAYMENT,
EPIX HAS NO OBLIGATION TO PAY THE SCHERING PAYMENT BACK.

 

3.2.                              FUNDING PAYMENTS.  THE SCHERING PAYMENT SHALL
BE PAID TO EPIX AS FOLLOWS:

 

(A)                                  US$ [*****] SHALL BE PAID TO EPIX WITHIN
TEN (10) BUSINESS DAYS OF THE DATE APPEARING IN THE FIRST PARAGRAPH OF THIS
AGREEMENT; AND

 

(B)                                 US$ [*****] SHALL BE PAID TO EPIX IN SUCH
INSTALLMENTS AS INDICATED BELOW, NOT LESS THAN FIVE (5) BUSINESS DAYS PRIOR TO
THE START OF CALENDAR QUARTER INDICATED BELOW:

 

Calendar Quarter

 

Amount to be paid to EPIX (US$)

Third quarter of 2003

 

[*****]

Fourth quarter of 2003

 

[*****]

First quarter of 2004

 

[*****]

Second quarter of 2004

 

[*****]

Third quarter of 2004

 

[*****]

Fourth quarter of 2004

 

[*****]

First quarter of 2005

 

[*****]

 

9

--------------------------------------------------------------------------------

 

ARTICLE 4:  LICENSE OPTION

 

4.1.                              SCHERING’S DEVELOPMENT OPTION.  SUBJECT TO THE
TERMS AND CONDITIONS SET FORTH HEREIN, EPIX HEREBY GRANTS TO SCHERING THE
EXCLUSIVE RIGHT AND OPTION  (THE “DEVELOPMENT OPTION”) TO ACQUIRE A LICENSE AS
PROVIDED UNDER SECTION 5.1.2. HEREOF TO FURTHER DEVELOP AND COMMERCIALIZE
PRODUCTS BASED UPON, DERIVED FROM OR INCORPORATING A THROMBUS COMPOUND(S), AFTER
COMPLETION OF THE CLINICAL PROOF OF CONCEPT STUDY FOR SUCH THROMBUS COMPOUND(S)
(EACH A “SCHERING OPTION PRODUCT”).

 

4.1.1.                     COMMENCEMENT OF OPTION PERIOD AND EXERCISE.  UPON
COMPLETION OF THE CLINICAL PROOF OF CONCEPT STUDY, EPIX SHALL PREPARE, AND
DELIVER TO SCHERING, A FINAL STUDY REPORT CONTAINING THE DELIVERABLES IN ORDER
TO ENABLE SCHERING TO EVALUATE THE DATA FOR ITS OPTION PURPOSES (THE “FINAL
REPORT”).  SCHERING SHALL EXERCISE THE DEVELOPMENT OPTION, IF AT ALL, BY
DELIVERING TO EPIX WITHIN NINETY (90) DAYS OF DELIVERY BY EPIX OF THE FINAL
REPORT (THE “OPTION PERIOD”): (I) A WRITTEN NOTICE TO EPIX OF ITS DESIRE TO
EXERCISE THE DEVELOPMENT OPTION AND (II) PAYMENT OF THE UPFRONT LICENSE FEE
DESCRIBED IN SECTION 6.1.1 HEREOF (THE DATE UPON WHICH EPIX RECEIVES SUCH NOTICE
AND PAYMENT IS, THE “EXERCISE DATE”).

 

4.1.2.                     EPIX LICENSED PRODUCT.  IF SCHERING DECLINES OR FAILS
TO EXERCISE THE DEVELOPMENT OPTION ON OR BEFORE EXPIRATION OF THE OPTION PERIOD
(THE “EPIX LICENSE DATE”), THE DEVELOPMENT OPTION SHALL IMMEDIATELY TERMINATE
AND  EPIX SHALL HAVE THE SOLE RIGHT, BUT NOT THE OBLIGATION, UNDER THE LICENSE
GRANTED PURSUANT TO SECTION 5.1.1 HEREOF TO FURTHER DEVELOP AND COMMERCIALIZE
SUCH SCHERING OPTION PRODUCT (THEREAFTER, AN “EPIX LICENSED PRODUCT”). SUCH
RIGHT AND LICENSE OF EPIX SHALL SURVIVE TERMINATION OF THIS AGREEMENT BY (I)
SCHERING, PURSUANT TO SECTION 12.2 HEREOF AND (II) EPIX, PURSUANT TO SECTION
12.3 HEREOF.

 

ARTICLE 5:  LICENSES

 

5.1.                              LICENSE GRANTS.

 

5.1.1.                     EPIX LICENSE.  SCHERING HEREBY GRANTS TO EPIX (I) A
NON-EXCLUSIVE, FULLY PAID-UP, ROYALTY-FREE, WORLDWIDE LICENSE IN THE FIELD UNDER
THE SCHERING PATENT RIGHTS AND SCHERING TECHNOLOGY, AND SCHERING’S INTERESTS IN
THE JOINT PATENT RIGHTS AND JOINT TECHNOLOGY, FOR THE SOLE PURPOSE OF CONDUCTING
THE ACTIVITIES REQUIRED IN THE PERFORMANCE OF EPIX’S OBLIGATIONS UNDER THE PROOF
OF CONCEPT DEVELOPMENT PROGRAM, AND (II), SUBJECT TO SCHERING’S FAILURE TO
EXERCISE THE DEVELOPMENT OPTION AS SET FORTH IN SECTION 4.1 HEREOF OR IN THE
EVENT EPIX TERMINATES THIS AGREEMENT PURSUANT TO THE TERMS OF SECTION 12.3.2
HEREOF, A NON-EXCLUSIVE, WORLDWIDE LICENSE UNDER THE SCHERING PATENT RIGHTS AND
THE SCHERING TECHNOLOGY, TO THE EXTENT REQUIRED, AND AN EXCLUSIVE,
ROYALTY-BEARING LICENSE UNDER SCHERING’S INTERESTS IN THE JOINT PATENT RIGHTS
AND JOINT TECHNOLOGY, EACH WITH THE RIGHT TO GRANT SUBLICENSES SOLELY AS
PROVIDED UNDER SECTION 5.1.3 BELOW, TO PERMIT EPIX TO DEVELOP, HAVE DEVELOPED,
MAKE, HAVE MADE, USE, HAVE USED, SELL, OFFER FOR SALE, HAVE SOLD, IMPORT, AND
HAVE IMPORTED EPIX LICENSED PRODUCTS IN THE TERRITORY, FOR ANY AND ALL USES
WITHIN THE FIELD.

 

10

--------------------------------------------------------------------------------

 

5.1.2.                     SCHERING LICENSE.  EFFECTIVE AS OF THE EXERCISE DATE
AND SUBJECT TO THE TERMS AND CONDITIONS HEREIN, EPIX GRANTS TO SCHERING (I) A
NON-EXCLUSIVE WORLDWIDE LICENSE UNDER THE EPIX PATENT RIGHTS AND EPIX
TECHNOLOGY, TO THE EXTENT REQUIRED, AND (II) AN EXCLUSIVE, WORLDWIDE,
ROYALTY-BEARING LICENSE UNDER EPIX’S INTERESTS IN THE JOINT PATENT RIGHTS AND
JOINT TECHNOLOGY, EACH WITH THE RIGHT TO GRANT SUBLICENSES SOLELY AS PROVIDED
UNDER SECTION 5.1.3 BELOW, TO PERMIT SCHERING, TO DEVELOP, HAVE DEVELOPED, TO
MAKE, HAVE MADE, USE, HAVE USED, SELL, OFFER FOR SALE, HAVE SOLD, IMPORT, AND
HAVE IMPORTED SCHERING OPTION PRODUCTS (EACH, THEREAFTER, A “SCHERING LICENSED
PRODUCT”) IN THE TERRITORY DURING THE LICENSE TERM, FOR ANY AND ALL USES WITHIN
THE FIELD.

 

5.1.3.                     SUBLICENSING.  EACH PARTY SHALL HAVE THE RIGHT TO
EXTEND THE RIGHTS AND LICENSES GRANTED TO IT UNDER SECTION 5.1.1 OR
SECTION 5.1.2, AS APPLICABLE, TO ITS AFFILIATES AND THIRD PARTIES; PROVIDED,
THAT, IT SHALL BE A CONDITION OF ANY SUCH EXTENSION OR SUBLICENSE THAT THE
SUBLICENSEES AGREE TO BE BOUND BY ALL OF THE APPLICABLE TERMS AND CONDITIONS OF
THIS AGREEMENT.  EACH PARTY GRANTING SUCH RIGHTS SHALL PROVIDE COPIES (REDACTED
AS TO THE FINANCIAL TERMS) TO THE OTHER PARTY OF EACH EXTENSION OR SUBLICENSE TO
BE GRANTED TO ANY AFFILIATE OR THIRD PARTIES UNDER THIS SECTION WITHIN TEN (10)
BUSINESS DAYS AFTER SUCH EXECUTION.

 

5.2.                              RETAINED RIGHTS.  EACH PARTY RESERVES THE
RIGHT TO PRACTICE ALL TECHNOLOGY AND ALL PATENT RIGHTS THAT IT CONTROLS TO THE
EXTENT NOT EXPRESSLY SUBJECT TO A RIGHT, LICENSE OR OPTION HEREUNDER.  NO RIGHTS
ARE GRANTED HEREUNDER BY IMPLICATION OR ESTOPPEL.

 

5.3.                              DILIGENCE.  SCHERING WILL EXERCISE
COMMERCIALLY REASONABLE, CONTINUOUS EFFORTS AND DILIGENCE IN DEVELOPING AND
COMMERCIALIZING SCHERING LICENSED PRODUCTS AND IN UNDERTAKING INVESTIGATIONS AND
ACTIONS REQUIRED TO OBTAIN REGULATORY APPROVALS NECESSARY TO MARKET SCHERING
LICENSED PRODUCTS IN THE FIELD IN THE TERRITORY, SUCH DILIGENCE TO BE NO LESS
THAN THE EFFORTS AND RESOURCES SCHERING WOULD USE FOR A PRODUCT CANDIDATE OWNED
BY IT OR TO WHICH IT HAS RIGHTS, WHICH IS OF SIMILAR MARKET POTENTIAL AS THE
APPLICABLE SCHERING LICENSED PRODUCT.  FAILURE OF SCHERING TO COMPLY WITH THE
TERMS OF THIS SECTION 5.3 SHALL CONSTITUTE A DEFAULT UNDER SECTION 12.3 HEREOF
AND SHALL BE SUBJECT TO THE TERMS OF SECTION 12.3.2 HEREOF.

 

5.4.                              LABELING AND PACKAGING.   IF EPIX HAS
EXERCISED ITS BUY-UP OPTION PURSUANT TO THE TERMS OF SECTION 6.1.4 HEREOF TO THE
MAXIMUM PERCENTAGE PROVIDED THEREUNDER FOR A SCHERING LICENSED PRODUCT, THE
LABELING AND PACKAGING FOR SUCH SCHERING LICENSED PRODUCTS SHALL BEAR EPIX’S
NAME AND LOGO, IN A FORM TO BE MUTUALLY AGREED UPON BY THE PARTIES, IN ADDITION
TO SCHERING’S NAME, TRADEMARK (TO BE SELECTED BY SCHERING IN ITS SOLE
DISCRETION), AND TRADE DRESS AND SUBJECT TO APPLICABLE LAWS AND REGULATIONS.

 

5.5.                              REPORTS AND FORECASTS.

 

5.5.1.  REPORTS.  COMMENCING ON THE DATE THAT IS THREE MONTHS FOLLOWING THE
EXERCISE DATE SCHERING SHALL PROVIDE EPIX, NO LESS FREQUENTLY THAN ANNUALLY,
WITH BRIEF WRITTEN REPORTS SUMMARIZING SCHERING’S EFFORTS TO DEVELOP AND
COMMERCIALIZE SCHERING LICENSED PRODUCTS HEREUNDER.

 

11

--------------------------------------------------------------------------------

 

5.5.2.                     NOTIFICATION OF EVENTS.  IN ADDITION, SCHERING SHALL
PROVIDE EPIX WITH PROMPT WRITTEN NOTICE OF THE OCCURRENCE OF THE FIRST
COMMERCIAL SALE OF ANY SCHERING LICENSED PRODUCT IN ANY COUNTRY AND AGREES TO
PROVIDE EPIX WITH ADVERSE EVENT INFORMATION AND PRODUCT COMPLAINT INFORMATION
RELATING TO SCHERING LICENSED PRODUCTS AS COMPILED AND PREPARED BY SCHERING IN
THE NORMAL COURSE OF BUSINESS IN CONNECTION WITH THE DEVELOPMENT,
COMMERCIALIZATION OR SALE OF ANY SCHERING LICENSED PRODUCT, WITHIN TIME FRAMES
CONSISTENT WITH REPORTING OBLIGATIONS UNDER APPLICABLE LAWS AND REGULATIONS. 
ALL REPORTS, UPDATES, ADVERSE EVENT, PRODUCT COMPLAINT, FORECASTS AND OTHER
INFORMATION PROVIDED BY ONE PARTY TO THE OTHER PARTY UNDER THIS AGREEMENT
(INCLUDING UNDER THIS SECTION 5.4), SHALL BE CONSIDERED CONFIDENTIAL INFORMATION
OF THE DISCLOSING PARTY, SUBJECT TO THE TERMS OF ARTICLE 9.

 

ARTICLE 6:  LICENSE PAYMENTS

 

6.1.                              SCHERING LICENSE TERMS.

 

6.1.1.                     UP-FRONT LICENSING FEE.  IN CONSIDERATION OF THE
GRANT OF THE LICENSE TO SCHERING BY EPIX AS DESCRIBED IN SECTION 5.1.2. HEREOF,
UPON THE EXERCISE DATE, SCHERING SHALL PAY TO EPIX AN UPFRONT LICENSE FEE (THE
“UPFRONT LICENSE FEE”) EQUAL TO THE SUM OF [*****] ($[*****]) U.S. DOLLARS. THE
UPFRONT LICENSE FEE SHALL BE NONREFUNDABLE AND NONCREDITABLE.

 

6.1.2.                     MILESTONE PAYMENTS.  IN FURTHER CONSIDERATION OF THE
GRANT OF THE LICENSE TO SCHERING BY EPIX AS DESCRIBED IN SECTION 5.1.2 AND
SUBJECT TO THE OTHER TERMS AND CONDITIONS OF THIS AGREEMENT, SCHERING SHALL MAKE
THE FOLLOWING NONREFUNDABLE, NONCREDITABLE PAYMENTS IN UNITED STATES DOLLARS TO
EPIX WITHIN THIRTY (30) DAYS OF THE FIRST OCCURRENCE OF EACH OF THE FOLLOWING
EVENTS BY SCHERING, ITS AFFILIATES OR SUBLICENSEES:

 

Milestone

 

Payment

 

 

 

[*****]

 

$

[*****]

[*****]

 

$

[*****]

[*****]

 

$

[*****]

 

It is hereby acknowledged and agreed that any milestone payment shall be made
only once, with respect to the first achievement of the relevant milestone for
the first Schering Licensed Product, regardless of how many times such
milestones are achieved by Schering Licensed Products and regardless of how many
times a particular Schering Licensed Product achieves such milestones.

 

6.1.3.                     ROYALTIES.  IN FURTHER CONSIDERATION OF THE GRANT OF
THE LICENSE TO SCHERING BY EPIX AS DESCRIBED IN SECTION 5.1.2. HEREOF, SUBJECT
TO REDUCTION AS SET FORTH IN SECTION 6.1.6 BELOW SCHERING SHALL PAY EPIX A
ROYALTY BASED ON TOTAL ANNUAL NET SALES OF EACH SCHERING

 

12

--------------------------------------------------------------------------------

 

Licensed Product sold by Schering, its Affiliates and Sublicensees during the
License Term, at the following rates:

 

For Annual Net Sales of a Schering Licensed Product:

 

Royalty Rate (%)

 

 

 

Above $[*****]and up to $[*****]

 

[*****]

Above $[*****]

 

[*****]

 

6.1.4.                     BUY-UP OPTION FOR EPIX.  IN ADDITION TO THE ROYALTIES
TO BE PAID UNDER SECTION 6.1.3 ABOVE EPIX SHALL HAVE THE OPTION (THE “BUY-UP
OPTION”) OF INCREASING SUCH ROYALTY RATES PAYABLE WITH RESPECT TO EACH SCHERING
LICENSED PRODUCT BY REIMBURSING SCHERING FOR A PERCENTAGE OF ALL DEVELOPMENT
COSTS INCURRED BY SCHERING SINCE THE EXERCISE DATE AS FOLLOWS.  FOR EVERY
[*****] OF THE TOTAL DEVELOPMENT COSTS INCURRED BY SCHERING FOLLOWING THE
EXERCISE DATE FOR A PARTICULAR SCHERING OPTION PRODUCT THAT EPIX REIMBURSES
SCHERING FOR, THE ROYALTY RATE OTHERWISE PAYABLE UNDER THE TABLE ABOVE WILL BE
INCREASED BY [*****].  THIS OPTION IS LIMITED SUCH THAT EPIX CANNOT REIMBURSE
SCHERING FOR MORE THAN [*****] [*****] OF SUCH DEVELOPMENT COSTS INCURRED BY
SCHERING FOR ANY SCHERING LICENSED PRODUCT AND SO THE MAXIMUM ROYALTY RATES
PAYABLE FOR ANY SCHERING LICENSED PRODUCT ARE [*****] [*****]; PROVIDED,
HOWEVER, IF THE AGGREGATE COST OF GOODS SOLD AND ANY ROYALTIES PAYABLE HEREUNDER
AND TO THIRD PARTIES ([*****]) FOR ANY SCHERING LICENSED PRODUCT IS [*****] THAN
[*****] OF THE [*****] OF [*****], THEN [*****] THIS [*****] HEREUNDER.  EPIX
MUST EXERCISE THIS OPTION WITH RESPECT TO A SCHERING LICENSED PRODUCT BY
PROVIDING WRITTEN NOTICE TO SCHERING WITHIN [*****] OF THE EXERCISE DATE.

 

6.1.5.                     PAYMENTS OF EPIX UNDER BUY-UP OPTION.  WITHIN TEN
(10) BUSINESS DAYS FROM THE END OF THE CALENDAR QUARTER IN WHICH EPIX HAS
EXERCISED ITS BUY-UP OPTION AND ON A QUARTERLY BASIS THEREAFTER, EPIX SHALL PAY
ITS SHARE OF THE DEVELOPMENT COSTS INCURRED BY SCHERING DURING THE RELEVANT
CALENDAR QUARTER EXCEPT THAT THE FIRST SUCH PAYMENT SHALL INCLUDE REIMBURSEMENT
BASED ON TOTAL DEVELOPMENT COSTS INCURRED BY SCHERING FROM THE DATE IT EXERCISED
THE SCHERING OPTION. THE DEVELOPMENT COSTS INCURRED BY SCHERING DURING EACH
CALENDAR QUARTER SHALL BE CONVERTED FROM EURO INTO UNITED STATES DOLLARS BY THE
EURO FOREIGN EXCHANGE REFERENCE RATE PUBLISHED BY THE EUROPEAN CENTRAL BANK IN
FRANKFURT/MAIN ON THE LAST DAY OF THE APPLICABLE CALENDAR QUARTER. THE
CORRESPONDING CALCULATION WILL BE PROVIDED BY SCHERING TO EPIX WITHIN FIFTEEN15
BUSINESS DAYS FROM THE END OF THE RESPECTIVE CALENDAR QUARTER.

 

6.1.6.                     ROYALTY REDUCTION.  THE PARTIES HEREBY ACKNOWLEDGE
THAT ROYALTIES MAY BE PAYABLE HEREUNDER FOR A SCHERING LICENSED PRODUCT THAT IS
NOT COVERED BY ANY CLAIM IN PATENT RIGHTS SUBJECT TO A LICENSE GRANTED
HEREUNDER.  UNDER SUCH CIRCUMSTANCES, ROYALTIES SHALL BE PAYABLE AS SET FORTH
HEREIN, BUT AT A REDUCED RATE EQUAL TO FIFTY PERCENT (50%) OF THE ROYALTY RATE
WHICH WOULD OTHERWISE BE PAYABLE HEREUNDER, IF THE MANUFACTURE, USE, SALE OR
IMPORTATION OF SUCH SCHERING LICENSED PRODUCT WERE COVERED BY A CLAIM IN PATENT
RIGHTS SUBJECT TO A LICENSE GRANTED HEREUNDER.  SUCH REDUCED ROYALTIES SHALL BE
IN CONSIDERATION OF: (I) THE COMMERCIAL ADVANTAGE AND BACKGROUND INFORMATION
GAINED FROM THE PROOF OF CONCEPT DEVELOPMENT PROGRAM,

 

13

--------------------------------------------------------------------------------

 

(II) THE CONTRIBUTION OF THE UNPATENTED TECHNOLOGY TO THE SUCCESSFUL DEVELOPMENT
OF THE SCHERING LICENSED PRODUCT AND (III) THE EXCLUSIVITY OF THE COLLABORATION.

 

6.2.                              EPIX LICENSE TERMS.

 

6.2.1.                     ROYALTIES.  IN CONSIDERATION OF THE GRANT OF THE
LICENSES TO EPIX BY SCHERING AS DESCRIBED IN SECTION 5.1.1(II) HEREOF, SUBJECT
TO REDUCTION AS SET FORTH IN SECTION 6.2.3 BELOW, EPIX SHALL PAY SCHERING A
ROYALTY EQUAL TO [*****] PERCENT OF NET SALES OF EACH EPIX LICENSED PRODUCT SOLD
BY EPIX AND/OR ITS AFFILIATES AND/OR SUBLICENSEES DURING THE EPIX ROYALTY TERM.
UPON EXPIRATION OF THE EPIX ROYALTY TERM, EPIX SHALL HAVE A FULLY PAID-UP,
NON-EXCLUSIVE, IRREVOCABLE, FREELY TRANSFERABLE AND SUBLICENSABLE LICENSE IN THE
TERRITORY UNDER THE SCHERING PATENT RIGHTS, SCHERING TECHNOLOGY, AND JOINT
PATENT RIGHTS AND JOINT TECHNOLOGY TO DEVELOP, HAVE DEVELOPED, MAKE, HAVE MADE,
USE, HAVE USED, SELL, HAVE SOLD, OFFER FOR SALE, IMPORT AND HAVE IMPORTED EPIX
LICENSED PRODUCTS IN THE TERRITORY.

 

6.2.2.                     ROYALTY REDUCTION.  THE PARTIES HEREBY ACKNOWLEDGE
THAT ROYALTIES MAY BE PAYABLE HEREUNDER FOR AN EPIX LICENSED PRODUCT THAT IS NOT
COVERED BY ANY CLAIM IN PATENT RIGHTS SUBJECT TO A LICENSE GRANTED HEREUNDER. 
UNDER SUCH CIRCUMSTANCES, ROYALTIES SHALL BE PAYABLE AS SET FORTH HEREIN, BUT AT
A REDUCED RATE EQUAL TO FIFTY PERCENT (50%) OF THE ROYALTY RATE WHICH WOULD
OTHERWISE BE PAYABLE HEREUNDER, IF THE MANUFACTURE, USE, SALE OR IMPORTATION OF
SUCH EPIX LICENSED PRODUCT WERE COVERED BY A CLAIM IN PATENT RIGHTS SUBJECT TO A
LICENSE GRANTED HEREUNDER.  SUCH REDUCED ROYALTY PAYMENTS SHALL BE IN
CONSIDERATION OF: (I) THE COMMERCIAL ADVANTAGE AND BACKGROUND INFORMATION GAINED
FROM THE PROOF OF CONCEPT DEVELOPMENT PROGRAM, (II) THE CONTRIBUTION OF THE
UNPATENTED TECHNOLOGY TO THE SUCCESSFUL DEVELOPMENT OF THE EPIX LICENSED PRODUCT
AND (III) THE EXCLUSIVITY OF THE COLLABORATION.

 

ARTICLE 7:  GENERAL PAYMENT TERMS

 

7.1.                              PAYMENT DATES AND REPORTS.  ALL ROYALTY
PAYMENTS ON NET SALES SHALL BE PAID WITHIN SIXTY (60) DAYS AFTER THE END OF EACH
CALENDAR QUARTER IN WHICH SUCH NET SALES ARE MADE AND SHALL BE ACCOMPANIED BY A
REPORT FOR THE APPLICABLE CALENDAR QUARTER SHOWING THE NET SALES OF EACH
LICENSED PRODUCT SOLD, IN EACH COUNTRY, THE APPLICABLE ROYALTY RATE FOR SUCH
LICENSED PRODUCT, AND A CALCULATION OF THE AMOUNT OF ROYALTY DUE.

 

7.2.                              PAYMENTS; CURRENCY CONVERSION.

 

7.2.1.                     PAYMENTS.  PAYMENTS BY EITHER PARTY TO THE OTHER
PARTY UNDER THIS AGREEMENT SHALL BE MADE IN UNITED STATES DOLLARS BY WIRE
TRANSFER OF IMMEDIATELY AVAILABLE FUNDS TO AN ACCOUNT AT A COMMERCIAL BANK
DESIGNATED BY THE RECEIVING PARTY AT LEAST TEN (10) BUSINESS DAYS BEFORE SUCH
PAYMENT IS DUE.

 

7.2.2.                     ROYALTY PAYMENTS WITHIN SCHERING.  THE CALCULATION OF
ROYALTY PAYMENTS WITHIN SCHERING IS BASED ON EURO. THEREFORE, WHERE PAYMENTS ARE
BASED ON NET SALES IN COUNTRIES OTHER THAN THE MEMBER STATES OF THE EUROPEAN
MONETARY UNION, THE AMOUNT OF SUCH NET SALES EXPRESSED IN THE CURRENCY OF EACH
COUNTRY SHALL BE CONVERTED INTO EURO AT THE EURO

 

14

--------------------------------------------------------------------------------

 

FOREIGN EXCHANGE REFERENCE RATES PUBLISHED BY THE EUROPEAN CENTRAL BANK IN
FRANKFURT / MAIN, GERMANY ON THE LAST BUSINESS DAY OF THE APPLICABLE CALENDAR
QUARTER. THE RESULTING EURO AMOUNT WILL BE CONVERTED INTO UNITED STATES DOLLARS
AGAIN AT THE EURO FOREIGN EXCHANGE REFERENCE RATES PUBLISHED BY THE EUROPEAN
CENTRAL BANK IN FRANKFURT / MAIN, GERMANY ON THE LAST BUSINESS DAY OF THE
APPLICABLE CALENDAR QUARTER. THESE EURO FOREIGN EXCHANGE REFERENCE RATES ARE, AS
OF THE EFFECTIVE DATE, PUBLISHED ON REUTERS SCREEN <ECB37>. IF NO EURO FOREIGN
EXCHANGE REFERENCE RATE IS DETERMINED FOR THE RELEVANT CURRENCY THE PARTIES
SHALL AGREE UPON ANOTHER REFERENCE RATE.

 

7.2.3.                     ROYALTY PAYMENTS WITHIN EPIX.  THE CALCULATION OF
ROYALTY PAYMENTS WITHIN EPIX IS BASED ON UNITED STATES DOLLARS. THEREFORE, WHERE
PAYMENTS ARE BASED ON NET SALES IN COUNTRIES OTHER THAN THE UNITED STATES, THE
AMOUNT OF SUCH NET SALES EXPRESSED IN THE CURRENCY OF EACH COUNTRY SHALL BE
CONVERTED INTO UNITED STATES DOLLARS AT THE EURO FOREIGN EXCHANGE REFERENCE
RATES PUBLISHED BY THE EUROPEAN CENTRAL BANK IN FRANKFURT / MAIN, GERMANY ON THE
LAST BUSINESS DAY OF THE APPLICABLE CALENDAR QUARTER. IF NO EURO FOREIGN
EXCHANGE REFERENCE RATE IS DETERMINED FOR THE RELEVANT CURRENCY THE PARTIES
SHALL AGREE UPON ANOTHER REFERENCE RATE.

 

7.3.                              RECORDS; AUDIT RIGHTS; DISPUTES.

 

7.3.1.                     RECORDS OF REVENUES AND EXPENSES; AUDIT RIGHTS.  EACH
PARTY WILL MAINTAIN COMPLETE AND ACCURATE RECORDS WHICH ARE RELEVANT TO THE
DETERMINATION OF DEVELOPMENT COSTS, MILESTONE PAYMENTS AND ROYALTY PAYMENTS
UNDER THIS AGREEMENT AND SUCH RECORDS SHALL BE OPEN DURING REASONABLE BUSINESS
HOURS FOR A PERIOD OF TWO (2) YEARS FROM CREATION OF INDIVIDUAL RECORDS FOR
EXAMINATION AT THE OTHER PARTY’S EXPENSE AND NOT MORE OFTEN THAN ONCE EACH
CALENDAR YEAR BY A CERTIFIED PUBLIC ACCOUNTANT SELECTED BY THE OTHER PARTY
(SUBJECT TO THE CONSENT OF THE PARTY TO BE AUDITED, SUCH CONSENT NOT TO BE
UNREASONABLY WITHHELD OR DELAYED), OR THE OTHER PARTY’S INTERNAL ACCOUNTANTS
(UNLESS THE PARTY TO BE AUDITED OBJECTS TO THE USE OF SUCH INTERNAL ACCOUNTANTS)
FOR THE SOLE PURPOSE OF VERIFYING FOR THE INSPECTING PARTY THE CORRECTNESS OF
CALCULATIONS AND CLASSIFICATIONS OF SUCH DEVELOPMENT COSTS, MILESTONE PAYMENTS
AND ROYALTY PAYMENTS UNDER THIS AGREEMENT. EACH PARTY SHALL BEAR ITS OWN COSTS
RELATED TO SUCH AUDIT; PROVIDED, THAT, FOR ANY UNDERPAYMENTS GREATER THAN
[*****] OF ANNUAL DEVELOPMENT COSTS, MILESTONE PAYMENTS AND/OR ROYALTY PAYMENTS
BY THE AUDITED PARTY, THE AUDITED PARTY SHALL PAY THE OTHER PARTY THE AMOUNT OF
UNDERPAYMENT, TOGETHER WITH INTEREST AS PROVIDED IN SECTION 7.3.3 BELOW, FROM
THE TIME THE AMOUNT WAS DUE AND THE INSPECTING PARTY’S OUT-OF-POCKET EXPENSES
RELATED TO THE AUDIT.  FOR ANY UNDERPAYMENTS LESS THAN [*****] OF ANNUAL
DEVELOPMENT COSTS AND/OR ROYALTY PAYMENTS (AS THE CASE MAY BE), FOUND UNDER THIS
SECTION, THE AUDITED PARTY SHALL PAY THE INSPECTING PARTY THE AMOUNT OF THE
UNDERPAYMENT.  ANY OVERPAYMENTS BY THE AUDITED PARTY WILL BE REFUNDED TO THE
AUDITED PARTY OR CREDITED TO FUTURE PAYMENTS BY THE AUDITED PARTY TO THE
INSPECTING PARTY, AT THE AUDITED PARTY’S ELECTION.  ANY RECORDS OR ACCOUNTING
INFORMATION RECEIVED FROM THE AUDITED PARTY SHALL BE INFORMATION OF THE AUDITED
PARTY FOR PURPOSES OF ARTICLE 9.  RESULTS OF ANY SUCH AUDIT SHALL BE PROVIDED TO
BOTH PARTIES, AND SHALL BE INFORMATION OF THE AUDITED PARTY FOR PURPOSES OF
ARTICLE 9.

 

15

--------------------------------------------------------------------------------

 

7.3.2.                     RESOLUTIONS OF PAYMENT DISPUTES.  EXCEPT AS SET FORTH
IN THIS SECTION, THE PROVISIONS OF SECTION 13.6 SHALL NOT BE APPLICABLE TO
DISPUTES DESCRIBED IN THIS SECTION.  IF THERE IS A DISPUTE BETWEEN THE PARTIES
FOLLOWING ANY AUDIT PERFORMED PURSUANT TO THIS SECTION 7.3 (AN “AUDIT
DISAGREEMENT”) (I) WITHIN THIRTY (30) BUSINESS DAYS OF THE IDENTIFICATION OF AN
AUDIT DISPUTE AND NOTICE THEREOF TO THE OTHER PARTY, THE PARTIES SHALL JOINTLY
SELECT A RECOGNIZED INTERNATIONAL ACCOUNTING FIRM TO ACT AS AN INDEPENDENT
EXPERT TO RESOLVE SUCH AUDIT DISAGREEMENT; (II) THE AUDIT DISAGREEMENT SUBMITTED
FOR RESOLUTION SHALL BE DESCRIBED BY THE PARTIES TO THE INDEPENDENT EXPERT,
WHICH DESCRIPTION MAY BE IN WRITTEN OR ORAL FORM, WITHIN TEN (10) BUSINESS DAYS
OF THE SELECTION OF SUCH INDEPENDENT EXPERT; (III) THE INDEPENDENT EXPERT SHALL
RENDER A DECISION ON THE MATTER AS SOON AS PRACTICABLE; (IV) THE DECISION OF THE
INDEPENDENT EXPERT SHALL BE FINAL AND BINDING UNLESS SUCH AUDIT DISAGREEMENT
INVOLVES ALLEGED FRAUD, BREACH OF THIS AGREEMENT OR CONSTRUCTION OR
INTERPRETATION OF ANY OF THE TERMS AND CONDITIONS THEREOF, WHICH AUDIT
DISAGREEMENTS SHALL BE RESOLVED AS SET FORTH IN SECTION 13.6; AND (V) ALL FEES
AND EXPENSES OF THE INDEPENDENT EXPERT, INCLUDING ANY THIRD PARTY SUPPORT STAFF
OR OTHER COSTS INCURRED WITH RESPECT TO CARRYING OUT THE PROCEDURES SPECIFIED AT
THE DIRECTION OF THE INDEPENDENT EXPERT IN CONNECTION WITH SUCH AUDIT
DISAGREEMENT, SHALL BE BORNE BY EACH PARTY IN INVERSE PROPORTION TO THE DISPUTED
AMOUNTS AWARDED TO SUCH PARTY BY THE INDEPENDENT EXPERT THROUGH SUCH DECISION
(E.G., EPIX DISPUTES $100; THE INDEPENDENT EXPERT AWARDS EPIX $60; EPIX PAYS FOR
FORTY PERCENT (40%) OF THE INDEPENDENT EXPERT’S COSTS, AND SCHERING PAYS FOR
SIXTY PERCENT (60%) OF THE INDEPENDENT EXPERT’S COSTS.)

 

7.3.3.                     PAYMENTS; INTEREST.  ANY PAYMENTS DUE UNDER THIS
AGREEMENT SHALL BE DUE ON SUCH DATE AS SPECIFIED IN THE AGREEMENT AND, IN THE
EVENT SUCH DATE IS NOT A BUSINESS DAY, THEN THE NEXT SUCCEEDING BUSINESS DAY. 
ANY FAILURE BY A PARTY TO MAKE A PAYMENT WITHIN TEN (10) DAYS AFTER THE DATE
WHEN DUE SHALL OBLIGATE SUCH PARTY TO PAY COMPUTED INTEREST, THE INTEREST PERIOD
COMMENCING ON THE DUE DATE AND ENDING ON THE PAYMENT DAY, TO THE RECEIVING PARTY
AT A RATE PER ANNUM [*****].  THE INTEREST SHALL BE COMPUTED ON THE BASIS OF A
365/360 YEAR; INTEREST SHALL BE COMPOUNDED ANNUALLY IN ARREARS.  SUCH INTEREST
SHALL BE DUE AND PAYABLE ON THE TENDER OF THE UNDERLYING PRINCIPLE PAYMENT.

 

7.3.4.                     FINANCIAL PROCEDURES.  EACH PARTY SHALL INCLUDE IN
ANY AGREEMENT WITH ITS AFFILIATES OR SUBLICENSEES TERMS REQUIRING SUCH PARTY TO
RETAIN RECORDS AS REQUIRED IN THIS SECTION 8.3 AND TO PERMIT THE SUCH PARTY TO
INSPECT SUCH RECORDS AS REQUIRED BY THIS SECTION 7.3.

 

7.4.                              WITHHOLDING TAXES.  EACH PARTY SHALL PAY ANY
AND ALL TAXES LEVIED ON ACCOUNT OF SIGNING FEES, RESEARCH AND DEVELOPMENT
FUNDING, MILESTONE PAYMENTS, ROYALTIES OR OTHER PAYMENTS RECEIVED FROM THE OTHER
PARTY UNDER THIS AGREEMENT. IF LAWS OR REGULATIONS REQUIRE THAT TAXES BE
WITHHELD BY THE PAYING PARTY ON ANY SUCH PAYMENTS, THE PAYING PARTY SHALL: (I)
DEDUCT THOSE TAXES FROM THE REMITTABLE PAYMENT; (II) TIMELY PAY THE DEDUCTED
TAXES TO THE PROPER TAXING AUTHORITY; AND (III) SEND PROOF OF PAYMENT TO THE
RECEIVING PARTY WITHIN THIRTY (30) DAYS OF RECEIPT OF CONFIRMATION OF PAYMENT
FROM THE RELEVANT TAXING AUTHORITY.

 

16

--------------------------------------------------------------------------------

 

ARTICLE 8:  INTELLECTUAL PROPERTY

 

8.1.                              INVENTORSHIP.  INVENTORSHIP OF ANY AND ALL
INVENTIONS OR DISCOVERIES CONCEIVED AND/OR FIRST REDUCED TO PRACTICE UNDER THE
PROOF OF CONCEPT DEVELOPMENT PROGRAM OR WITHIN SIX (6) MONTHS OF TERMINATION OF
THE PROOF OF CONCEPT DEVELOPMENT PROGRAM WILL BE DETERMINED IN ACCORDANCE WITH
THE APPLICABLE PATENT LAWS.

 

8.2.                              OWNERSHIP.

 

8.2.1.                     EPIX INTELLECTUAL PROPERTY RIGHTS.  AS BETWEEN THE
PARTIES, EPIX SHALL HAVE SOLE AND EXCLUSIVE OWNERSHIP OF ALL RIGHT, TITLE AND
INTEREST ON A WORLDWIDE BASIS IN AND TO ANY AND ALL EPIX TECHNOLOGY AND EPIX
PATENT RIGHTS, WITH FULL RIGHTS TO LICENSE OR SUBLICENSE, SUBJECT TO THE RIGHTS
GRANTED TO SCHERING AS SET FORTH HEREIN.  WITHOUT LIMITING THE FOREGOING, EPIX
SHALL SOLELY CONTROL ALL PATENT RIGHTS, ALL TRADE SECRET RIGHTS, ALL KNOW-HOW
AND ANY OTHER INTELLECTUAL PROPERTY RIGHTS IN THE EPIX TECHNOLOGY, INCLUDING THE
SOLE AND EXCLUSIVE RIGHT TO EXCLUDE OTHERS FROM MAKING, USING, SELLING, OFFERING
FOR SALE OR IMPORTING THE EPIX TECHNOLOGY OR ANY PRODUCTS THAT CONSIST OF,
INCORPORATE OR ARE DERIVED FROM ANY EPIX TECHNOLOGY.

 

8.2.2.                     SCHERING INTELLECTUAL PROPERTY RIGHTS.  AS BETWEEN
THE PARTIES, SCHERING SHALL HAVE SOLE AND EXCLUSIVE OWNERSHIP OF ALL RIGHT,
TITLE AND INTEREST ON A WORLDWIDE BASIS IN AND TO ANY AND ALL SCHERING
TECHNOLOGY AND SCHERING PATENT RIGHTS, WITH FULL RIGHTS TO LICENSE OR
SUBLICENSE, SUBJECT TO THE RIGHTS GRANTED TO EPIX AS SET FORTH HEREIN.  WITHOUT
LIMITING THE FOREGOING, SCHERING SHALL SOLELY CONTROL ALL PATENT RIGHTS, ALL
TRADE SECRET RIGHTS, ALL KNOW-HOW AND ANY OTHER INTELLECTUAL PROPERTY RIGHTS IN
THE SCHERING TECHNOLOGY INCLUDING THE SOLE AND EXCLUSIVE RIGHT TO EXCLUDE OTHERS
FROM MAKING, USING, SELLING, OFFERING FOR SALE OR IMPORTING THE SCHERING
TECHNOLOGY OR ANY PRODUCTS THAT CONSIST OF, INCORPORATE OR ARE DERIVED FROM ANY
SCHERING TECHNOLOGY.

 

8.2.3.                     JOINT INTELLECTUAL PROPERTY RIGHTS.  THE PARTIES
SHALL JOINTLY OWN ALL JOINT TECHNOLOGY AND JOINT PATENT RIGHTS, SUBJECT TO THE
RIGHTS OF, AND THE LICENSES GRANTED TO, EACH PARTY HEREIN.

 

8.3.                              FILING, PROSECUTION, MAINTENANCE, ENFORCEMENT
AND DEFENSE.

 

8.3.1.                     FILING, PROSECUTION, MAINTENANCE, ENFORCEMENT AND
DEFENSE OF EPIX PATENT RIGHTS AND JOINT PATENT RIGHTS.  DURING THE PROOF OF
CONCEPT PERIOD AND LICENSE TERM, SUBJECT TO DYAX CORP.’S RIGHTS UNDER THAT
CERTAIN COLLABORATION AGREEMENT BETWEEN DYAX CORP. AND EPIX DATED JUNE 20, 1997,
AS AMENDED (THE “DYAX AGREEMENT”), EPIX SHALL BE SOLELY RESPONSIBLE FOR THE
FILING, PROSECUTION AND MAINTENANCE OF THE EPIX PATENT RIGHTS AND JOINT PATENT
RIGHTS, KEEPING SCHERING REASONABLY INFORMED THEREOF, AND ENFORCEMENT AND
DEFENSE OF THE EPIX PATENT RIGHTS DURING THE PROOF OF CONCEPT PERIOD AND LICENSE
TERM SHALL BE CONDUCTED IN ACCORDANCE WITH THIS SECTION 8.3. WITH REGARD TO ANY
APPLICATION FOR JOINT PATENT RIGHTS, EPIX SHALL INFORM SCHERING AT LEAST NINETY
(90) DAYS BEFORE THE END OF THE PRIORITY YEAR FOR SUCH APPLICATION IN WHICH
COUNTRIES EPIX INTENDS TO FILE. THE SAME INFORMATION OBLIGATION SHALL APPLY FOR
ANY TRANSFER OF PCT OR EP APPLICATIONS OR PATENTS TO NATIONAL STAGES. PATENT
COSTS FOR JOINT

 

17

--------------------------------------------------------------------------------

 

PATENT RIGHTS SHALL BE PAID BY EPIX SUBJECT TO REIMBURSEMENT BY SCHERING UP TO A
MAXIMUM ANNUAL SUM OF [*****] DOLLARS ($[*****]), PAYABLE UPON RECEIPT OF
QUARTERLY INVOICES.

 

(A)                                  ABANDONMENT; FAILURE TO PAY.  SUBJECT TO
THE TERMS OF THE DYAX AGREEMENT, IF EPIX FAILS TO UNDERTAKE (I) ANY FILING OF
ANY PATENT APPLICATION OR SUBMISSION, (II) MAKING ANY PAYMENT, OR (III) ANY
OTHER ACTION NECESSARY TO OBTAIN OR MAINTAIN A PATENT UNDER THE EPIX PATENT
RIGHTS OR JOINT PATENT RIGHTS, THEN FOLLOWING WRITTEN NOTICE OF SUCH INTENTION,
WHICH NOTICE SHALL BE PROVIDED BY EPIX TO SCHERING, IF AT ALL, NOT LESS THAN
NINETY (90) DAYS PRIOR TO THE LAST DATE FOR MAKING THE APPLICABLE FILING,
SUBMISSION OR PAYMENT TO PRESERVE RIGHTS UNDER SUCH PATENT OR PATENT
APPLICATION, SCHERING MAY UNDERTAKE SUCH FILING, SUBMISSION OR PAYMENT, AT ITS
OWN EXPENSE, IN EPIX’S NAME.

 

(B)                                 INFRINGEMENT BY OTHERS.  EPIX AND SCHERING
SHALL EACH PROMPTLY NOTIFY THE OTHER IN WRITING OF ANY ALLEGED OR THREATENED
INFRINGEMENT IN THE FIELD OF ANY EPIX LICENSED PATENT RIGHTS, OR JOINT PATENT
RIGHTS, OF WHICH THEY BECOME AWARE.  BETWEEN THE PARTIES, EPIX SHALL HAVE THE
FIRST RIGHT (BUT NOT THE OBLIGATION), AT ITS OWN EXPENSE AND WITH LEGAL COUNSEL
OF ITS OWN CHOICE, TO BRING SUIT (OR TAKE OTHER APPROPRIATE LEGAL ACTION)
AGAINST ANY ACTUAL, ALLEGED OR THREATENED INFRINGEMENT OF THE EPIX PATENT RIGHTS
IN THE FIELD.  SCHERING SHALL HAVE THE RIGHT, AT ITS OWN EXPENSE, TO BE
REPRESENTED IN ANY SUCH ACTION BY EPIX BY COUNSEL OF SCHERING’S OWN CHOICE;
PROVIDED, HOWEVER, THAT UNDER NO CIRCUMSTANCES SHALL THE FOREGOING AFFECT THE
RIGHT OF EPIX TO CONTROL THE SUIT AS DESCRIBED ABOVE.  SUBJECT TO THE TERMS OF
THE DYAX AGREEMENT, IF EPIX DOES NOT FILE ANY ACTION OR PROCEEDING AGAINST ANY
SUCH INFRINGEMENT WITHIN SIX (6) MONTHS AFTER THE LATER OF (I) EPIX’S NOTICE TO
SCHERING UNDER THIS SECTION 8.3.1, (II) SCHERING’S NOTICE TO EPIX UNDER THIS
SECTION 8.3.1, OR (III) A WRITTEN REQUEST FROM SCHERING TO TAKE ACTION WITH
RESPECT TO SUCH INFRINGEMENT, THEN SCHERING SHALL HAVE THE RIGHT (BUT NOT THE
OBLIGATION), AT ITS OWN EXPENSE, TO BRING SUIT (OR TAKE OTHER APPROPRIATE LEGAL
ACTION) AGAINST SUCH ACTUAL, ALLEGED OR THREATENED INFRINGEMENT, WITH LEGAL
COUNSEL OF ITS OWN CHOICE, BUT SHALL NOT BE PERMITTED TO SETTLE ANY SUCH SUIT
WITHOUT THE PRIOR CONSENT OF EPIX, WHICH CONSENT SHALL NOT BE UNREASONABLY
WITHHELD.  WITH REGARD TO JOINT PATENT RIGHTS THE ABOVE MECHANISMS SHALL APPLY
ACCORDINGLY; PROVIDED, HOWEVER, THAT SCHERING SHALL HAVE THE FIRST RIGHT (BUT
NOT THE OBLIGATION) TO BRING SUIT.

 

(C)                                  MONETARY AWARDS.  ANY DAMAGES, MONETARY
AWARDS OR OTHER AMOUNTS RECOVERED, WHETHER BY JUDGMENT OR SETTLEMENT, PURSUANT
TO ANY SUIT, PROCEEDING OR OTHER LEGAL ACTION TAKEN UNDER THIS SECTION, SHALL
APPLIED AS FOLLOWS:

 

(I)                                     FIRST, TO REIMBURSE THE PARTIES FOR
THEIR RESPECTIVE COSTS AND EXPENSES (INCLUDING REASONABLE ATTORNEYS’ FEES AND
COSTS) INCURRED IN PROSECUTING SUCH ENFORCEMENT ACTION;

 

(II)                                  SECOND, TO SCHERING IN REIMBURSEMENT FOR
LOST SALES (NET OF ROYALTIES) ASSOCIATED WITH SCHERING LICENSED PRODUCTS AND TO
EPIX IN REIMBURSEMENT FOR LOST ROYALTIES OWING HEREUNDER BASED ON SUCH LOST
SALES;

 

18

--------------------------------------------------------------------------------

 

(III)                               THIRD, ANY AMOUNTS REMAINING SHALL BE
ALLOCATED AS FOLLOWS:  (A) IF EPIX IS THE PARTY BRINGING SUCH SUIT OR PROCEEDING
OR TAKING SUCH OTHER LEGAL ACTION, ONE HUNDRED PERCENT (100%) TO EPIX, (B) IF
SCHERING IS THE PARTY BRINGING SUCH SUIT OR PROCEEDING OR TAKING SUCH OTHER
LEGAL ACTION, ONE HUNDRED PERCENT (100%) TO SCHERING, AND (C) IF THE SUIT IS
BROUGHT JOINTLY, FIFTY PERCENT (50%) TO EACH PARTY.

 

8.3.2.                     DECLARATORY ACTIONS.  IN THE EVENT THAT A DECLARATORY
JUDGMENT ACTION ALLEGING INVALIDITY OR NON-INFRINGEMENT IN THE FIELD OF ANY OF
THE EPIX PATENT RIGHTS, OR JOINT PATENT RIGHTS, IN THE TERRITORY SHALL BE
BROUGHT AGAINST EITHER PARTY, THE PARTY AGAINST WHICH SUCH ACTION IS BROUGHT
SHALL PROMPTLY NOTIFY THE OTHER PARTY IN WRITING.  THE PARTY AGAINST WHICH SUCH
ACTION IS BROUGHT WILL DEFEND SAID ACTION USING COUNSEL SELECTED BY IT AND IN
THE CASE OF AN ACTION AGAINST SCHERING, APPROVED BY EPIX, SUCH APPROVAL NOT TO
BE UNREASONABLY WITHHELD OR DELAYED.  SCHERING MAY NOT ENTER INTO ANY
SETTLEMENT, CONSENT JUDGMENT OR OTHER VOLUNTARY FINAL DISPOSITION OF THE ACTION
WITHOUT THE CONSENT OF EPIX, SUCH CONSENT NOT TO BE UNREASONABLY WITHHELD OR
DELAYED.  THE COSTS OF ANY DEFENSE UNDER THIS SECTION 8.3.2 WILL BE THE
RESPONSIBILITY OF THE DEFENDING PARTY.

 

8.3.3.                     FILING, PROSECUTION, MAINTENANCE, ENFORCEMENT AND
DEFENSE OF SCHERING PATENT RIGHTS.  DURING THE TERM OF THIS AGREEMENT, SCHERING
SHALL BE SOLELY RESPONSIBLE, AT ITS OWN EXPENSE FOR THE FILING, PROSECUTION AND
MAINTENANCE OF THE SCHERING LICENSED PATENT RIGHTS, KEEPING EPIX REASONABLY
INFORMED THEREOF AND ENFORCEMENT AND DEFENSE OF THE SCHERING LICENSED PATENT
RIGHTS DURING THE PROOF OF CONCEPT PERIOD AND EPIX ROYALTY TERM SHALL BE
CONDUCTED IN ACCORDANCE WITH THIS SECTION 8.3.

 

(A)                                  ABANDONMENT; FAILURE TO PAY.  IF SCHERING
FAILS TO UNDERTAKE (I) ANY FILING OF ANY PATENT APPLICATION OR SUBMISSION, (II)
MAKING ANY PAYMENT, OR (III) ANY OTHER ACTION NECESSARY TO OBTAIN OR MAINTAIN A
PATENT UNDER THE SCHERING PATENT RIGHTS THEN FOLLOWING WRITTEN NOTICE OF SUCH
INTENTION, WHICH NOTICE SHALL BE PROVIDED BY SCHERING TO EPIX, IF AT ALL, NOT
LESS THAN NINETY (90) DAYS PRIOR TO THE LAST DATE FOR MAKING THE APPLICABLE
FILING, SUBMISSION OR PAYMENT TO PRESERVE RIGHTS UNDER SUCH PATENT OR PATENT
APPLICATION, EPIX MAY UNDERTAKE SUCH FILING, SUBMISSION OR PAYMENT, AT ITS OWN
EXPENSE, IN SCHERING’S NAME.

 

(B)                                 INFRINGEMENT BY OTHERS.  EPIX AND SCHERING
SHALL EACH PROMPTLY NOTIFY THE OTHER IN WRITING OF ANY ALLEGED OR THREATENED
INFRINGEMENT IN THE FIELD OF ANY SCHERING  PATENT RIGHTS OF WHICH THEY BECOME
AWARE.  SCHERING SHALL HAVE THE FIRST RIGHT (BUT NOT THE OBLIGATION), AT ITS OWN
EXPENSE AND WITH LEGAL COUNSEL OF ITS OWN CHOICE, TO BRING SUIT (OR TAKE OTHER
APPROPRIATE LEGAL ACTION) AGAINST ANY ACTUAL, ALLEGED OR THREATENED INFRINGEMENT
OF THE SCHERING PATENT RIGHTS IN THE FIELD.  EPIX SHALL HAVE THE RIGHT, AT ITS
OWN EXPENSE, TO BE REPRESENTED IN ANY SUCH ACTION BY SCHERING BY COUNSEL OF
EPIX’S OWN CHOICE; PROVIDED, HOWEVER, THAT UNDER NO CIRCUMSTANCES SHALL THE
FOREGOING AFFECT THE RIGHT OF SCHERING TO CONTROL THE SUIT AS DESCRIBED ABOVE. 
IF SCHERING DOES NOT FILE ANY ACTION OR PROCEEDING AGAINST ANY SUCH MATERIAL
INFRINGEMENT WITHIN SIX (6) MONTHS AFTER THE LATER OF (I) EPIX’S NOTICE TO
SCHERING UNDER THIS SECTION 8.3.3, (II) SCHERING’S NOTICE TO EPIX UNDER THIS
SECTION 8.3.3, OR (III) A WRITTEN REQUEST FROM EPIX TO TAKE ACTION WITH RESPECT
TO SUCH INFRINGEMENT, THEN EPIX SHALL HAVE THE RIGHT (BUT NOT THE OBLIGATION),
AT ITS OWN EXPENSE, TO BRING SUIT (OR TAKE OTHER APPROPRIATE LEGAL

 

19

--------------------------------------------------------------------------------

 

action) against such actual, alleged or threatened infringement, with legal
counsel of its own choice, but shall not be permitted to settle any such suit
without the prior consent of Schering, which consent shall not be unreasonably
withheld.

 

(C)                                  MONETARY AWARDS.  SECTION 8.3.1(C) SHALL
APPLY ACCORDINGLY.

 

(D)                                 DECLARATORY ACTIONS.  SECTION 8.3.2 SHALL
APPLY ACCORDINGLY.

 

8.4.                              If either Party brings an action or proceeding
under Section 8.3 above, the other Party agrees to be joined as party plaintiff
if necessary to prosecute such action or proceeding, and to give the Party
bringing such action or proceeding reasonable assistance and authority to file
and prosecute the suit; provided, however, that neither Party shall be required
to transfer any right, title or interest in or to any property to the other
Party or any Third Party to confer standing on a Party hereunder.

 

ARTICLE 9:  CONFIDENTIALITY

 

9.1.                              NONDISCLOSURE OBLIGATIONS.

 

9.1.1.                     GENERAL.  EXCEPT AS PROVIDED IN THIS ARTICLE 9,
DURING THE TERM AND FOR A PERIOD OF TEN (10) YEARS THEREAFTER, BOTH PARTIES
SHALL MAINTAIN IN CONFIDENCE AND USE ONLY FOR PURPOSES SPECIFICALLY AUTHORIZED
UNDER THIS AGREEMENT (I) INFORMATION AND DATA RECEIVED FROM THE OTHER PARTY
RESULTING FROM OR RELATED TO THE DEVELOPMENT OF THE THROMBUS COMPOUND(S) AND/OR
LICENSED PRODUCTS AND (II) ALL INFORMATION AND DATA NOT DESCRIBED IN CLAUSE (I)
BUT SUPPLIED BY THE OTHER PARTY UNDER THIS AGREEMENT MARKED “CONFIDENTIAL.”  FOR
PURPOSES OF THIS ARTICLE 9, INFORMATION AND DATA DESCRIBED IN CLAUSE (I) OR (II)
SHALL BE REFERRED TO AS “INFORMATION.”

 

9.1.2.                     LIMITATIONS.  TO THE EXTENT IT IS REASONABLY
NECESSARY OR APPROPRIATE TO FULFILL ITS OBLIGATIONS OR EXERCISE ITS RIGHTS UNDER
THIS AGREEMENT, A PARTY MAY DISCLOSE INFORMATION IT IS OTHERWISE OBLIGATED UNDER
THIS SECTION 9.1 NOT TO DISCLOSE TO ITS AFFILIATES, SUBLICENSEES, CONSULTANTS,
OUTSIDE CONTRACTORS AND CLINICAL INVESTIGATORS, ON A NEED-TO-KNOW BASIS ON
CONDITION THAT SUCH ENTITIES OR PERSONS ENTER INTO WRITTEN AGREEMENTS TO KEEP
THE INFORMATION CONFIDENTIAL FOR THE SAME TIME PERIODS AND TO THE SAME EXTENT AS
SUCH PARTY IS REQUIRED TO KEEP THE INFORMATION CONFIDENTIAL. IN ADDITION A PARTY
OR ITS AFFILIATES OR SUBLICENSEES MAY DISCLOSE SUCH INFORMATION TO GOVERNMENT OR
OTHER REGULATORY AUTHORITIES TO THE EXTENT THAT SUCH DISCLOSURE IS REASONABLY
NECESSARY TO OBTAIN PATENTS OR AUTHORIZATIONS TO CONDUCT CLINICAL TRIALS OF, AND
TO COMMERCIALLY MARKET, THE THROMBUS COMPOUND(S) AND/OR LICENSED PRODUCTS. 
HOWEVER, FOR THE AVOIDANCE OF DOUBT, THE PARTIES STATE THAT NEITHER SCHERING NOR
EPIX SHALL DISCLOSE PRE-CLINICAL OR CLINICAL DATA OR THE CONTENTS OR
PRE-CLINICAL OR CLINICAL STUDY, REPORTS DERIVED FROM STUDIES OF LICENSED
PRODUCTS THAT HAS BEEN RECEIVED FROM THE OTHER PARTY TO ADVERTISING AGENCIES,
MARKETING RESEARCH CONSULTANTS, CUSTOMERS, HEALTHCARE PROFESSIONALS, CONSUMERS
OR REGULATORY AGENCIES WITHOUT THE PRIOR WRITTEN APPROVAL OF THE OTHER PARTY.

 

The obligation not to disclose Information shall not apply to any part of such
Information that: (i) is or becomes part of the public domain other than by
unauthorized acts of the Party

 

20

--------------------------------------------------------------------------------

 

obligated not to disclose such Information or those of its Affiliates or
Sublicensees; (ii) can be shown by competent evidence to have been disclosed to
the receiving Party or its or Sublicensees by a Third Party, provided, that such
Information was not obtained by such Third Party directly or indirectly from the
other Party under this Agreement pursuant to a confidentiality agreement; (iii)
can be shown by competent evidence, prior to disclosure under this Agreement, to
already have been in the possession of the receiving Party or its Affiliates or
Sublicensees, provided, that such Information was not obtained directly or
indirectly from the other Party under this Agreement pursuant to a
confidentiality agreement; (iv) can be shown by competent evidence to have been
independently developed by the receiving Party or its Affiliates without breach
of any of the provisions of this Agreement; or (v) is disclosed by the receiving
Party pursuant to interrogatories, requests for information or documents,
subpoena, civil investigative demand issued by a court or governmental agency or
as otherwise required by law; provided, that, the receiving Party notifies the
other Party immediately upon receipt thereof so that such other Party (with the
cooperation of the receiving Party) can seek a protective order or other order
limiting or preventing disclosure; and provided, further, that the disclosing
Party furnishes only that portion of the Information which it is advised by
counsel is legally required under the circumstances.

 

9.2.                              TERMS OF THIS AGREEMENT.  EXCEPT AS PROVIDED
IN SECTION 9.3 HEREOF, EPIX AND SCHERING EACH AGREE NOT TO DISCLOSE ANY TERMS OR
CONDITIONS OF THIS AGREEMENT TO ANY THIRD PARTY WITHOUT THE PRIOR WRITTEN
CONSENT OF THE OTHER PARTY, EXCEPT AS REQUIRED BY APPLICABLE LAW.  IF EITHER
PARTY DETERMINES THAT IT IS REQUIRED TO FILE THIS AGREEMENT WITH THE SECURITIES
AND EXCHANGE COMMISSION OR OTHER GOVERNMENTAL AGENCY FOR ANY REASON, SUCH PARTY
SHALL REQUEST CONFIDENTIAL TREATMENT OF SUCH PORTIONS OF THIS AGREEMENT AS THE
PARTIES SHALL TOGETHER DETERMINE IS APPROPRIATE.  NOTWITHSTANDING THE FOREGOING,
PRIOR TO EXECUTION OF THIS AGREEMENT, EPIX AND SCHERING HAVE AGREED UPON THE
SUBSTANCE OF INFORMATION THAT CAN BE USED AS A ROUTINE REFERENCE IN THE USUAL
COURSE OF BUSINESS TO DESCRIBE THE TERMS OF THIS TRANSACTION, AND EPIX AND
SCHERING MAY DISCLOSE SUCH INFORMATION, AS MODIFIED BY MUTUAL AGREEMENT FROM
TIME TO TIME, WITHOUT THE OTHER PARTY’S CONSENT AS MAY BE NECESSARY FROM TIME TO
TIME.

 

9.3.                              PUBLICATIONS.

 

9.3.1.                     PROCEDURE.  EACH PARTY RECOGNIZES THE MUTUAL INTEREST
IN OBTAINING PATENT PROTECTION FOR INVENTIONS THAT ARISE UNDER THIS AGREEMENT. 
IN THE EVENT THAT EITHER PARTY, ITS EMPLOYEES OR CONSULTANTS OR ANY THIRD PARTY
UNDER CONTRACT TO SUCH PARTY WISHES TO MAKE A PUBLICATION (INCLUDING ANY ORAL
DISCLOSURE MADE WITHOUT OBLIGATION OF CONFIDENTIALITY) RELATING TO WORK
PERFORMED UNDER THIS AGREEMENT (THE “PUBLISHING PARTY”), SUCH PARTY SHALL
TRANSMIT TO THE OTHER PARTY (THE “REVIEWING PARTY”) A COPY OF THE PROPOSED
WRITTEN PUBLICATION AT LEAST THIRTY (30) DAYS PRIOR TO SUBMISSION FOR
PUBLICATION, OR AN ABSTRACT OF SUCH ORAL DISCLOSURE AT LEAST SEVEN (7) DAYS
PRIOR TO SUBMISSION OF THE ABSTRACT OR THE ORAL DISCLOSURE, WHICHEVER IS
EARLIER. THE REVIEWING PARTY SHALL HAVE THE RIGHT (A) TO PROPOSE MODIFICATIONS
TO THE PUBLICATION FOR PATENT REASONS, (B) TO REQUEST A DELAY IN PUBLICATION OR
PRESENTATION IN ORDER TO PROTECT PATENTABLE INFORMATION, OR (C) TO REQUEST THAT
THE INFORMATION BE MAINTAINED AS A TRADE SECRET.

 

9.3.2.                     MODIFICATIONS; DELAY: RESOLUTION.  IF THE REVIEWING
PARTY REQUESTS A MODIFICATION TO THE PUBLICATION FOR PATENT REASONS, THE
PROPOSED PUBLICATION SHALL NOT BE

 

21

--------------------------------------------------------------------------------

 

SUBMITTED UNTIL THE PARTIES HAVE AGREED TO APPROPRIATE MODIFICATIONS.  IF THE
REVIEWING PARTY REQUESTS A DELAY AS DESCRIBED IN SECTION 9.3.1, THE PUBLISHING
PARTY SHALL DELAY SUBMISSION OR PRESENTATION OF THE PUBLICATION FOR A PERIOD OF
NINETY (90) DAYS TO ENABLE PATENT APPLICATIONS PROTECTING EACH PARTY’S RIGHTS IN
SUCH INFORMATION TO BE FILED.  IF THE REVIEWING PARTY REQUESTS THAT INFORMATION
BE MAINTAINED AS A TRADE SECRET, THE PROPOSED PUBLICATION SHALL NOT BE DISCLOSED
UNTIL SUCH INFORMATION IS DELETED THEREFROM.

 

9.4.                              INJUNCTIVE RELIEF.  THE PARTIES HERETO
UNDERSTAND AND AGREE THAT REMEDIES, AT LAW MAY BE INADEQUATE TO PROTECT AGAINST
ANY BREACH OF ANY OF THE PROVISIONS OF THIS ARTICLE 9 BY EITHER PARTY OR THEIR
EMPLOYEES, AGENTS, OFFICERS OR DIRECTORS OR ANY OTHER PERSON ACTING IN CONCERT
WITH IT OR ON ITS BEHALF.  ACCORDINGLY, EACH PARTY SHALL BE ENTITLED TO THE
GRANTING OF INJUNCTIVE RELIEF OR OTHER EQUITABLE RELIEF BY A COURT OF COMPETENT
JURISDICTION AGAINST ANY ACTION THAT CONSTITUTES ANY SUCH BREACH OF THIS ARTICLE
9, IN ADDITION TO ANY MONETARY DAMAGES TO WHICH A PARTY MAY BE ENTITLED.

 

ARTICLE 10:  REPRESENTATIONS AND WARRANTIES

 

10.1.                        REPRESENTATIONS AND WARRANTIES.  EPIX AND SCHERING
EACH REPRESENTS AND WARRANTS TO THE OTHER, AS OF THE EFFECTIVE DATE AS FOLLOWS:

 

10.2.                        ORGANIZATION.  IT IS A CORPORATION DULY ORGANIZED,
VALIDLY EXISTING AND IS IN GOOD STANDING UNDER THE LAWS OF THE JURISDICTION OF
ITS ORGANIZATION, IS QUALIFIED TO DO BUSINESS AND IS IN GOOD STANDING AS A
FOREIGN CORPORATION IN EACH JURISDICTION IN WHICH THE PERFORMANCE OF ITS
OBLIGATIONS HEREUNDER REQUIRES SUCH QUALIFICATION AND HAS ALL REQUISITE POWER
AND AUTHORITY, CORPORATE OR OTHERWISE, TO CONDUCT ITS BUSINESS AS NOW BEING
CONDUCTED, TO OWN, LEASE AND OPERATE ITS PROPERTIES AND TO EXECUTE, DELIVER AND
PERFORM THIS AGREEMENT.

 

10.3.                        AUTHORIZATION.  THE EXECUTION, DELIVERY AND
PERFORMANCE BY IT OF THIS AGREEMENT (A) HAVE BEEN DULY AUTHORIZED BY ALL
NECESSARY CORPORATE ACTION AND (B) DO NOT AND WILL NOT VIOLATE ANY PROVISION OF
ANY AGREEMENT, LAW, RULE, REGULATION, ORDER, WRIT, JUDGMENT, INJUNCTION, DECREE,
DETERMINATION OR AWARD PRESENTLY IN EFFECT HAVING APPLICABILITY TO IT OR ANY
PROVISION OF ITS CHARTER DOCUMENTS.

 

10.4.                        NO INCONSISTENT OBLIGATION.  IT IS NOT UNDER ANY
OBLIGATION TO ANY PERSON, OR ENTITY, CONTRACTUAL OR OTHERWISE, THAT IS
CONFLICTING OR INCONSISTENT IN ANY RESPECT WITH THE TERMS OF THIS AGREEMENT OR
THAT WOULD IMPEDE THE DILIGENT AND COMPLETE FULFILLMENT OF ITS OBLIGATIONS
HEREUNDER AND THAT IT HAS ALL POWER AND AUTHORITY UNDER ALL INSTRUMENTS OR
AGREEMENTS TO WHICH IT IS A PARTY TO ENTER INTO THIS AGREEMENT AND TO PERFORM
ITS OBLIGATIONS HEREUNDER.

 

10.5.                        WARRANTY DISCLAIMER.  EXCEPT AS OTHERWISE EXPRESSLY
PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY
TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT
AND HEREBY DISCLAIMS WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE AND NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING.

 

22

--------------------------------------------------------------------------------

 

ARTICLE 11:  INDEMNITY

 

11.1.                        CLAIM.  FOR PURPOSES OF THIS ARTICLE 11 “CLAIM”
SHALL MEAN ANY AND ALL THIRD PARTY SUITS, ACTIONS, CLAIMS, DEMANDS, LIABILITIES,
EXPENSES, AND/OR LOSSES, INCLUDING WITHOUT LIMITATION REASONABLE ATTORNEYS’
FEES, BASED UPON, ARISING IN CONNECTION WITH, OR RESULTING FROM THE DEVELOPMENT,
CLINICAL STUDY IN HUMANS, OR COMMERCIALIZATION OF THE THROMBUS COMPOUND(S)
AND/OR LICENSED PRODUCTS, BUT EXCLUDING ANY SUITS, ACTIONS, CLAIMS, DEMANDS,
LIABILITIES, EXPENSES, AND/OR LOSSES BASED UPON, ARISING IN CONNECTION WITH, OR
RESULTING FROM INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD
PARTY OR THIRD PARTIES.

 

11.2.                        SCHERING INDEMNITY OBLIGATIONS.  SUBJECT TO THE
PROVISIONS OF SECTIONS 11.3 AND 11.4, SCHERING AGREES TO DEFEND, INDEMNIFY AND
HOLD EPIX, ITS AFFILIATES AND THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES
AND AGENTS HARMLESS FROM (EACH, AN “EPIX INDEMNITEE”) ALL CLAIMS AGAINST EPIX,
ITS AFFILIATES OR THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES OR AGENTS
SOLELY BASED UPON, ARISING IN CONNECTION WITH OR RESULTING FROM (A) ACTUAL OR
ASSERTED VIOLATIONS OF ANY APPLICABLE LAW OR REGULATION BY SCHERING, ITS
AFFILIATES, SUBLICENSEES, OR AGENTS BY VIRTUE OF WHICH ANY THROMBUS COMPOUND(S)
OR SCHERING LICENSED PRODUCT IS DEVELOPED, DISTRIBUTED OR SOLD BY SCHERING SHALL
BE ALLEGED OR DETERMINED TO BE ADULTERATED, MISBRANDED, MISLABELED OR OTHERWISE
NOT IN COMPLIANCE WITH SUCH APPLICABLE LAW OR REGULATION, (B) THE MANUFACTURE,
USE, SALE, DISTRIBUTION OF A THROMBUS COMPOUND(S) OR SCHERING LICENSED PRODUCT
BY SCHERING, ITS AFFILIATES, SUBLICENSEES, OR AGENTS; (C) ANY NEGLIGENT OR
WILLFUL OR INTENTIONAL ACT OR OMISSION TO ACT BY SCHERING, ITS AFFILIATES,
SUBLICENSEES, OR AGENTS IN ANY MANNER IN CONNECTION WITH PERFORMANCE HEREUNDER;
OR (D) THE BREACH OF ANY REPRESENTATION OR WARRANTY OF SCHERING IN THIS
AGREEMENT.

 

11.3.                        EPIX INDEMNITY OBLIGATIONS.  SUBJECT TO THE
PROVISIONS OF SECTIONS 11.2 AND 11.4, EPIX AGREES TO DEFEND, INDEMNIFY AND HOLD
SCHERING, ITS AFFILIATES AND THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES AND
AGENTS HARMLESS FROM ALL CLAIMS AGAINST SCHERING, ITS AFFILIATES OR THEIR
RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES OR AGENTS (EACH, A “SCHERING
INDEMNITEE”) SOLELY BASED UPON, ARISING IN CONNECTION WITH OR RESULTING FROM (A)
ACTUAL OR ASSERTED VIOLATIONS OF ANY APPLICABLE LAW OR REGULATION BY EPIX, ITS
AFFILIATES, SUBLICENSEES, OR AGENTS BY VIRTUE OF WHICH ANY THROMBUS COMPOUND(S)
OR EPIX LICENSED PRODUCT IS DEVELOPED, DISTRIBUTED OR SOLD BY EPIX SHALL BE
ALLEGED OR DETERMINED TO BE ADULTERATED, MISBRANDED, MISLABELED OR OTHERWISE NOT
IN COMPLIANCE WITH SUCH APPLICABLE LAW OR REGULATION, (B) THE MANUFACTURE, USE,
SALE, DISTRIBUTION OF A THROMBUS COMPOUND(S) OR AN EPIX LICENSED PRODUCT; (C)
ANY NEGLIGENT OR WILLFUL OR INTENTIONAL ACT OR OMISSION TO ACT BY EPIX, ITS
AFFILIATES OR AGENTS IN ANY MANNER IN CONNECTION WITH PERFORMANCE HEREUNDER; OR
(D) THE BREACH OF ANY REPRESENTATION OR WARRANTY OF EPIX IN THIS AGREEMENT.

 

11.4.                        PROCEDURE.  AN EPIX INDEMNITEE AND/OR A SCHERING
INDEMNITEE (EACH, AN “INDEMNITEE”) THAT INTENDS TO CLAIM INDEMNIFICATION UNDER
SECTIONS 11.2 OR 11.3 SHALL PROMPTLY NOTIFY THE OTHER PARTY (THE “INDEMNITOR”)
OF THE CLAIM IN RESPECT OF WHICH THE INDEMNITEE INTENDS TO CLAIM SUCH
INDEMNIFICATION, AND THE INDEMNITOR SHALL ASSUME THE DEFENSE THEREOF WITH
COUNSEL MUTUALLY SATISFACTORY TO THE PARTIES; PROVIDED, HOWEVER, THAT AN
INDEMNITEE SHALL HAVE THE RIGHT TO RETAIN ITS OWN COUNSEL, WITH THE FEES AND
EXPENSES TO BE PAID BY THE INDEMNITOR, IF REPRESENTATION

 

23

--------------------------------------------------------------------------------

 

OF SUCH INDEMNITEE IN THE OPINION OF THE PARTIES WOULD BE INAPPROPRIATE DUE TO
ACTUAL OR POTENTIAL DIFFERING INTERESTS BETWEEN SUCH INDEMNITEE AND ANY OTHER
PARTY REPRESENTED BY SUCH COUNSEL IN SUCH PROCEEDINGS. AN INDEMNITEE SHALL NOT
BE ENTITLED TO INDEMNIFICATION UNDER SECTIONS 11.2 OR 11.3 IF ANY SETTLEMENT OR
COMPROMISE OF A CLAIM IS EFFECTED BY THE INDEMNITEE WITHOUT THE CONSENT OF THE
INDEMNITOR, WHICH CONSENT SHALL NOT BE UNREASONABLY WITHHELD OR DELAYED.  THE
FAILURE TO DELIVER NOTICE TO THE INDEMNITOR WITHIN A REASONABLE TIME AFTER
NOTICE OF A CLAIM, IF PREJUDICIAL TO ITS ABILITY TO DEFEND SUCH ACTION, SHALL
RELIEVE SUCH INDEMNITOR OF ANY LIABILITY TO THE LNDEMNITEE UNDER SECTIONS 11.2
OR 11.3.  THE INDEMNITEE UNDER SECTIONS 11.2 OR 11.3, ITS EMPLOYEES AND AGENTS
(AND THOSE OF ANY INDEMNIFIED AFFILIATES OR OTHER INDEMNITEES), SHALL COOPERATE
FULLY WITH THE INDEMNITOR AND ITS LEGAL REPRESENTATIVES IN THE INVESTIGATION AND
DEFENSE OF THE CLAIM COVERED BY THIS INDEMNIFICATION.  ANY COSTS PAID BY AN
INDEMNITOR SHALL BE WITHOUT PREJUDICE TO THE INDEMNITOR’S RIGHT TO CONTEST THE
INDEMNITEE’S RIGHT TO BE INDEMNIFIED, AND SUBJECT TO REFUND IN THE EVENT THAT
THE INDEMNITOR IS ULTIMATELY HELD NOT TO BE OBLIGATED TO INDEMNIFY THE
INDEMNITEE.

 

11.5.                        LIMITED LIABILITY.  NOTWITHSTANDING ANYTHING TO THE
CONTRARY IN THIS AGREEMENT, NEITHER EPIX NOR SCHERING WILL BE LIABLE WITH
RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE,
STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR PUNITIVE DAMAGES OR LOST
PROFITS.

 

ARTICLE 12:  EXPIRATION AND TERMINATION

 

12.1.                        TERM.  THE TERM OF THIS AGREEMENT SHALL COMMENCE ON
THE EFFECTIVE DATE AND SHALL CONTINUE UNTIL THE LAST TO OCCUR OF THE FOLLOWING:
(I) THE EXPIRATION OR TERMINATION OF THE PROOF OF CONCEPT DEVELOPMENT PROGRAM,
(II) THE EXPIRATION OF THE LICENSE TERM OR (III) THE EXPIRATION OF THE EPIX
ROYALTY TERM (THE “TERM”).

 

12.2.                        TERMINATION WITHOUT CAUSE.  SCHERING SHALL HAVE THE
RIGHT TO PARTIALLY TERMINATE THIS AGREEMENT WITHOUT CAUSE WITH REGARD TO (I) THE
PROOF OF CONCEPT DEVELOPMENT PROGRAM AT ANY TIME PRIOR TO EXPIRATION OF THE
RELEVANT PROOF OF CONCEPT DEVELOPMENT PERIOD, AND (II) ANY EXCLUSIVE OR
NON-EXCLUSIVE LICENSE GRANTED TO SCHERING HEREUNDER, UPON SIXTY (60) DAYS PRIOR
WRITTEN NOTICE TO EPIX. FOLLOWING SUCH TERMINATION, ALL RIGHTS AND LICENSES
GRANTED TO SCHERING UNDER THIS AGREEMENT SHALL TERMINATE AND SCHERING SHALL
RETURN OR DESTROY ALL TANGIBLE MANIFESTATIONS OF EPIX’S INFORMATION AND EPIX’S
TECHNOLOGY. IF ALL OR PART OF THE WORK UNDER THE APPLICABLE PROOF OF CONCEPT
DEVELOPMENT PROGRAM IS TERMINATED FOR ANY REASON, THEN SCHERING SHALL HAVE NO
OBLIGATION TO CONTINUE PAYMENT THEREAFTER OF INSTALLMENTS UNDER SECTION 3.2;
PROVIDED, HOWEVER, THAT SCHERING SHALL PAY REASONABLE, NON-CANCELABLE, THIRD
PARTY EXPENSES INCURRED BY EPIX UP UNTIL THE EFFECTIVE DATE OF THE TERMINATION.
EPIX SHALL USE GOOD FAITH EFFORT TO LIMIT SUCH OBLIGATIONS FOLLOWING SUCH NOTICE
FROM SCHERING. FOR THE AVOIDANCE OF DOUBT, IF SCHERING TERMINATES THIS AGREEMENT
PURSUANT TO CLAUSE (II) OF THIS SECTION 12.2, THE RIGHTS AND LICENSES GRANTED TO
SCHERING UNDER SECTIONS 4.1.2 AND 5.1.2 HEREOF SHALL IMMEDIATELY TERMINATE WITH
REGARD TO THE RELEVANT EXCLUSIVE OR NON-EXCLUSIVE LICENSE TERMINATED BY SCHERING
HEREUNDER, AND EPIX SHALL HAVE THE SOLE RIGHT, BUT NOT THE OBLIGATION, UNDER THE
LICENSE GRANTED PURSUANT TO SECTION 5.1.1 HEREOF TO FURTHER DEVELOP AND
COMMERCIALIZE ANY SCHERING LICENSED PRODUCT

 

24

--------------------------------------------------------------------------------

 

COVERED BY THE TERMINATED LICENSE (THEREAFTER BECOMING AN EPIX LICENSED PRODUCT
AS DEFINED IN SECTION 4.1.2).

 

12.3.                        TERMINATION FOR MATERIAL BREACH.  IF EITHER PARTY
COMMITS A MATERIAL BREACH OF THIS AGREEMENT (A “DEFAULT”), THE OTHER PARTY MAY
NOTIFY THE BREACHING PARTY IN WRITING OF SUCH BREACH, SETTING FORTH THE NATURE
OF THE BREACH IN REASONABLE DETAIL.  IF THE BREACHING PARTY FAILS TO CURE SUCH
BREACH WITHIN THIRTY (30) DAYS (IN THE CASE OF A PAYMENT DUE UNDER THIS
AGREEMENT) OR SIXTY (60) DAYS (IN THE CASE OF ANY OTHER BREACH) OF THE RECEIPT
OF THE FOREGOING NOTICE FROM THE NON-BREACHING PARTY, THEN, SUBJECT TO THE TERMS
OF THIS SECTION 12.3, THE NON-BREACHING PARTY MAY TERMINATE (I) THE RESPECTIVE
PART OF THIS AGREEMENT WHICH IS IMPACTED BY THE UNCURED MATERIAL BREACH, OR (II)
IF THE BREACH IS OF A GENERAL NATURE HAVING A MATERIAL IMPACT ON ALL PARTS, THE
ENTIRE AGREEMENT EFFECTIVE IMMEDIATELY UPON A SECOND WRITTEN NOTICE TO THE
BREACHING PARTY. THE RIGHT OF EITHER PARTY TO TERMINATE THIS AGREEMENT AS HEREIN
ABOVE PROVIDED SHALL NOT BE AFFECTED IN ANY WAY BY ITS WAIVER OF, OR FAILURE TO
TAKE ACTION WITH RESPECT TO ANY PREVIOUS DEFAULT.

 

12.3.1.               TERMINATION BY SCHERING FOR EPIX DEFAULT.  UPON A
TERMINATION OF THIS AGREEMENT BY SCHERING BECAUSE OF A DEFAULT BY EPIX, SUBJECT
TO THE NOTICE AND CURE PROVISIONS SET FORTH IN THIS SECTION 12.3, (I) ALL RIGHTS
AND LICENSES GRANTED TO EPIX PURSUANT TO SECTION 5.1.1 HEREOF SHALL SURVIVE SUCH
TERMINATION; PROVIDED, HOWEVER, THE EPIX ROYALTY TERM, AS DEFINED IN SECTION
1.14, SHALL BE EXTENDED AS IF THE PHRASE “[*****] OF THE SCHERING PAYMENT” WERE
DELETED AND REPLACED BY THE PHRASE “[*****] OF THE SCHERING PAYMENT” AND (II)
ALL RIGHTS, LICENSES AND OPTIONS GRANTED TO SCHERING HEREUNDER SHALL SURVIVE
SUCH TERMINATION, PROVIDED, HOWEVER, SCHERING SHALL PAY, FOR THE REMAINDER OF
THE LICENSE TERM, IN LIEU OF ANY PAYMENTS IT WOULD OTHERWISE OWE TO EPIX UNDER
THIS AGREEMENT, [*****] OF MILESTONES AND ROYALTY PAYMENTS EQUAL TO [*****] OF
THE ROYALTY PAYMENTS THAT WOULD OTHERWISE APPLY WITH RESPECT TO SCHERING
LICENSED PRODUCTS UNDER SECTION 6.1. HEREOF.

 

12.3.2.               TERMINATION BY EPIX FOR SCHERING DEFAULT.

 

(A)                                  UPON A TERMINATION OF THIS AGREEMENT BY
EPIX BECAUSE OF ANY DEFAULT BY SCHERING, EXCEPT FOR A DEFAULT SUBJECT TO
SECTIONS 12.3.2(B) OR 12.3.2 (C) BELOW, SUBJECT TO THE NOTICE AND CURE
PROVISIONS SET FORTH IN SECTION 12.3, (I) ALL RIGHTS AND LICENSES GRANTED TO
SCHERING PURSUANT TO SECTION 5.1.2 HEREOF HEREUNDER SHALL SURVIVE SUCH
TERMINATION; PROVIDED, HOWEVER, ALL MILESTONE AND ROYALTY OBLIGATIONS OF
SCHERING PURSUANT TO SECTION 6.1 HEREOF, SHALL BE INCREASED BY [*****]
RESPECTIVELY, (II) THE EPIX ROYALTY TERM, AS DEFINED IN SECTION 1.15, SHALL BE
SHORTENED AS IF THE PHRASE “[*****]OF THE SCHERING PAYMENT” WERE DELETED AND
REPLACED BY THE PHRASE “[*****] OF THE SCHERING PAYMENT” AND (III) ALL RIGHTS,
LICENSES AND OPTIONS GRANTED TO EPIX HEREUNDER SHALL SURVIVE TERMINATION,
PROVIDED, HOWEVER, EPIX SHALL PAY, FOR THE REMAINDER OF THE EPIX ROYALTY TERM,
IN LIEU OF ANY PAYMENTS IT WOULD OTHERWISE OWE TO SCHERING UNDER THIS AGREEMENT,
ROYALTY PAYMENTS EQUAL TO [*****] PERCENT OF THE ROYALTY PAYMENTS THAT WOULD
OTHERWISE APPLY WITH RESPECT TO EPIX LICENSED PRODUCTS UNDER SECTION 6.2 HEREOF.

 

12.4.                        TERMINATION FOR FAILURE OF SCHERING TO USE DUE
DILIGENCE.  NOTWITHSTANDING ANY OTHER PROVISIONS OF THIS AGREEMENT, IN CASE OF
ANY FAILURE BY SCHERING TO USE DUE DILIGENCE AS

 

25

--------------------------------------------------------------------------------

 

REQUIRED PURSUANT TO SECTION 5.3 HEREOF, EPIX MAY, IN ITS SOLE DISCRETION
TERMINATE THE RELEVANT LICENSES GRANTED UNDER SECTION 5.1.2 HEREOF UPON WRITTEN
NOTICE TO SCHERING; PROVIDED THAT SCHERING HAS NOT CURED SUCH FAILURE WITHIN
NINETY (90) DAYS OF EPIX’S NOTICE TO SCHERING OF SUCH ALLEGED FAILURE. AFTER A
TERMINATION UNDER THIS SECTION 12.4 EPIX SHALL HAVE THE SOLE RIGHT, BUT NOT THE
OBLIGATION, UNDER THE LICENSE GRANTED PURSUANT TO SECTION 5.1.1 HEREOF TO
FURTHER DEVELOP AND COMMERCIALIZE SUCH SCHERING LICENSED PRODUCT (THEREAFTER,
BECOMING AN “EPIX LICENSED PRODUCT”), SUBJECT TO PAYMENT OF ROYALTIES AS
PROVIDED IN SECTION 6.2.2 AND THE PAYMENT OF [*****] OF SUBLICENSE INCOME
RECEIVED BY EPIX IN CONNECTION WITH THE SUBLICENSE OF RIGHTS TO SUCH EPIX
LICENSED PRODUCT TO A THIRD PARTY UNTIL THE DATE UPON WHICH THE AGGREGATE TOTAL
OF SUCH SUBLICENSE INCOME AND ROYALTIES PAID EQUALS [*****] OF THE PREVIOUSLY
UNREIMBURSED DEVELOPMENT COSTS INCURRED BY SCHERING FOR THE RELEVANT SCHERING
LICENSED PRODUCT.

 

12.5.                        EFFECTS TERMINATION ON SUBLICENSES. 
NOTWITHSTANDING THE FOREGOING, TERMINATION OF THIS AGREEMENT BY SCHERING UNDER
SECTION 12.3.1 OR BY EPIX PURSUANT TO SECTIONS 12.3.2 OR 12.4 SHALL NOT BE
CONSTRUED AS A TERMINATION OF ANY VALID SUBLICENSE OF ANY SUBLICENSEE HEREUNDER,
AND THEREAFTER EACH SUCH SUBLICENSEE SHALL BE CONSIDERED A DIRECT LICENSEE OF
THE TERMINATING PARTY, PROVIDED THAT (I) SUCH SUBLICENSEE IS THEN IN FULL
COMPLIANCE WITH ALL TERMS AND CONDITIONS OF ITS SUBLICENSE, (II) ALL ACCRUED
PAYMENTS OBLIGATIONS TO TERMINATING PARTY HAVE BEEN PAID, AND (III) SUCH
SUBLICENSEE AGREES IN WRITING TO ASSUME ALL APPLICABLE OBLIGATIONS OF THE
NON-TERMINATING PARTY UNDER THIS AGREEMENT.

 

12.6.                        TERMINATION UPON INSOLVENCY.  THIS AGREEMENT MAY BE
TERMINATED BY EITHER PARTY UPON NOTICE TO THE OTHER PARTY SHOULD SUCH OTHER
PARTY:  (A) CONSENT TO THE APPOINTMENT OF A RECEIVER OR A GENERAL ASSIGNMENT FOR
THE BENEFIT OF CREDITORS, OR (B) FILE OR CONSENT TO THE FILING OF A PETITION
UNDER ANY BANKRUPTCY OR INSOLVENCY LAW OR HAVE ANY SUCH PETITION FILED AGAINST
IT WHICH HAS NOT BEEN STAYED WITHIN SIXTY (60) DAYS OF SUCH FILING.

 

12.7.                        RIGHTS IN BANKRUPTCY.  ALL RIGHTS AND LICENSES
GRANTED UNDER OR PURSUANT TO THIS AGREEMENT ARE, AND SHALL OTHERWISE BE DEEMED
TO BE, FOR PURPOSES OF SECTION 365(N) OF THE U.S. BANKRUPTCY CODE, LICENSES OF
RIGHT TO “INTELLECTUAL PROPERTY” AS DEFINED UNDER SECTION 101 OF THE U.S.
BANKRUPTCY CODE.

 

12.8.                        ACCRUED RIGHTS; SURVIVING OBLIGATIONS.  TERMINATION
OF THIS AGREEMENT FOR ANY REASON SHALL BE WITHOUT PREJUDICE TO ANY RIGHTS THAT
SHALL HAVE ACCRUED TO THE BENEFIT OF A PARTY PRIOR TO OR ON ACCOUNT OF SUCH
TERMINATION.  ALL REMEDIES PROVIDED HEREUNDER OR ELSEWHERE ARE CUMULATIVE. 
SECTIONS 7.3, 12.7 AND 13.5 AND ARTICLES 8, 9, 10 AND 11 OF THIS AGREEMENT SHALL
SURVIVE THE TERMINATION OF THIS AGREEMENT FOR ANY REASON AND SECTION 1 HEREOF
SHALL SURVIVE SUCH TERMINATION TO THE EXTENT ANY TERMS DEFINED THEREIN ARE USED
IN SUCH OTHER SURVIVING PROVISIONS.

 

ARTICLE 13:  MISCELLANEOUS

 

13.1.                        FORCE MAJEURE.  NEITHER PARTY SHALL BE HELD LIABLE
OR RESPONSIBLE TO THE OTHER PARTY NOR BE DEEMED TO HAVE DEFAULTED UNDER OR
BREACHED THIS AGREEMENT FOR FAILURE OR DELAY IN FULFILLING OR PERFORMING ANY
TERM OF THIS AGREEMENT WHEN SUCH FAILURE OR DELAY IS CAUSED BY OR RESULTS FROM
CAUSES BEYOND THE REASONABLE CONTROL OF THE AFFECTED PARTY, INCLUDING BUT NOT
LIMITED

 

26

--------------------------------------------------------------------------------

 

TO FIRE, FLOODS, EMBARGOES, WAR, ACTS OF WAR (WHETHER WAR IS DECLARED OR NOT),
INSURRECTIONS, RIOTS, CIVIL COMMOTIONS, STRIKES, LOCKOUTS OR OTHER LABOR
DISTURBANCES, ACTS OF GOD OR ACTS, OMISSIONS OR DELAYS IN ACTING BY ANY
GOVERNMENTAL AUTHORITY OR THE OTHER PARTY; PROVIDED, HOWEVER, THAT THE PARTY SO
AFFECTED SHALL USE REASONABLE COMMERCIAL EFFORTS TO AVOID OR REMOVE SUCH CAUSES
OF NONPERFORMANCE, AND SHALL CONTINUE PERFORMANCE HEREUNDER WITH REASONABLE
DISPATCH WHENEVER SUCH CAUSES ARE REMOVED. EITHER PARTY SHALL PROVIDE THE OTHER
PARTY WITH PROMPT WRITTEN NOTICE OF ANY DELAY OR FAILURE TO PERFORM THAT OCCURS
BY REASON OF FORCE MAJEURE.  THE PARTIES SHALL MUTUALLY SEEK A RESOLUTION OF THE
DELAY OR THE FAILURE TO PERFORM AS NOTED ABOVE.

 

13.2.                        ASSIGNMENT.  THIS AGREEMENT MAY NOT BE ASSIGNED OR
OTHERWISE TRANSFERRED BY EITHER PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF THE
OTHER PARTY; PROVIDED, HOWEVER, THAT EITHER EPIX OR SCHERING MAY, WITHOUT SUCH
CONSENT, ASSIGN ITS RIGHTS AND OBLIGATIONS UNDER THIS AGREEMENT: (I) TO ANY
AFFILIATE, OR (II) IN CONNECTION WITH A MERGER, CONSOLIDATION OR SALE OF
SUBSTANTIALLY ALL OF SUCH PARTY’S ASSETS TO AN UNRELATED THIRD PARTY; PROVIDED,
HOWEVER, WITH RESPECT TO THIS SUBSECTION (II), THAT SUCH PARTY’S RIGHTS AND
OBLIGATIONS UNDER THIS AGREEMENT SHALL BE ASSUMED IN WRITING BY ITS SUCCESSOR IN
INTEREST IN ANY SUCH TRANSACTION AND SHALL NOT BE TRANSFERRED SEPARATELY FROM
ALL OR SUBSTANTIALLY ALL OF ITS DIAGNOSTIC IMAGING BUSINESS ASSETS.  ANY
PURPORTED ASSIGNMENT IN VIOLATION OF THE PRECEDING SENTENCE SHALL BE VOID.  ANY
PERMITTED ASSIGNEE SHALL ASSUME ALL OBLIGATIONS OF ITS ASSIGNOR UNDER THIS
AGREEMENT.

 

13.3.                        SEVERABILITY.  EACH PARTY HEREBY AGREES THAT IT
DOES NOT INTEND, BY ITS EXECUTION HEREOF, TO VIOLATE ANY PUBLIC POLICY,
STATUTORY OR COMMON LAWS, RULES, REGULATIONS, TREATY OR DECISION OF ANY
GOVERNMENT AGENCY OR EXECUTIVE BODY THEREOF OF ANY COUNTRY OR COMMUNITY OR
ASSOCIATION OF COUNTRIES.  SHOULD ONE OR MORE PROVISIONS OF THIS AGREEMENT BE OR
BECOME INVALID, THE PARTIES HERETO SHALL SUBSTITUTE, BY MUTUAL CONSENT, VALID
PROVISIONS FOR SUCH INVALID PROVISIONS WHICH VALID PROVISIONS IN THEIR ECONOMIC
AND OTHER EFFECTS ARE SUFFICIENTLY SIMILAR TO THE INVALID PROVISIONS THAT IT CAN
BE REASONABLY ASSUMED THAT THE PARTIES WOULD HAVE ENTERED INTO THIS AGREEMENT
WITH SUCH VALID PROVISIONS.  IN CASE SUCH VALID PROVISIONS CANNOT BE AGREED
UPON, THE INVALIDITY OF ONE OR SEVERAL PROVISIONS OF THIS AGREEMENT SHALL NOT
AFFECT THE VALIDITY OF THIS AGREEMENT AS A WHOLE OR THE VALIDITY OF ANY PORTIONS
HEREOF, UNLESS THE INVALID PROVISIONS ARE OF SUCH ESSENTIAL IMPORTANCE TO THIS
AGREEMENT THAT IT IS TO BE REASONABLY ASSUMED THAT THE PARTIES WOULD NOT HAVE
ENTERED INTO THIS AGREEMENT WITHOUT THE INVALID PROVISIONS.

 

13.4.                        NOTICES.  ANY CONSENT, NOTICE OR REPORT REQUIRED OR
PERMITTED TO BE GIVEN OR MADE UNDER THIS AGREEMENT BY ONE OF THE PARTIES HERETO
TO THE OTHER SHALL BE IN WRITING, DELIVERED PERSONALLY OR BY COURIER, POSTAGE
PREPAID (WHERE APPLICABLE), ADDRESSED TO SUCH OTHER PARTY AT ITS ADDRESS
INDICATED BELOW, OR TO SUCH OTHER ADDRESS AS THE ADDRESSEE SHALL HAVE LAST
FURNISHED IN WRITING TO THE ADDRESSOR AND SHALL BE EFFECTIVE UPON RECEIPT BY THE
ADDRESSEE.

 

If to EPIX:

 

EPIX Medical, Inc.

 

 

71 Rogers Street

 

 

Cambridge, Massachusetts 02142-1118

 

 

Attention:  Chief Executive Officer

 

 

 

with a copy to:

 

Mintz Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

 

27

--------------------------------------------------------------------------------

 

 

 

One Financial Center

 

 

Boston, Massachusetts 02111

 

 

Attention:  William T. Whelan, Esq.

 

 

 

If to Schering:

 

Schering Aktiengesellschaft

 

 

13342 Berlin

 

 

Germany

 

 

Attention:  Head of Diagnostic Imaging SBU

 

 

 

with a copy to:

 

Schering Aktiengesellschaft

 

 

13342 Berlin

 

 

Germany

 

 

Attention:  Legal Department

 

13.5.                        APPLICABLE LAW.  THIS AGREEMENT SHALL BE GOVERNED
BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT
GIVING EFFECT TO THE CHOICE OF LAWS PROVISIONS THEREOF.

 

13.6.                        DISPUTE RESOLUTION.

 

13.6.1.               SUBJECT TO ANY OTHER DISPUTE RESOLUTION PRINCIPLES AND
MECHANISMS SET FORTH IN THIS AGREEMENT THE PARTIES HEREBY AGREE THAT THEY WILL
ATTEMPT IN GOOD FAITH TO, RESOLVE ANY CONTROVERSY OR CLAIM ARISING OUT OF OR
RELATING TO THIS AGREEMENT PROMPTLY BY NEGOTIATIONS.  IF A CONTROVERSY OR CLAIM
SHOULD ARISE HEREUNDER, THE REPRESENTATIVES OF THE PARTIES WILL CONFER AT LEAST
ONCE AND WILL ATTEMPT TO RESOLVE THE MATTER.   IF THE MATTER HAS NOT BEEN
RESOLVED WITHIN SIXTY (60) DAYS OF THEIR FIRST MEETING, THE REPRESENTATIVES
SHALL REFER THE MATTER TO THE CHIEF EXECUTIVE OFFICER OF EPIX AND THE HEAD OF
SCHERING’S STRATEGIC BUSINESS UNIT (SBU) DIAGNOSTICS (DG) & RADIOPHARMACEUTICALS
(RP).  IF THE MATTER HAS NOT BEEN RESOLVED WITHIN SIXTY (60) DAYS OF THE FIRST
MEETING OF THE CHIEF EXECUTIVE OFFICER OF EPIX AND THE HEAD OF SCHERING’S SBU DG
& RP (WHICH PERIOD MAY BE EXTENDED BY MUTUAL AGREEMENT), THEN THE MATTER SHALL
BE DECIDED BY THE HEAD OF SCHERING’S SBU DG & RP IF THE DISPUTE IS RELATED TO
DEVELOPMENT ISSUES OR THE FINANCING THEREOF. SUBJECT TO RIGHTS TO INJUNCTIVE
RELIEF AND SPECIFIC PERFORMANCE, AND UNLESS OTHERWISE SPECIFICALLY PROVIDED FOR
HEREIN, ANY OTHER CONTROVERSY OR CLAIM ARISING OUT OF OR RELATING TO THIS
AGREEMENT, OR THE BREACH THEREOF, WILL BE SETTLED AS SET FORTH IN
SECTION 13.6.2.

 

13.6.2.               ALL DISPUTES, CONTROVERSIES OR DIFFERENCES WHICH MAY ARISE
BETWEEN THE PARTIES OUT OF OR IN RELATION TO THIS AGREEMENT OR ANY DEFAULT OR
BREACH THEREOF MAY BE RESOLVED BY ARBITRATION IN ACCORDANCE WITH THE COMMERCIAL
ARBITRATION RULES (EXCEPT AS OTHERWISE SPECIFIED HEREIN) OF THE AMERICAN
ARBITRATION ASSOCIATION BY THREE ARBITRATORS, ONE TO BE SELECTED BY EACH OF THE
PARTIES FROM A LIST OF ARBITRATORS SUPPLIED BY THE AMERICAN ARBITRATION
ASSOCIATION WITHIN THIRTY DAYS OF RECEIPT OF SUCH LIST, AND A THIRD TO BE
SELECTED BY THE FIRST TWO FROM SUCH LIST WITHIN A REASONABLE TIME. THE
ARBITRATORS SHALL BE EXPERIENCED IN THE SUBJECT MATTER OF THE ARBITRATION (FOR
EXAMPLE, ARBITRATION OF A SCIENTIFIC ISSUE WOULD REQUIRE APPOINTMENT OF
ARBITRATORS WITH KNOWLEDGE OF THE RELEVANT AREA OF SCIENCE).  THE ARBITRATION
SHALL TAKE PLACE IN NEW YORK, NEW YORK.  EITHER PARTY MAY INITIATE AN
ARBITRATION BY WRITTEN NOTICE TO THE OTHER PARTY, SUCH NOTICE

 

28

--------------------------------------------------------------------------------

 

SHALL SET FORTH THE PARTICULARS OF THE ISSUE TO BE ARBITRATED IN SUFFICIENT
DETAIL TO PERMIT THE PARTY RECEIVING THE NOTICE TO CONDUCT AN INVESTIGATION AND
FORMULATE A POSITION (SUCH NOTICE SHALL NOT PRECLUDE THE PARTIES FROM ATTEMPTING
TO INFORMALLY SETTLE THEIR DIFFERENCES).  THE ARBITRATORS SHALL SELECT ONE OF
THEIR NUMBER TO SERVE AS PRESIDING ARBITRATOR, WITH THE RESPONSIBILITY FOR
HANDLING ADMINISTRATIVE MATTERS RELATING TO THE ARBITRATION.  WITHIN SIXTY DAYS
OF WRITTEN NOTICE TO THE PARTIES OF THE SELECTION OF THE THIRD ARBITRATOR, EACH
PARTY SHALL CONTEMPORANEOUSLY SUBMIT IN WRITING TO THE PRESIDING ARBITRATOR AND
THE OTHER PARTY ITS POSITION FOR THE RESOLUTION OF THE ISSUE THAT IS THE SUBJECT
MATTER OF THE ARBITRATION.  AT THE REQUEST OF EITHER PARTY, TO BE SUBMITTED TO
THE PRESIDING ARBITRATOR AND THE OTHER PARTY WITHIN SIXTY DAYS RECEIPT OF THE
WRITTEN POSITION OF THE OTHER PARTY, THE ARBITRATORS SHALL SCHEDULE IN-PERSON
PRESENTATIONS OF THE PARTIES (AT WHICH BOTH PARTIES AND ALL THREE ARBITRATORS
SHALL BE PRESENT), WHICH MAY INCLUDE THE PRESENTATION OF WITNESSES, ORAL
ARGUMENT, OR BOTH, AT THE DISCRETION OF EACH OF THE PARTIES, AND WHICH SHALL NOT
EXCEED FIVE HOURS FOR EACH OF THE PARTIES.  THE IN-PERSON PRESENTATIONS SHALL BE
SCHEDULED BY THE ARBITRATORS AT THEIR CONVENIENCE AND THE REASONABLE CONVENIENCE
OF THE PARTIES, BUT SHALL BE HELD WITHIN NINETY AND ONE HUNDRED FIFTY DAYS OF
RECEIPT BY THE PRESIDING ARBITRATOR OF THE FIRST REQUEST FOR AN IN-PERSON
PRESENTATION.  IF NEITHER PARTY MAKES A REQUEST FOR AN IN-PERSON PRESENTATION,
THEN THE DECISION OF THE ARBITRATORS SHALL BE BASED SOLELY ON THE WRITTEN
POSITIONS OF THE PARTIES.  THE ARBITRATORS SHALL HAVE THE POWER ONLY TO SELECT
ONE OF THE PARTY’S POSITIONS, AND THE DECISION OF ANY TWO OF THE ARBITRATORS
SHALL BE THE RESULT OF THE ARBITRATION.  THE NON-PREVAILING PARTY SHALL BEAR THE
COSTS OF THE ARBITRATION.  THE DECISION RESULTING FROM THE ARBITRATION PROVIDED
FOR HEREIN SHALL BE FINAL AND BINDING ON THE PARTIES HERETO.  NOTWITHSTANDING
THE ABOVE, WITHOUT RESORT TO ARBITRATION IN THE FIRST INSTANCE, EITHER PARTY HAS
THE RIGHT TO BRING SUIT AGAINST THE OTHER PARTY FOR (I) ANY BREACH OF SUCH OTHER
PARTY’S DUTIES OF CONFIDENTIALITY PURSUANT TO ARTICLE 9 OF THIS AGREEMENT AND
(II) ANY INFRINGEMENT OF ITS OWN PROPRIETARY RIGHTS BY THE OTHER PARTY. 
JUDGMENT UPON THE ARBITRATORS’ AWARD MAY BE ENTERED IN ANY COURT OF COMPETENT
JURISDICTION.  THE PARTIES AGREE NOT TO INSTITUTE ANY LITIGATION OR PROCEEDINGS
AGAINST EACH OTHER IN CONNECTION WITH THIS AGREEMENT UNLESS THEY HAVE COMPLIED
WITH THE PROVISIONS OF THIS SECTION 13.6, AS THEY MAY BE APPLICABLE, UNLESS
OTHERWISE PROVIDED HEREIN.

 

13.7.                        PUBLIC ANNOUNCEMENTS.  ANY PROVISION OF ARTICLE 9
TO THE CONTRARY NOTWITHSTANDING, THE PARTIES AGREE THAT PRESS RELEASES AND OTHER
ANNOUNCEMENTS TO BE MADE BY EITHER OF THEM IN RELATION TO THIS AGREEMENT SHALL
BE SUBJECT TO THE WRITTEN CONSENT OF THE OTHER PARTY, WHICH CONSENT SHALL NOT BE
UNREASONABLY WITHHELD OR DELAYED, EXCEPT TO THE EXTENT THAT ANY SUCH PRESS
RELEASE IS REQUIRED TO BE MADE BY LAW OR THE RULES OF ANY RELEVANT NATIONAL
STOCK EXCHANGE AND THE CONSENT OF THE OTHER PARTY IS NOT OBTAINED AFTER
REASONABLE EFFORTS TO DO SO.  THE PARTIES WILL AGREE TO ISSUE A JOINT PRESS
RELEASE IMMEDIATELY FOLLOWING THE EXECUTION OF THIS AGREEMENT, THE FORM AND
CONTENT OF WHICH SHALL BE REASONABLY SATISFACTORY TO BOTH PARTIES.

 

13.8.                        ENTIRE AGREEMENT; AMENDMENT.  THIS AGREEMENT,
TOGETHER WITH THE EXHIBITS HERETO, CONTAINS THE ENTIRE UNDERSTANDING OF THE
PARTIES WITH RESPECT TO THE SUBJECT MATTER HEREOF.  ALL EXPRESS OR IMPLIED
AGREEMENTS AND UNDERSTANDINGS, EITHER ORAL OR WRITTEN, HERETOFORE MADE ARE
EXPRESSLY SUPERCEDED MERGED BY THIS AGREEMENT.  THIS AGREEMENT MAY BE AMENDED,
OR ANY TERM HEREOF MODIFIED, ONLY BY A WRITTEN INSTRUMENT DULY EXECUTED BY BOTH
PARTIES HERETO.

 

29

--------------------------------------------------------------------------------

 

13.9.                        HEADINGS.  THE CAPTIONS TO THE SEVERAL ARTICLES AND
SECTIONS HEREOF ARE NOT A PART OF THIS AGREEMENT, BUT ARE MERELY GUIDES OR
LABELS TO ASSIST IN LOCATING AND READING THE SEVERAL ARTICLES AND SECTIONS
HEREOF.

 

13.10.                  AGREEMENT NOT TO SOLICIT EMPLOYEES.  DURING THE TERM AND
FOR A PERIOD OF TWO (2) YEARS FOLLOWING THE EXPIRATION PURSUANT TO SECTION 13.1
OR TERMINATION PURSUANT TO SECTIONS 12.2., OR 12.3. OF THIS AGREEMENT, EPIX AND
SCHERING AGREE NOT TO SEEK TO PERSUADE OR INDUCE ANY EMPLOYEE OF THE OTHER
COMPANY TO DISCONTINUE HIS OR HER EMPLOYMENT WITH THAT COMPANY IN ORDER TO
BECOME EMPLOYED BY OR ASSOCIATED WITH ANY BUSINESS, ENTERPRISE OR EFFORT THAT IS
ASSOCIATED WITH ITS OWN BUSINESS.

 

13.11.                  EXPORTS.  THE PARTIES ACKNOWLEDGE THAT THE EXPORT OF
TECHNICAL DATA, MATERIALS OR PRODUCTS IS SUBJECT TO THE EXPORTING PARTY
RECEIVING ANY NECESSARY EXPORT LICENSES AND THAT THE PARTIES CANNOT BE
RESPONSIBLE FOR ANY DELAYS ATTRIBUTABLE TO EXPORT CONTROLS WHICH ARE BEYOND THE
REASONABLE CONTROL OF EITHER PARTY.  EPIX AND SCHERING AGREE NOT TO EXPORT OR
RE-EXPORT, DIRECTLY OR INDIRECTLY, ANY INFORMATION, TECHNICAL DATA, THE DIRECT
PRODUCT OF SUCH DATA, SAMPLES OR EQUIPMENT RECEIVED OR GENERATED UNDER THIS
AGREEMENT IN VIOLATION OF ANY APPLICABLE EXPORT CONTROL LAWS OR GOVERNMENTAL
REGULATIONS.  EPIX AND SCHERING AGREE TO OBTAIN SIMILAR COVENANTS FROM THEIR
LICENSEES, SUBLICENSEES AND CONTRACTORS WITH RESPECT TO THE SUBJECT MATTER OF
THIS SECTION 13.11.

 

13.12.                  WAIVER.  THE WAIVER BY EITHER PARTY HERETO OF ANY RIGHT
HEREUNDER OR THE FAILURE TO PERFORM OR OF A BREACH BY THE OTHER PARTY SHALL NOT
BE DEEMED A WAIVER OF ANY OTHER RIGHT HEREUNDER OR OF ANY OTHER BREACH OR
FAILURE BY SAID OTHER PARTY WHETHER OF A SIMILAR NATURE OR OTHERWISE.

 

13.13.                  COUNTERPARTS.  THIS AGREEMENT MAY BE EXECUTED IN TWO OR
MORE COUNTERPARTS, EACH OF WHICH SHALL BE DEEMED AN ORIGINAL, BUT ALL OF WHICH
TOGETHER SHALL CONSTITUTE ONE AND THE SAME INSTRUMENT.

 

13.14.                  INDEPENDENT CONTRACTORS; NEGATION OF PARTNERSHIP.  THE
RELATIONSHIP OF EPIX AND SCHERING ESTABLISHED BY THIS AGREEMENT IS THAT OF
INDEPENDENT CONTRACTORS, AND NOTHING CONTAINED IN THIS AGREEMENT SHALL BE
CONSTRUED TO GIVE EITHER PARTY THE POWER TO DIRECT OR CONTROL THE DAY-TO-DAY
ACTIVITIES OF THE OTHER, OR ALLOW ONE PARTY TO CREATE OR ASSUME AN OBLIGATION ON
BEHALF OF THE OTHER PARTY FOR ANY PURPOSE WHATSOEVER.  THIS AGREEMENT IS NOT
INTENDED TO CREATE A PARTNERSHIP BETWEEN EPIX AND SCHERING FOR UNITED STATES
FEDERAL INCOME TAX PURPOSES (AS DEFINED IN SECTION 761 OF THE INTERNAL REVENUE
CODE), FOR ANY STATE OR LOCAL JURISDICTION IN THE UNITED STATES, OR FOR ANY
COUNTRY OTHER THAN THE UNITED STATES.  THEREFORE, THERE IS NO REQUIREMENT IN THE
UNITED STATES TO FILE FORM 1065, UNITED STATES PARTNERSHIP RETURN OF INCOME, OR
ANY SIMILAR STATE OR LOCAL INCOME TAX RETURN IN ANY POLITICAL SUBDIVISION OF THE
UNITED STATES, OR ANY SIMILAR TAX DOCUMENT IN ANY COUNTRY OTHER THAN THE UNITED
STATES, IN REGARD TO THE CONTRACTUAL RELATIONSHIP DESCRIBED IN THIS AGREEMENT.

 

13.15.                  AMBIGUITIES.  THE PARTIES ACKNOWLEDGE AND AGREE THAT:
(I) EACH PARTY AND ITS COUNSEL REVIEWED AND NEGOTIATED THE TERMS AND PROVISIONS
OF THIS AGREEMENT AND HAVE

 

30

--------------------------------------------------------------------------------

 

CONTRIBUTED TO ITS REVISION; (II) THE RULE OF CONSTRUCTION TO THE EFFECT THAT
ANY AMBIGUITIES ARE RESOLVED AGAINST THE DRAFTING PARTY SHALL NOT BE EMPLOYED IN
THE INTERPRETATION OF THIS AGREEMENT; AND (III) THE TERMS AND PROVISIONS OF THIS
AGREEMENT SHALL BE CONSTRUED FAIRLY AS TO ALL PARTIES HERETO AND NOT IN A FAVOR
OF OR AGAINST ANY PARTY, REGARDLESS OF WHICH PARTY WAS GENERALLY RESPONSIBLE FOR
THE PREPARATION OF THIS AGREEMENT.

 

[Signature page shall follow]

 

31

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date
first set forth above.

 

 

EPIX MEDICAL, INC.

 

 

 

 

 

By:

 

 

 

 

Michael D. Webb

 

 

Chief Executive Officer

 

 

 

 

 

SCHERING AKTIENGESELLSCHAFT

 

 

 

 

 

By:

 

 

 

 

Prof. Dr. Günter Stock

 

 

Member of the Vorstand

 

 

 

 

 

By:

 

 

 

 

Hans-Michael Rook

 

 

Head SBU DG & RP

 

 

32

--------------------------------------------------------------------------------

 

Exhibit 1.12

 

EP-2104R

[*****]

 

33

--------------------------------------------------------------------------------

 

Exhibit 1.14

 

EPIX Patent Rights

 

MET-8

 

US Application

 

[*****]

 

 

PCT

 

[*****]

 

 

 

 

 

MET-9

 

US Application

 

[*****]

 

 

PCT

 

[*****]

 

 

 

 

 

MET-14A

 

US Application

 

[*****]

MET-14B

 

US Application

 

[*****]

MET-14

 

PCT

 

[*****]

 

 

 

 

 

MET-16

 

US Publication

 

[*****]

 

 

PCT

 

[*****]

 

34

--------------------------------------------------------------------------------

 

Exhibit 1.42

 

Schering Patent Rights

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

02346A

 

NL

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

NL

 

[*****]

 

[*****]

 

04/FEB/2003

02346A

 

NO

 

 

 

[*****]

 

23/JUL/2002

02346A

 

NO

 

[*****]

 

[*****]

 

05/FEB/2003

02346A

 

SE

 

[*****]

 

[*****]

 

07/SEP/2004

02346A

 

NL

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

IT

 

[*****]

 

[*****]

 

31/DEC/2007

02346A

 

JP

 

 

 

[*****]

 

23/JUL/2002

02346A

 

LU

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

GB

 

[*****]

 

[*****]

 

04/FEB/2003

02346A

 

GB

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

GB

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

FR

 

[*****]

 

[*****]

 

21/JUN/2005

02346A

 

FR

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

FR

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

IT

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

LU

 

[*****]

 

[*****]

 

05/FEB/2003

02346A

 

LU

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

DE

 

[*****]

 

[*****]

 

05/FEB/2003

02346A

 

DE

 

 

 

[*****]

 

24/JUL/2001

02346A

 

DE 0071564

 

[*****]

 

[*****]

 

 

02346A

 

DE

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

CH

 

[*****]

 

[*****]

 

19/SEP/2003

02346A

 

CH

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

CH

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

IE

 

 

 

[*****]

 

03/FEB/2003

02346A

 

IE

 

 

 

[*****]

 

23/JUL/2002

02346A

 

AT

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

AT

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

CA

 

 

 

[*****]

 

16/AUG/2005

02346A

 

BE

 

[*****]

 

[*****]

 

 

02346A

 

BE

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

BE

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

AU

 

 

 

[*****]

 

22/JUL/2007

02346A

 

AU

 

 

 

[*****]

 

22/JUL/2002

02346A

 

AU

 

[*****]

 

[*****]

 

22/JUL/2002

02346A

 

AT

 

[*****]

 

[*****]

 

05/FEB/2003

02346A

 

CA

 

[*****]

 

[*****]

 

03/MAR/2004

02346A

 

JP

 

 

 

[*****]

 

23/JUL/2002

02346A

 

JP

 

 

 

[*****]

 

23/JUL/2002

02346A

 

IT

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

ZA

 

 

 

[*****]

 

23/JUL/2002

02346A

 

SE

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

SE

 

[*****]

 

[*****]

 

19/JUL/2002

02346A

 

NZ

 

 

 

[*****]

 

23/JUL/2002

 

35

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

02491A

 

US

 

 

 

[*****]

 

01/OCT/2013

02491A

 

US

 

 

 

 

 

 

02491A

 

US

 

 

 

[*****]

 

04/JUN/2008

02491A

 

US

 

 

 

[*****]

 

03/MAR/2004

02491A

 

US

 

 

 

[*****]

 

02/MAR/2004

02491A

 

US

 

 

 

[*****]

 

08/NOV/2011

02491A

 

US

 

 

 

[*****]

 

02/MAR/2004

02491A

 

SE

 

[*****]

 

 

 

19/JAN/2004

02491A

 

SG

 

 

 

[*****]

 

20/JAN/2004

02491A

 

JP

 

 

 

[*****]

 

18/JAN/2004

02491A

 

JP

 

 

 

[*****]

 

 

02491A

 

IT

 

 

 

[*****]

 

19/JAN/2004

02491A

 

IL

 

 

 

[*****]

 

18/JAN/2004

02491A

 

NZ

 

 

 

[*****]

 

18/JAN/2004

02491A

 

US

 

 

 

 

 

 

02491A

 

US

 

 

 

 

 

 

02491A

 

US

 

 

 

[*****]

 

02/MAR/2004

02491A

 

SG

 

 

 

[*****]

 

20/JAN/2004

02491A

 

GB

 

 

 

[*****]

 

20/JAN/2004

02491A

 

FR

 

[*****]

 

[*****]

 

19/JAN/2004

02491A

 

FR

 

[*****]

 

[*****]

 

19/JAN/2004

02491A

 

IL

 

 

 

[*****]

 

18/JAN/2004

02491A

 

NZ

 

 

 

[*****]

 

18/JAN/2004

02491A

 

NO

 

 

 

[*****]

 

20/JAN/2004

02491A

 

NL

 

[*****]

 

[*****]

 

10/JAN/2004

02491A

 

NL

 

 

 

 

 

10/JAN/2004

02491A

 

LU

 

 

 

[*****]

 

20/JAN/2004

02491A

 

BE

 

 

 

[*****]

 

19/JAN/2004

02491A

 

AU

 

[*****]

 

[*****]

 

18/JAN/2004

02491A

 

AU

 

[*****]

 

[*****]

 

18/JAN/2004

02491A

 

FI

 

[*****]

 

[*****]

 

19/JAN/2004

02491A

 

IE

 

 

 

[*****]

 

20/JAN/2004

02491A

 

IE

 

 

 

[*****]

 

20/JAN/2004

02491A

 

GR

 

 

 

[*****]

 

19/JAN/2004

02491A

 

GB

 

[*****]

 

 

 

20/JAN/2004

02491A

 

GB

 

 

 

[*****]

 

20/JAN/2004

02491A

 

AT

 

 

 

[*****]

 

15/SEP/2011

02491A

 

ES

 

 

 

[*****]

 

22/NOV/2004

02491A

 

DK

 

 

 

[*****]

 

20/JAN/2004

02491A

 

DK

 

 

 

[*****]

 

20/JAN/2004

02491A

 

CH

 

 

 

[*****]

 

20/JAN/2004

02491A

 

CA

 

 

 

[*****]

 

20/JUN/2006

02491A

 

SE

 

[*****]

 

[*****]

 

19/JAN/2004

02491A

 

PT

 

 

 

[*****]

 

09/APR/2004

02491A

 

US

 

 

 

 

 

 

02491A

 

US

 

 

 

 

 

 

02491A

 

US

 

 

 

 

 

 

02491A

 

US

 

 

 

[*****]

 

03/JUN/2008

02491A

 

ZA

 

 

 

[*****]

 

20/JAN/2004

 

36

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

02491A

 

SG

 

 

 

 

 

20/JAN/2004

02491A

 

SG

 

 

 

 

 

20/JAN/2004

02575A

 

DE

 

 

 

[*****]

 

11/JAN/2004

02575A

 

DE

 

[*****]

 

[*****]

 

11/JAN/2004

02969A

 

AT

 

[*****]

 

[*****]

 

24/JUL/2007

02969A

 

AU

 

[*****]

 

[*****]

 

27/JUL/2007

02969A

 

BE

 

[*****]

 

[*****]

 

24/JUL/2007

02969A

 

CA

 

 

 

[*****]

 

30/JAN/2018

02969A

 

CH

 

[*****]

 

[*****]

 

24/JUL/2007

02969A

 

DE

 

[*****]

 

[*****]

 

24/JUL/2007

02969A

 

DE

 

 

 

[*****]

 

28/JUL/2006

02969A

 

DK

 

 

 

[*****]

 

28/JUL/2007

02969A

 

ES

 

[*****]

 

[*****]

 

24/JUL/2007

02969A

 

FR

 

[*****]

 

[*****]

 

24/JUL/2007

02969A

 

GB

 

[*****]

 

[*****]

 

24/JUL/2007

02969A

 

GR

 

[*****]

 

[*****]

 

24/JUL/2007

02969A

 

IE

 

 

 

[*****]

 

28/JUL/2007

02969A

 

IT

 

[*****]

 

[*****]

 

24/JUL/2007

02969A

 

JP

 

 

 

[*****]

 

28/JUL/2007

02969A

 

LU

 

[*****]

 

[*****]

 

24/JUL/2007

02969A

 

NL

 

[*****]

 

[*****]

 

24/JUL/2007

02969A

 

NO

 

 

 

[*****]

 

27/JUL/2007

02969A

 

NZ

 

 

 

[*****]

 

28/JUL/2007

02969A

 

PT

 

 

 

[*****]

 

03/DEC/2007

02969A

 

SE

 

[*****]

 

[*****]

 

24/JUL/2007

02969A

 

US

 

 

 

 

 

 

02969A

 

US

 

 

 

[*****]

 

16/FEB/2016

02969A

 

US

 

 

 

 

 

 

02969A

 

US

 

 

 

 

 

 

02969A

 

US

 

 

 

 

 

 

02969A

 

US

 

 

 

 

 

 

02969A

 

ZA

 

 

 

[*****]

 

28/JUL/2007

03035A

 

AT

 

[*****]

 

[*****]

 

23/NOV/2007

03035A

 

AU

 

[*****]

 

[*****]

 

27/NOV/2007

03035A

 

AU

 

 

 

 

 

 

03035A

 

BE

 

[*****]

 

[*****]

 

23/NOV/2007

03035A

 

CA

 

 

 

[*****]

 

14/SEP/2010

03035A

 

CH

 

[*****]

 

[*****]

 

23/NOV/2007

03035A

 

DE

 

[*****]

 

[*****]

 

23/NOV/2007

03035A

 

DE

 

 

 

[*****]

 

28/NOV/2006

03035A

 

DK

 

 

 

[*****]

 

10/NOV/2007

03035A

 

ES

 

[*****]

 

[*****]

 

23/NOV/2007

03035A

 

FR

 

[*****]

 

[*****]

 

23/NOV/2007

03035A

 

GB

 

[*****]

 

[*****]

 

23/NOV/2007

03035A

 

GR

 

[*****]

 

[*****]

 

23/NOV/2007

03035A

 

IE

 

 

 

[*****]

 

27/NOV/2007

03035A

 

IL

 

 

 

[*****]

 

25/NOV/2007

03035A

 

IT

 

[*****]

 

[*****]

 

23/NOV/2007

03035A

 

JP

 

 

 

[*****]

 

27/NOV/2007

 

37

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

03035A

 

LU

 

[*****]

 

[*****]

 

23/NOV/2007

03035A

 

NL

 

[*****]

 

[*****]

 

23/NOV/2007

03035A

 

NO

 

 

 

[*****]

 

27/NOV/2007

03035A

 

NZ

 

 

 

[*****]

 

25/NOV/2007

03035A

 

PT

 

 

 

[*****]

 

06/MAR/2008

03035A

 

SE

 

[*****]

 

[*****]

 

23/NOV/2007

03035A

 

US

 

 

 

[*****]

 

24/MAR/2009

03035A

 

US

 

 

 

 

 

 

03035A

 

US

 

 

 

[*****]

 

02/MAR/2016

03035A

 

US

 

 

 

 

 

30/NOV/2007

03035A

 

US

 

 

 

 

 

 

03035A

 

ZA

 

 

 

[*****]

 

27/NOV/2007

03193A

 

DE

 

[*****]

 

[*****]

 

27/FEB/2009

03193A

 

JP

 

 

 

[*****]

 

 

03193A

 

US

 

 

 

[*****]

 

28/OCT/2014

03193A

 

US

 

 

 

[*****]

 

28/OCT/2014

03226A

 

DE

 

[*****]

 

[*****]

 

17/MAR/2009

03226A

 

US

 

 

 

[*****]

 

08/FEB/2011

03226A

 

US

 

 

 

 

 

 

50116A

 

DE

 

[*****]

 

[*****]

 

11/AUG/2009

50116A

 

US

 

 

 

[*****]

 

04/JAN/2011

50235A

 

AT

 

[*****]

 

[*****]

 

27/JUN/2010

50235A

 

AU

 

[*****]

 

[*****]

 

29/JUN/2010

50235A

 

BE

 

[*****]

 

[*****]

 

27/JUN/2010

50235A

 

BY

 

 

 

[*****]

 

19/NOV/2013

50235A

 

CA

 

 

 

[*****]

 

29/JUN/2010

50235A

 

CH

 

[*****]

 

[*****]

 

27/JUN/2010

50235A

 

CZ

 

 

 

[*****]

 

26/JUN/2010

50235A

 

DD

 

 

 

[*****]

 

29/JUN/2008

50235A

 

DE

 

[*****]

 

[*****]

 

27/JUN/2010

50235A

 

DK

 

[*****]

 

[*****]

 

27/JUN/2010

50235A

 

ES

 

[*****]

 

[*****]

 

27/JUN/2010

50235A

 

FI

 

 

 

[*****]

 

29/JUN/2010

50235A

 

FR

 

[*****]

 

[*****]

 

27/JUN/2010

50235A

 

GB

 

[*****]

 

[*****]

 

27/JUN/2010

50235A

 

GR

 

[*****]

 

[*****]

 

27/JUN/2010

50235A

 

HK

 

[*****]

 

[*****]

 

27/JUN/2010

50235A

 

HU

 

 

 

[*****]

 

29/JUN/2010

50235A

 

IE

 

 

 

[*****]

 

26/JUN/2010

50235A

 

IL

 

 

 

[*****]

 

21/JUN/2010

50235A

 

IT

 

[*****]

 

[*****]

 

27/JUN/2010

50235A

 

JP

 

 

 

[*****]

 

29/JUN/2010

50235A

 

KR

 

 

 

[*****]

 

27/JUN/2010

50235A

 

LU

 

[*****]

 

[*****]

 

27/JUN/2010

50235A

 

NL

 

[*****]

 

[*****]

 

27/JUN/2010

50235A

 

NO

 

 

 

[*****]

 

29/JUN/2010

50235A

 

NZ

 

[*****]

 

[*****]

 

28/JUN/2010

50235A

 

PT

 

 

 

[*****]

 

25/NOV/2011

50235A

 

RU

 

 

 

[*****]

 

29/JUN/2010

 

38

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

50235A

 

SE

 

[*****]

 

[*****]

 

27/JUN/2010

50235A

 

SK

 

 

 

[*****]

 

26/JUN/2010

50235A

 

TW

 

 

 

[*****]

 

08/NOV/2010

50235A

 

UA

 

 

 

[*****]

 

28/JUN/2010

50235A

 

US

 

 

 

 

 

 

50235A

 

US

 

 

 

 

 

 

50235A

 

US

 

 

 

 

 

 

50235A

 

US

 

 

 

[*****]

 

25/AUG/2015

50235A

 

US

 

 

 

[*****]

 

21/MAR/2017

50235A

 

US

 

 

 

[*****]

 

09/DEC/2014

50235A

 

US

 

 

 

 

 

 

50235A

 

ZA

 

 

 

[*****]

 

29/JUN/2010

50298A

 

AT

 

[*****]

 

[*****]

 

19/NOV/2010

50298A

 

AU

 

 

 

[*****]

 

21/NOV/2010

50298A

 

BE

 

[*****]

 

[*****]

 

19/NOV/2010

50298A

 

CA

 

 

 

 

 

21/NOV/2010

50298A

 

CH

 

[*****]

 

[*****]

 

19/NOV/2010

50298A

 

DE

 

[*****]

 

[*****]

 

19/NOV/2010

50298A

 

DK

 

[*****]

 

[*****]

 

19/NOV/2010

50298A

 

ES

 

[*****]

 

[*****]

 

19/NOV/2010

50298A

 

FI

 

 

 

[*****]

 

21/NOV/2010

50298A

 

FR

 

[*****]

 

[*****]

 

19/NOV/2010

50298A

 

GB

 

[*****]

 

[*****]

 

19/NOV/2010

50298A

 

GR

 

[*****]

 

[*****]

 

19/NOV/2010

50298A

 

IE

 

 

 

[*****]

 

21/NOV/2010

50298A

 

IL

 

 

 

[*****]

 

21/NOV/2010

50298A

 

IT

 

[*****]

 

[*****]

 

19/NOV/2010

50298A

 

JP

 

 

 

[*****]

 

21/NOV/2010

50298A

 

KR

 

 

 

[*****]

 

21/NOV/2010

50298A

 

LU

 

[*****]

 

[*****]

 

19/NOV/2010

50298A

 

NL

 

[*****]

 

[*****]

 

19/NOV/2010

50298A

 

NO

 

 

 

[*****]

 

21/NOV/2010

50298A

 

NZ

 

[*****]

 

[*****]

 

20/NOV/2010

50298A

 

PT

 

 

 

[*****]

 

22/SEP/2014

50298A

 

SE

 

[*****]

 

[*****]

 

19/NOV/2010

50298A

 

US

 

 

 

[*****]

 

22/JUL/2014

50298A

 

US

 

 

 

[*****]

 

21/NOV/2010

50298A

 

US

 

 

 

[*****]

 

21/NOV/2010

50298A

 

US

 

 

 

[*****]

 

21/NOV/2010

50298A

 

US

 

 

 

[*****]

 

21/NOV/2010

50298A

 

US

 

 

 

[*****]

 

21/NOV/2010

50298A

 

US

 

 

 

 

 

21/NOV/2010

50298A

 

US

 

 

 

[*****]

 

15/NOV/2011

50298A

 

ZA

 

 

 

[*****]

 

21/NOV/2010

50298A

 

US

 

 

 

 

 

21/NOV/2010

50340A

 

AT

 

[*****]

 

[*****]

 

18/MAR/2011

50340A

 

AU

 

[*****]

 

[*****]

 

19/MAR/2011

50340A

 

AU

 

 

 

[*****]

 

19/MAR/2016

50340A

 

BE

 

[*****]

 

[*****]

 

18/MAR/2011

 

39

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

50340A

 

BE

 

[*****]

 

[*****]

 

24/JAN/2015

50340A

 

CA

 

 

 

[*****]

 

18/MAR/2011

50340A

 

CH

 

[*****]

 

[*****]

 

18/MAR/2011

50340A

 

CH

 

[*****]

 

[*****]

 

26/FEB/2013

50340A

 

DE

 

[*****]

 

[*****]

 

18/MAR/2011

50340A

 

DE

 

 

 

[*****]

 

24/JAN/2015

50340A

 

DK

 

[*****]

 

[*****]

 

18/MAR/2011

50340A

 

DK

 

 

 

 

 

18/MAR/2016

50340A

 

ES

 

[*****]

 

[*****]

 

18/MAR/2011

50340A

 

FI

 

 

 

[*****]

 

19/MAR/2011

50340A

 

FI

 

 

 

 

 

19/MAR/2016

50340A

 

FR

 

[*****]

 

[*****]

 

18/MAR/2011

50340A

 

GB

 

[*****]

 

[*****]

 

18/MAR/2011

50340A

 

GR

 

[*****]

 

[*****]

 

18/MAR/2011

50340A

 

GR

 

 

 

 

 

18/MAR/2016

50340A

 

HK

 

[*****]

 

[*****]

 

18/MAR/2011

50340A

 

HU

 

 

 

[*****]

 

18/MAR/2011

50340A

 

IE

 

 

 

[*****]

 

19/MAR/2011

50340A

 

IL

 

 

 

[*****]

 

19/MAR/2011

50340A

 

IT

 

[*****]

 

[*****]

 

18/MAR/2011

50340A

 

IT

 

[*****]

 

[*****]

 

18/MAR/2016

50340A

 

JP

 

 

 

[*****]

 

18/MAR/2011

50340A

 

LU

 

[*****]

 

[*****]

 

18/MAR/2011

50340A

 

NL

 

[*****]

 

[*****]

 

18/MAR/2011

50340A

 

NO

 

 

 

[*****]

 

18/MAR/2011

50340A

 

NO

 

 

 

 

 

18/MAR/2016

50340A

 

NZ

 

 

 

[*****]

 

18/MAR/2011

50340A

 

 

 

[*****]

 

[*****]

 

 

50340A

 

PT

 

 

 

 

 

24/FEB/2017

50340A

 

SE

 

[*****]

 

[*****]

 

18/MAR/2011

50340A

 

SE

 

 

 

[*****]

 

18/MAR/2016

50340A

 

US

 

 

 

[*****]

 

09/NOV/2016

50340A

 

US

 

 

 

[*****]

 

19/MAR/2011

50340A

 

US

 

[*****]

 

 

 

19/MAR/2011

50340A

 

US

 

 

 

 

 

 

50340A

 

US

 

 

 

 

 

 

50340A

 

US

 

 

 

 

 

 

50351A

 

DE

 

[*****]

 

[*****]

 

05/APR/2011

50351A

 

FR

 

[*****]

 

[*****]

 

05/APR/2011

50351A

 

GB

 

[*****]

 

[*****]

 

05/APR/2011

50351A

 

IE

 

 

 

[*****]

 

08/APR/2011

50351A

 

IT

 

[*****]

 

[*****]

 

05/APR/2011

50351A

 

JP

 

 

 

[*****]

 

04/APR/2011

50351A

 

NO

 

 

 

[*****]

 

05/APR/2011

50351A

 

US

 

 

 

[*****]

 

12/JAN/2016

50351A

 

US

 

 

 

[*****]

 

08/APR/2011

50351A

 

US

 

 

 

[*****]

 

01/DEC/2015

50351A

 

US

 

 

 

 

 

08/APR/2011

50351A

 

US

 

 

 

 

 

 

 

40

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

50351A

 

US

 

 

 

 

 

08/APR/2011

50384A

 

IE

 

 

 

[*****]

 

08/NOV/2011

50384A

 

AT

 

[*****]

 

[*****]

 

07/NOV/2011

50384A

 

BE

 

[*****]

 

[*****]

 

07/NOV/2011

50384A

 

CH

 

[*****]

 

[*****]

 

07/NOV/2011

50384A

 

DE

 

[*****]

 

[*****]

 

07/NOV/2011

50384A

 

DK

 

[*****]

 

[*****]

 

07/NOV/2011

50384A

 

ES

 

[*****]

 

[*****]

 

07/NOV/2011

50384A

 

FR

 

[*****]

 

[*****]

 

07/NOV/2011

50384A

 

GB

 

[*****]

 

[*****]

 

07/NOV/2011

50384A

 

GR

 

[*****]

 

[*****]

 

07/NOV/2011

50384A

 

IT

 

[*****]

 

[*****]

 

07/NOV/2011

50384A

 

JP

 

 

 

[*****]

 

 

50384A

 

LU

 

[*****]

 

[*****]

 

07/NOV/2011

50384A

 

NL

 

[*****]

 

[*****]

 

07/NOV/2011

50384A

 

PT

 

 

 

[*****]

 

19/JAN/2014

50384A

 

SE

 

[*****]

 

[*****]

 

07/NOV/2011

50384A

 

US

 

 

 

[*****]

 

08/NOV/2011

50396B

 

CA

 

 

 

 

 

04/DEC/2012

50396B

 

CZ

 

 

 

[*****]

 

04/DEC/2012

50396B

 

DE

 

[*****]

 

 

 

06/DEC/2011

50396B

 

EP

 

[*****]

 

[*****]

 

03/DEC/2012

50396B

 

HU

 

 

 

 

 

04/DEC/2012

50396B

 

IL

 

[*****]

 

[*****]

 

06/DEC/2012

50396B

 

JP

 

 

 

 

 

07/DEC/2012

50396B

 

NO

 

 

 

[*****]

 

04/DEC/2012

50396B

 

NO

 

 

 

[*****]

 

04/DEC/2012

50396B

 

NO

 

 

 

[*****]

 

04/DEC/2012

50396B

 

NO

 

 

 

[*****]

 

04/DEC/2012

50396B

 

NO

 

 

 

[*****]

 

04/DEC/2012

50396B

 

SK

 

 

 

[*****]

 

04/DEC/2012

50396B

 

US

 

 

 

[*****]

 

06/DEC/2012

50396B

 

US

 

 

 

 

 

 

50396B

 

AT

 

 

 

[*****]

 

03/DEC/2012

50396B

 

BE

 

 

 

 

 

03/DEC/2012

50396B

 

DK

 

 

 

 

 

03/DEC/2012

50396B

 

FR

 

 

 

 

 

03/DEC/2012

50396B

 

LU

 

 

 

 

 

03/DEC/2012

50396B

 

NL

 

 

 

 

 

03/DEC/2012

50396B

 

ES

 

 

 

 

 

03/DEC/2012

50396B

 

CH

 

 

 

 

 

03/DEC/2012

50396B

 

GR

 

 

 

 

 

03/DEC/2012

50396B

 

GB

 

 

 

 

 

03/DEC/2012

50396B

 

SE

 

 

 

 

 

03/DEC/2012

50396B

 

PT

 

 

 

 

 

03/DEC/2012

50396B

 

MC

 

 

 

 

 

03/DEC/2012

50396B

 

IT

 

 

 

 

 

03/DEC/2012

50396B

 

IE

 

 

 

 

 

03/DEC/2012

50396B

 

DE

 

 

 

[*****]

 

03/DEC/2012

 

41

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

50449A

 

AT

 

[*****]

 

[*****]

 

13/APR/2012

50449A

 

AU

 

[*****]

 

[*****]

 

11/MAY/2012

50449A

 

BE

 

[*****]

 

[*****]

 

13/APR/2012

50449A

 

CA

 

 

 

[*****]

 

13/MAY/2012

50449A

 

CH

 

[*****]

 

[*****]

 

13/APR/2012

50449A

 

DE

 

[*****]

 

[*****]

 

13/APR/2012

50449A

 

DK

 

[*****]

 

[*****]

 

13/APR/2012

50449A

 

ES

 

[*****]

 

[*****]

 

13/APR/2012

50449A

 

FR

 

[*****]

 

[*****]

 

13/APR/2012

50449A

 

GB

 

[*****]

 

[*****]

 

13/APR/2012

50449A

 

GR

 

[*****]

 

[*****]

 

13/APR/2012

50449A

 

IE

 

 

 

[*****]

 

19/MAY/2012

50449A

 

IL

 

 

 

[*****]

 

20/MAY/2012

50449A

 

IT

 

[*****]

 

[*****]

 

13/APR/2012

50449A

 

JP

 

 

 

[*****]

 

28/MAY/2012

50449A

 

LU

 

[*****]

 

[*****]

 

13/APR/2012

50449A

 

MC

 

[*****]

 

[*****]

 

13/APR/2012

50449A

 

NL

 

[*****]

 

[*****]

 

13/APR/2012

50449A

 

NO

 

 

 

[*****]

 

05/MAY/2012

50449A

 

NZ

 

[*****]

 

[*****]

 

08/MAY/2012

50449A

 

PT

 

[*****]

 

[*****]

 

13/APR/2012

50449A

 

SE

 

[*****]

 

[*****]

 

13/APR/2012

50449A

 

US

 

 

 

[*****]

 

27/JUN/2012

50449A

 

ZA

 

 

 

[*****]

 

07/MAY/2012

50479A

 

AT

 

[*****]

 

[*****]

 

28/MAY/2013

50479A

 

BE

 

[*****]

 

[*****]

 

28/MAY/2013

50479A

 

CA

 

 

 

 

 

28/MAY/2013

50479A

 

CH

 

[*****]

 

[*****]

 

28/MAY/2013

50479A

 

CZ

 

 

 

[*****]

 

28/MAY/2013

50479A

 

DE

 

[*****]

 

[*****]

 

28/MAY/2013

50479A

 

DE

 

[*****]

 

[*****]

 

04/JUN/2012

50479A

 

DK

 

[*****]

 

[*****]

 

28/MAY/2013

50479A

 

ES

 

[*****]

 

[*****]

 

28/MAY/2013

50479A

 

FR

 

[*****]

 

[*****]

 

28/MAY/2013

50479A

 

GB

 

[*****]

 

[*****]

 

28/MAY/2013

50479A

 

GR

 

[*****]

 

[*****]

 

28/MAY/2013

50479A

 

HU

 

 

 

[*****]

 

28/MAY/2013

50479A

 

IE

 

[*****]

 

[*****]

 

28/MAY/2013

50479A

 

IL

 

 

 

[*****]

 

25/MAY/2013

50479A

 

IT

 

[*****]

 

[*****]

 

28/MAY/2013

50479A

 

JP

 

 

 

 

 

28/MAY/2013

50479A

 

KR

 

 

 

[*****]

 

28/MAY/2013

50479A

 

LU

 

[*****]

 

[*****]

 

28/MAY/2013

50479A

 

MC

 

[*****]

 

[*****]

 

28/MAY/2013

50479A

 

NL

 

[*****]

 

[*****]

 

28/MAY/2013

50479A

 

NO

 

 

 

[*****]

 

28/MAY/2013

50479A

 

PT

 

[*****]

 

[*****]

 

28/MAY/2013

50479A

 

SE

 

[*****]

 

[*****]

 

28/MAY/2013

50479A

 

SK

 

 

 

[*****]

 

28/MAY/2013

 

42

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

50479A

 

US

 

 

 

[*****]

 

07/DEC/2012

50479A

 

US

 

 

 

 

 

 

50580A

 

CA

 

 

 

 

 

28/SEP/2013

50580A

 

DE

 

 

 

 

 

28/SEP/2012

50580A

 

EP

 

 

 

 

 

28/SEP/2013

50580A

 

JP

 

 

 

 

 

28/SEP/2013

50580A

 

NO

 

 

 

[*****]

 

28/SEP/2013

50580A

 

US

 

 

 

[*****]

 

15/DEC/2015

50580A

 

ZA

 

 

 

[*****]

 

28/SEP/2013

50658A

 

AT

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

AU

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

BE

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

CA

 

 

 

 

 

08/JAN/2014

50658A

 

CH

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

CN

 

[*****]

 

[*****]

 

24/JAN/2014

50658A

 

DE

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

DK

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

ES

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

FR

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

GB

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

GR

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

HU

 

 

 

[*****]

 

08/JAN/2014

50658A

 

ID

 

[*****]

 

[*****]

 

10/MAR/2014

50658A

 

IE

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

IL

 

 

 

[*****]

 

16/JAN/2014

50658A

 

IT

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

JP

 

 

 

 

 

08/JAN/2014

50658A

 

KR

 

 

 

[*****]

 

08/JAN/2014

50658A

 

LU

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

MC

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

MY

 

 

 

[*****]

 

31/JUL/2015

50658A

 

NL

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

NO

 

 

 

[*****]

 

08/JAN/2014

50658A

 

NZ

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

PT

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

SE

 

[*****]

 

[*****]

 

08/JAN/2014

50658A

 

TH

 

 

 

 

 

24/JAN/2014

50658A

 

TW

 

[*****]

 

[*****]

 

11/MAR/2014

50658A

 

US

 

 

 

[*****]

 

05/AUG/2014

50658A

 

ZA

 

 

 

[*****]

 

25/JAN/2014

50659A

 

AU

 

 

 

 

 

10/NOV/2014

50659A

 

KR

 

 

 

 

 

10/NOV/2014

50659A

 

NO

 

 

 

 

 

10/NOV/2014

50659A

 

NZ

 

 

 

 

 

10/NOV/2014

50735A

 

AT

 

[*****]

 

[*****]

 

05/NOV/2013

50735A

 

BE

 

[*****]

 

[*****]

 

05/NOV/2013

50735A

 

CA

 

 

 

 

 

04/NOV/2013

50735A

 

CH

 

[*****]

 

[*****]

 

05/NOV/2013

50735A

 

CZ

 

 

 

[*****]

 

05/NOV/2013

 

43

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

50735A

 

DE

 

[*****]

 

[*****]

 

05/NOV/2013

50735A

 

DE

 

[*****]

 

[*****]

 

06/NOV/2012

50735A

 

DK

 

[*****]

 

[*****]

 

05/NOV/2013

50735A

 

ES

 

[*****]

 

[*****]

 

05/NOV/2013

50735A

 

FR

 

[*****]

 

[*****]

 

05/NOV/2013

50735A

 

GB

 

[*****]

 

[*****]

 

05/NOV/2013

50735A

 

GR

 

[*****]

 

[*****]

 

05/NOV/2013

50735A

 

HU

 

 

 

[*****]

 

05/NOV/2013

50735A

 

IE

 

[*****]

 

[*****]

 

05/NOV/2013

50735A

 

IL

 

 

 

[*****]

 

25/OCT/2013

50735A

 

IT

 

[*****]

 

[*****]

 

05/NOV/2013

50735A

 

JP

 

 

 

 

 

05/NOV/2013

50735A

 

LU

 

[*****]

 

[*****]

 

05/NOV/2013

50735A

 

MC

 

[*****]

 

[*****]

 

05/NOV/2013

50735A

 

NL

 

[*****]

 

[*****]

 

05/NOV/2013

50735A

 

NO

 

 

 

[*****]

 

05/NOV/2013

50735A

 

PT

 

[*****]

 

[*****]

 

05/NOV/2013

50735A

 

SE

 

[*****]

 

[*****]

 

05/NOV/2013

50735A

 

SK

 

 

 

[*****]

 

05/NOV/2013

50784A

 

DE

 

[*****]

 

[*****]

 

08/JAN/2014

50856A

 

DE

 

[*****]

 

[*****]

 

29/APR/2014

50856A

 

DE

 

 

 

[*****]

 

28/MAY/2013

50856A

 

JP

 

 

 

 

 

 

50856A

 

US

 

 

 

[*****]

 

05/MAY/2015

51041A

 

AU

 

 

 

[*****]

 

02/DEC/2014

51041A

 

DE

 

[*****]

 

[*****]

 

02/DEC/2014

51041A

 

FR

 

[*****]

 

[*****]

 

02/DEC/2014

51041A

 

GB

 

[*****]

 

[*****]

 

02/DEC/2014

51041A

 

IT

 

[*****]

 

[*****]

 

02/DEC/2014

51041A

 

JP

 

 

 

 

 

 

51041A

 

US

 

 

 

[*****]

 

02/JUN/2015

51081A

 

CA

 

 

 

 

 

28/JAN/2015

51081A

 

JP

 

 

 

 

 

28/JAN/2015

51081A

 

US

 

 

 

 

 

 

51108A

 

AT

 

[*****]

 

[*****]

 

04/JUL/2015

51108A

 

PT

 

[*****]

 

[*****]

 

04/JUL/2015

51108A

 

NL

 

[*****]

 

[*****]

 

04/JUL/2015

51108A

 

LU

 

[*****]

 

[*****]

 

04/JUL/2015

51108A

 

GR

 

[*****]

 

[*****]

 

04/JUL/2015

51108A

 

DK

 

[*****]

 

[*****]

 

04/JUL/2015

51108A

 

GB

 

[*****]

 

[*****]

 

04/JUL/2015

51108A

 

CH

 

[*****]

 

[*****]

 

04/JUL/2015

51108A

 

SE

 

[*****]

 

[*****]

 

04/JUL/2015

51108A

 

ES

 

[*****]

 

[*****]

 

04/JUL/2015

51108A

 

MC

 

[*****]

 

[*****]

 

04/JUL/2015

51108A

 

BE

 

[*****]

 

[*****]

 

04/JUL/2015

51108A

 

DE

 

[*****]

 

[*****]

 

04/JUL/2015

51108A

 

IE

 

[*****]

 

[*****]

 

04/JUL/2015

51108A

 

IT

 

[*****]

 

[*****]

 

04/JUL/2015

 

44

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

51108A

 

FR

 

[*****]

 

[*****]

 

04/JUL/2015

51108A

 

AU

 

 

 

[*****]

 

04/JUL/2015

51108A

 

DE

 

 

 

 

 

07/JUL/2014

51108A

 

EP

 

[*****]

 

[*****]

 

04/JUL/2015

51108A

 

JP

 

 

 

 

 

 

51108A

 

US

 

 

 

 

 

06/JUN/2015

51108A

 

US

 

 

 

[*****]

 

05/JUN/2015

51121A

 

US

 

 

 

[*****]

 

05/JUN/2015

51121A

 

US

 

 

 

[*****]

 

05/JUN/2015

51126A

 

US

 

 

 

[*****]

 

02/JUN/2015

51130A

 

CA

 

 

 

 

 

28/MAY/2018

51130A

 

DE

 

[*****]

 

[*****]

 

02/JUN/2017

51130A

 

EP

 

 

 

[*****]

 

28/MAY/2018

51130A

 

IN

 

 

 

 

 

28/MAY/2012

51130A

 

JP

 

 

 

 

 

28/MAY/2018

51130A

 

MX

 

 

 

 

 

28/MAY/2018

51130A

 

NO

 

 

 

[*****]

 

28/MAY/2018

51130A

 

TW

 

[*****]

 

[*****]

 

01/JUN/2018

51130A

 

US

 

 

 

[*****]

 

02/JUN/2018

51130A

 

WO

 

[*****]

 

 

 

 

51130A

 

ZA

 

 

 

[*****]

 

02/JUN/2018

51142A

 

DE

 

[*****]

 

 

 

09/JUL/2016

51142A

 

EP

 

[*****]

 

[*****]

 

25/JUN/2017

51142A

 

JP

 

 

 

 

 

25/JUN/2017

51142A

 

US

 

 

 

[*****]

 

25/JUN/2017

51142A

 

WO

 

[*****]

 

 

 

 

51142A

 

FR

 

[*****]

 

[*****]

 

25/JUN/2017

51142A

 

DE

 

[*****]

 

[*****]

 

25/JUN/2017

51142A

 

GB

 

[*****]

 

[*****]

 

25/JUN/2017

51142A

 

IT

 

[*****]

 

[*****]

 

25/JUN/2017

51152A

 

DE

 

[*****]

 

 

 

21/FEB/2015

51152A

 

US

 

 

 

[*****]

 

07/JUN/2015

51155A

 

AT

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

AU

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

BE

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

BY

 

 

 

 

 

29/FEB/2016

51155A

 

CA

 

 

 

 

 

29/FEB/2016

51155A

 

CH

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

CN

 

[*****]

 

 

 

29/FEB/2016

51155A

 

DE

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

DE

 

[*****]

 

[*****]

 

01/MAR/2015

51155A

 

DK

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

ES

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

FI

 

 

 

 

 

29/FEB/2016

51155A

 

FR

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

GB

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

GR

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

HK

 

[*****]

 

 

 

29/FEB/2016

51155A

 

HU

 

 

 

[*****]

 

29/FEB/2016

 

45

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

51155A

 

IE

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

IL

 

 

 

[*****]

 

20/FEB/2016

51155A

 

IT

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

JP

 

 

 

 

 

29/FEB/2016

51155A

 

KR

 

[*****]

 

 

 

29/FEB/2016

51155A

 

LU

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

MC

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

MX

 

 

 

 

 

29/FEB/2016

51155A

 

NL

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

NO

 

 

 

[*****]

 

29/FEB/2016

51155A

 

NZ

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

PT

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

RU

 

 

 

[*****]

 

29/FEB/2016

51155A

 

SE

 

[*****]

 

[*****]

 

29/FEB/2016

51155A

 

UA

 

 

 

[*****]

 

29/FEB/2016

51155A

 

US

 

 

 

 

 

29/FEB/2016

51155A

 

VN

 

 

 

[*****]

 

01/MAR/2010

51155A

 

ZA

 

 

 

[*****]

 

01/MAR/2016

51156A

 

AT

 

[*****]

 

[*****]

 

29/JAN/2016

51156A

 

AU

 

[*****]

 

[*****]

 

29/JAN/2016

51156A

 

BE

 

[*****]

 

[*****]

 

29/JAN/2016

51156A

 

BY

 

 

 

[*****]

 

29/JAN/2016

51156A

 

CA

 

 

 

 

 

29/JAN/2016

51156A

 

CH

 

[*****]

 

[*****]

 

29/JAN/2016

51156A

 

CN

 

 

 

 

 

29/JAN/2016

51156A

 

DE

 

[*****]

 

[*****]

 

29/JAN/2016

51156A

 

DE

 

[*****]

 

[*****]

 

27/JAN/2015

51156A

 

DK

 

[*****]

 

[*****]

 

29/JAN/2016

51156A

 

ES

 

[*****]

 

[*****]

 

29/JAN/2016

51156A

 

FI

 

 

 

 

 

29/JAN/2016

51156A

 

FR

 

[*****]

 

[*****]

 

29/JAN/2016

51156A

 

GB

 

[*****]

 

[*****]

 

29/JAN/2016

51156A

 

GR

 

[*****]

 

[*****]

 

29/JAN/2016

51156A

 

HK

 

 

 

[*****]

 

29/JAN/2016

51156A

 

HU

 

 

 

[*****]

 

29/JAN/2016

51156A

 

IE

 

[*****]

 

[*****]

 

29/JAN/2016

51156A

 

IL

 

 

 

[*****]

 

26/JAN/2016

51156A

 

IT

 

[*****]

 

[*****]

 

29/JAN/2016

51156A

 

JP

 

 

 

 

 

29/JAN/2016

51156A

 

KR

 

 

 

[*****]

 

29/JAN/2016

51156A

 

LU

 

[*****]

 

[*****]

 

29/JAN/2016

51156A

 

MC

 

[*****]

 

[*****]

 

29/JAN/2016

51156A

 

MX

 

 

 

[*****]

 

29/JAN/2016

51156A

 

NL

 

[*****]

 

[*****]

 

29/JAN/2016

51156A

 

NO

 

 

 

 

 

29/JAN/2016

51156A

 

NZ

 

[*****]

 

[*****]

 

29/JAN/2016

51156A

 

PT

 

[*****]

 

[*****]

 

29/JAN/2016

51156A

 

RU

 

 

 

[*****]

 

29/JAN/2016

51156A

 

SE

 

[*****]

 

[*****]

 

29/JAN/2016

 

46

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

51156A

 

UA

 

 

 

[*****]

 

29/JAN/2016

51156A

 

US

 

 

 

[*****]

 

29/JAN/2016

51156A

 

US

 

 

 

[*****]

 

29/JAN/2016

51156A

 

VN

 

 

 

[*****]

 

29/JAN/2016

51156A

 

ZA

 

 

 

[*****]

 

26/JAN/2016

51164A

 

AU

 

[*****]

 

[*****]

 

10/JUL/2015

51164A

 

CA

 

 

 

[*****]

 

10/JUL/2015

51164A

 

CN

 

 

 

[*****]

 

10/JUL/2015

51164A

 

DE

 

 

 

[*****]

 

04/AUG/2014

51164A

 

EP

 

 

 

[*****]

 

10/JUL/2015

51164A

 

HU

 

 

 

 

 

10/JUL/2015

51164A

 

IL

 

 

 

[*****]

 

24/JUL/2015

51164A

 

IL

 

 

 

[*****]

 

24/JUL/2015

51164A

 

KR

 

 

 

[*****]

 

10/JUL/2015

51164A

 

NO

 

 

 

 

 

10/JUL/2015

51164A

 

US

 

 

 

 

 

10/JUL/2015

51164A

 

US

 

 

 

 

 

10/JUL/2015

51164A

 

US

 

 

 

 

 

10/JUL/2015

51164A

 

US

 

 

 

[*****]

 

10/JUL/2015

51164A

 

ZA

 

 

 

[*****]

 

19/JUL/2015

51201A

 

CN

 

[*****]

 

 

 

08/MAY/2015

51201A

 

CN

 

[*****]

 

 

 

08/MAY/2015

51201A

 

CN

 

[*****]

 

[*****]

 

08/MAY/2015

51201A

 

HK

 

[*****]

 

 

 

08/MAY/2015

51201A

 

HK

 

[*****]

 

 

 

08/MAY/2015

51229A

 

US

 

 

 

 

 

09/FEB/2016

51237A

 

US

 

 

 

[*****]

 

07/JUN/2015

51246A

 

CA

 

 

 

 

 

18/NOV/2016

51246A

 

JP

 

 

 

 

 

18/NOV/2016

51246A

 

NO

 

 

 

 

 

18/NOV/2016

51246A

 

US

 

 

 

 

 

18/NOV/2016

51246A

 

WO

 

[*****]

 

 

 

 

51263A

 

EP

 

 

 

 

 

26/APR/2016

51282A

 

AU

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

AU

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

BG

 

 

 

[*****]

 

20/JUN/2016

51282A

 

BR

 

 

 

 

 

20/JUN/2016

51282A

 

BY

 

 

 

 

 

20/JUN/2016

51282A

 

CA

 

 

 

 

 

20/JUN/2016

51282A

 

CN

 

[*****]

 

 

 

20/JUN/2016

51282A

 

CN

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

CZ

 

 

 

 

 

20/JUN/2016

51282A

 

DE

 

[*****]

 

 

 

04/JUL/2015

51282A

 

EP

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

HK

 

[*****]

 

 

 

20/JUN/2016

51282A

 

IL

 

 

 

 

 

20/JUN/2016

51282A

 

JP

 

 

 

 

 

20/JUN/2016

51282A

 

KR

 

[*****]

 

 

 

20/JUN/2016

51282A

 

MX

 

 

 

 

 

20/JUN/2016

 

47

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

51282A

 

NO

 

 

 

 

 

20/JUN/2016

51282A

 

NZ

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

PK

 

 

 

 

 

04/FEB/2018

51282A

 

PL

 

 

 

 

 

20/JUN/2016

51282A

 

RU

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

SK

 

 

 

 

 

20/JUN/2016

51282A

 

TW

 

 

 

 

 

26/SEP/2011

51282A

 

UA

 

 

 

 

 

20/JUN/2016

51282A

 

US

 

 

 

[*****]

 

03/JUL/2016

51282A

 

US

 

 

 

 

 

03/JUL/2016

51282A

 

US

 

 

 

[*****]

 

02/JUL/2016

51282A

 

US

 

 

 

[*****]

 

03/JUL/2016

51282A

 

US

 

 

 

[*****]

 

03/JUL/2016

51282A

 

US

 

[*****]

 

 

 

03/JUL/2016

51282A

 

US

 

 

 

[*****]

 

03/JUL/2016

51282A

 

VN

 

 

 

 

 

 

51282A

 

VN

 

 

 

 

 

04/JUL/2010

51282A

 

ZA

 

 

 

[*****]

 

04/JUL/2016

51282A

 

IL

 

 

 

 

 

20/JUN/2016

51282A

 

AT

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

CH

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

SE

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

ES

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

PT

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

MC

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

LU

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

IT

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

IE

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

GR

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

NL

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

FR

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

DK

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

GB

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

BE

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

DE

 

[*****]

 

[*****]

 

20/JUN/2016

51282A

 

FI

 

[*****]

 

[*****]

 

20/JUN/2016

51285A

 

AT

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

AU

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

BE

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

CA

 

 

 

 

 

26/FEB/2017

51285A

 

CH

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

CN

 

 

 

[*****]

 

26/FEB/2017

51285A

 

CZ

 

 

 

[*****]

 

26/FEB/2017

51285A

 

DE

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

DE

 

 

 

[*****]

 

26/FEB/2016

51285A

 

DK

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

ES

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

FI

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

FR

 

[*****]

 

[*****]

 

26/FEB/2017

 

48

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

51285A

 

GB

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

GR

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

HK

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

IE

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

IL

 

 

 

[*****]

 

26/FEB/2017

51285A

 

IT

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

JP

 

 

 

 

 

26/FEB/2017

51285A

 

KR

 

 

 

 

 

26/FEB/2017

51285A

 

LU

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

MC

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

NL

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

NO

 

 

 

[*****]

 

26/FEB/2017

51285A

 

NZ

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

PL

 

 

 

 

 

26/FEB/2017

51285A

 

PT

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

SE

 

[*****]

 

[*****]

 

26/FEB/2017

51285A

 

SK

 

 

 

[*****]

 

26/FEB/2017

51285A

 

US

 

 

 

[*****]

 

25/FEB/2017

51285A

 

US

 

 

 

 

 

16/DEC/1997

51285A

 

WO

 

[*****]

 

 

 

 

51285A

 

ZA

 

 

 

[*****]

 

26/FEB/2017

51315A

 

AT

 

[*****]

 

[*****]

 

20/DEC/2016

51315A

 

BE

 

[*****]

 

[*****]

 

20/DEC/2016

51315A

 

CA

 

 

 

 

 

20/DEC/2016

51315A

 

CH

 

[*****]

 

[*****]

 

20/DEC/2016

51315A

 

DE

 

[*****]

 

[*****]

 

20/DEC/2016

51315A

 

DE

 

[*****]

 

[*****]

 

04/JAN/2016

51315A

 

DK

 

[*****]

 

[*****]

 

20/DEC/2016

51315A

 

ES

 

[*****]

 

[*****]

 

20/DEC/2016

51315A

 

FI

 

[*****]

 

[*****]

 

20/DEC/2016

51315A

 

FR

 

[*****]

 

[*****]

 

20/DEC/2016

51315A

 

GB

 

[*****]

 

[*****]

 

20/DEC/2016

51315A

 

GR

 

[*****]

 

[*****]

 

20/DEC/2016

51315A

 

IE

 

[*****]

 

[*****]

 

20/DEC/2016

51315A

 

IT

 

[*****]

 

[*****]

 

20/DEC/2016

51315A

 

JP

 

 

 

 

 

20/DEC/2016

51315A

 

LU

 

[*****]

 

[*****]

 

20/DEC/2016

51315A

 

MC

 

[*****]

 

[*****]

 

20/DEC/2016

51315A

 

NL

 

[*****]

 

[*****]

 

20/DEC/2016

51315A

 

NO

 

 

 

 

 

20/DEC/2016

51315A

 

PT

 

[*****]

 

[*****]

 

20/DEC/2016

51315A

 

SE

 

[*****]

 

[*****]

 

20/DEC/2016

51315A

 

US

 

 

 

[*****]

 

20/DEC/2016

51315A

 

WO

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

BG

 

 

 

[*****]

 

16/JAN/2017

51322A

 

BR

 

 

 

 

 

16/JAN/2017

51322A

 

BY

 

 

 

 

 

16/JAN/2017

51322A

 

CA

 

 

 

 

 

16/JAN/2017

51322A

 

CN

 

[*****]

 

 

 

16/JAN/2017

 

49

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

51322A

 

CZ

 

 

 

 

 

16/JAN/2017

51322A

 

DE

 

[*****]

 

 

 

19/JAN/2016

51322A

 

EE

 

[*****]

 

 

 

16/JAN/2017

51322A

 

EP

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

HK

 

[*****]

 

 

 

16/JAN/2017

51322A

 

HU

 

 

 

 

 

16/JAN/2017

51322A

 

IL

 

 

 

[*****]

 

16/JAN/2017

51322A

 

IS

 

 

 

 

 

16/JAN/2017

51322A

 

JP

 

 

 

 

 

16/JAN/2017

51322A

 

KR

 

[*****]

 

 

 

16/JAN/2017

51322A

 

MX

 

 

 

[*****]

 

16/JAN/2017

51322A

 

NO

 

 

 

 

 

16/JAN/2017

51322A

 

NZ

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

PK

 

 

 

 

 

04/FEB/2018

51322A

 

PL

 

 

 

 

 

16/JAN/2017

51322A

 

RU

 

[*****]

 

 

 

16/JAN/2017

51322A

 

SK

 

 

 

 

 

16/JAN/2017

51322A

 

TW

 

 

 

 

 

18/JAN/2012

51322A

 

UA

 

 

 

 

 

16/JAN/2017

51322A

 

US

 

 

 

[*****]

 

17/JAN/2017

51322A

 

US

 

 

 

 

 

17/JAN/2017

51322A

 

US

 

 

 

 

 

17/JAN/2017

51322A

 

US

 

 

 

 

 

17/JAN/2017

51322A

 

US

 

 

 

 

 

28/FEB/1997

51322A

 

VN

 

 

 

[*****]

 

16/JAN/2017

51322A

 

WO

 

[*****]

 

 

 

 

51322A

 

ZA

 

 

 

[*****]

 

17/JAN/2017

51322A

 

LV

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

LT

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

RO

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

AT

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

FR

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

IT

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

GR

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

DE

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

BE

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

NL

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

PT

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

LU

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

IE

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

FI

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

DK

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

GB

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

CH

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

SE

 

[*****]

 

[*****]

 

16/JAN/2017

51322A

 

ES

 

[*****]

 

 

 

16/JAN/2017

51358A

 

AU

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

AU

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

BG

 

 

 

[*****]

 

29/NOV/2016

 

50

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

51358A

 

BY

 

 

 

 

 

29/NOV/2016

51358A

 

CA

 

 

 

 

 

29/NOV/2016

51358A

 

CZ

 

 

 

 

 

29/NOV/2016

51358A

 

DE

 

[*****]

 

 

 

22/DEC/2015

51358A

 

EP

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

IL

 

 

 

 

 

29/NOV/2016

51358A

 

IL

 

 

 

 

 

29/NOV/2016

51358A

 

JP

 

 

 

 

 

29/NOV/2016

51358A

 

KR

 

[*****]

 

 

 

29/NOV/2016

51358A

 

MX

 

 

 

 

 

29/NOV/2016

51358A

 

NO

 

 

 

[*****]

 

29/NOV/2016

51358A

 

NZ

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

PL

 

 

 

 

 

29/NOV/2016

51358A

 

RU

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

SK

 

 

 

[*****]

 

29/NOV/2016

51358A

 

TW

 

[*****]

 

 

 

20/DEC/2011

51358A

 

UA

 

 

 

[*****]

 

29/NOV/2016

51358A

 

US

 

 

 

[*****]

 

29/NOV/2016

51358A

 

US

 

 

 

[*****]

 

20/DEC/2016

51358A

 

US

 

 

 

 

 

05/JAN/1997

51358A

 

VN

 

 

 

 

 

 

51358A

 

VN

 

 

 

 

 

 

51358A

 

WO

 

[*****]

 

 

 

 

51358A

 

ZA

 

 

 

[*****]

 

20/DEC/2016

51358A

 

AT

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

BE

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

DE

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

IE

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

LI

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

MC

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

PT

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

GB

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

CH

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

SE

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

ES

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

NL

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

LU

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

IT

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

GR

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

FR

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

FI

 

[*****]

 

[*****]

 

29/NOV/2016

51358A

 

DK

 

[*****]

 

[*****]

 

29/NOV/2016

51378A

 

CA

 

 

 

 

 

17/AUG/2018

51378A

 

DE

 

[*****]

 

 

 

26/SEP/2017

51378A

 

EP

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

JP

 

 

 

 

 

17/AUG/2018

51378A

 

NO

 

 

 

 

 

17/AUG/2018

51378A

 

US

 

 

 

[*****]

 

22/SEP/2018

51378A

 

US

 

 

 

 

 

06/OCT/1998

 

51

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

51378A

 

WO

 

[*****]

 

 

 

 

51378A

 

AT

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

BE

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

CY

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

FI

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

IE

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

LU

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

DE

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

NL

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

FR

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

DK

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

GB

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

CH

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

SE

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

ES

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

PT

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

MC

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

IT

 

[*****]

 

[*****]

 

17/AUG/2018

51378A

 

GR

 

[*****]

 

[*****]

 

17/AUG/2018

51412B

 

AU

 

[*****]

 

[*****]

 

19/JUN/2018

51412B

 

BA

 

 

 

 

 

19/JUN/2018

51412B

 

BG

 

 

 

 

 

19/JUN/2018

51412B

 

BR

 

 

 

 

 

19/JUN/2018

51412B

 

CA

 

 

 

 

 

19/JUN/2018

51412B

 

CN

 

[*****]

 

 

 

19/JUN/2018

51412B

 

CZ

 

 

 

 

 

19/JUN/2018

51412B

 

EP

 

[*****]

 

[*****]

 

19/JUN/2018

51412B

 

HK

 

[*****]

 

 

 

19/JUN/2018

51412B

 

HU

 

 

 

 

 

19/JUN/2018

51412B

 

IL

 

 

 

 

 

19/JUN/2018

51412B

 

JP

 

 

 

 

 

19/JUN/2018

51412B

 

KR

 

[*****]

 

 

 

19/JUN/2018

51412B

 

MK

 

 

 

 

 

19/JUN/2018

51412B

 

MX

 

 

 

 

 

19/JUN/2018

51412B

 

NO

 

 

 

 

 

19/JUN/2018

51412B

 

NZ

 

[*****]

 

[*****]

 

19/JUN/2018

51412B

 

NZ

 

[*****]

 

[*****]

 

19/JUN/2018

51412B

 

PL

 

 

 

 

 

19/JUN/2018

51412B

 

RO

 

 

 

 

 

19/JUN/2018

51412B

 

RU

 

 

 

[*****]

 

19/JUN/2018

51412B

 

SI

 

 

 

[*****]

 

19/JUN/2018

51412B

 

SK2

 

 

 

[*****]

 

19/JUN/2018

51412B

 

TR

 

 

 

[*****]

 

19/JUN/2018

51412B

 

UA

 

 

 

 

 

19/JUN/2018

51412B

 

US

 

[*****]

 

 

 

19/JUN/2018

51412B

 

WO

 

[*****]

 

 

 

 

51412B

 

YU

 

 

 

 

 

19/JUN/2018

51412B

 

ZA

 

 

 

[*****]

 

19/JUN/2018

51412B

 

DK

 

[*****]

 

[*****]

 

19/JUN/2018

 

52

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

51412B

 

GB

 

[*****]

 

[*****]

 

19/JUN/2018

51412B

 

CH

 

[*****]

 

[*****]

 

19/JUN/2018

51412B

 

NL

 

[*****]

 

[*****]

 

19/JUN/2018

51412B

 

FR

 

[*****]

 

[*****]

 

19/JUN/2018

51412B

 

IT

 

[*****]

 

[*****]

 

19/JUN/2018

51412B

 

DE

 

[*****]

 

[*****]

 

19/JUN/2018

51433A

 

AR

 

 

 

 

 

04/AUG/2017

51433A

 

AT

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

AU

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

BE

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

CA

 

 

 

 

 

29/JUL/2017

51433A

 

CH

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

CN

 

 

 

 

 

29/JUL/2017

51433A

 

DE

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

DE

 

 

 

[*****]

 

29/JUL/2007

51433A

 

DK

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

ES

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

FI

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

FR

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

GB

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

GR

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

HK

 

[*****]

 

 

 

29/JUL/2017

51433A

 

HU

 

 

 

 

 

29/JUL/2017

51433A

 

IE

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

IL

 

 

 

[*****]

 

29/JUL/2017

51433A

 

IT

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

JP

 

 

 

 

 

29/JUL/2017

51433A

 

KR

 

[*****]

 

 

 

29/JUL/2017

51433A

 

LU

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

MC

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

MX

 

 

 

 

 

29/JUL/2017

51433A

 

NL

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

NO

 

 

 

 

 

29/JUL/2017

51433A

 

NZ

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

PT

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

SE

 

[*****]

 

[*****]

 

29/JUL/2017

51433A

 

TH

 

[*****]

 

 

 

04/AUG/2017

51433A

 

TW

 

 

 

 

 

05/AUG/2012

51433A

 

US

 

 

 

[*****]

 

01/AUG/2017

51433A

 

WO

 

[*****]

 

 

 

 

51433A

 

ZA

 

 

 

[*****]

 

05/AUG/2017

51433A

 

US

 

 

 

 

 

01/AUG/2017

51437A

 

AU

 

[*****]

 

[*****]

 

26/NOV/2017

51437A

 

CA

 

 

 

 

 

26/NOV/2017

51437A

 

CN

 

[*****]

 

[*****]

 

26/NOV/2017

51437A

 

DE

 

[*****]

 

 

 

04/DEC/2016

51437A

 

EP

 

[*****]

 

 

 

26/NOV/2017

51437A

 

HK

 

[*****]

 

 

 

26/NOV/2017

51437A

 

IL

 

 

 

 

 

26/NOV/2017

 

53

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

51437A

 

JP

 

 

 

 

 

26/NOV/2017

51437A

 

KR

 

[*****]

 

 

 

26/NOV/2017

51437A

 

MX

 

 

 

 

 

26/NOV/2017

51437A

 

TW

 

[*****]

 

[*****]

 

25/NOV/2017

51437A

 

US

 

 

 

[*****]

 

02/DEC/2017

51437A

 

WO

 

[*****]

 

 

 

 

51437A

 

ZA

 

 

 

[*****]

 

04/DEC/2017

51457A

 

DE

 

[*****]

 

 

 

04/DEC/2016

51457A

 

EP

 

[*****]

 

 

 

26/NOV/2017

51457A

 

JP

 

 

 

 

 

26/NOV/2017

51457A

 

NO

 

 

 

[*****]

 

26/NOV/2017

51457A

 

TW

 

[*****]

 

[*****]

 

25/NOV/2017

51457A

 

US

 

 

 

[*****]

 

02/DEC/2017

51457A

 

WO

 

[*****]

 

 

 

 

51457A

 

ZA

 

[*****]

 

 

 

04/DEC/2017

51479A

 

US

 

 

 

 

 

08/JUL/1998

51502A

 

DE

 

[*****]

 

 

 

03/JUL/2017

51502A

 

EP

 

[*****]

 

 

 

28/MAY/2018

51502A

 

JP

 

 

 

 

 

28/MAY/2018

51502A

 

TW

 

[*****]

 

 

 

02/JUL/2013

51502A

 

US

 

 

 

 

 

29/JUN/2018

51502A

 

US

 

[*****]

 

 

 

29/JUN/2018

51502A

 

US

 

 

 

 

 

29/JUL/1998

51502A

 

WO

 

[*****]

 

 

 

 

51502A

 

ZA

 

 

 

[*****]

 

03/JUL/2018

51502A

 

IN

 

 

 

 

 

09/OCT/2022

51519A

 

KP

 

 

 

[*****]

 

02/SEP/2013

51521A

 

DE

 

[*****]

 

[*****]

 

10/MAR/2020

51521A

 

EP

 

[*****]

 

 

 

22/FEB/2021

51521A

 

US

 

[*****]

 

 

 

08/MAR/2021

51521A

 

US

 

 

 

 

 

26/SEP/2001

51521A

 

WO

 

[*****]

 

 

 

 

51521A

 

JP

 

 

 

 

 

22/FEB/2021

51521A

 

NO

 

 

 

 

 

22/FEB/2021

51538A

 

US

 

 

 

 

 

24/SEP/2018

51538A

 

CA

 

 

 

 

 

17/AUG/2018

51538A

 

DE

 

 

 

[*****]

 

26/SEP/2017

51538A

 

EP

 

[*****]

 

 

 

17/AUG/2018

51538A

 

JP

 

 

 

 

 

17/AUG/2018

51538A

 

NO

 

 

 

 

 

17/AUG/2018

51538A

 

US

 

 

 

[*****]

 

24/SEP/2018

51538A

 

US

 

 

 

 

 

06/OCT/1998

51538A

 

WO

 

[*****]

 

 

 

 

51545A

 

AU

 

 

 

 

 

15/MAR/2020

51545A

 

CA

 

 

 

 

 

15/MAR/2020

51545A

 

CN

 

 

 

 

 

15/MAR/2020

51545A

 

DE

 

 

 

[*****]

 

22/MAR/2019

51545A

 

EP

 

[*****]

 

 

 

15/MAR/2020

51545A

 

HU

 

 

 

 

 

15/MAR/2020

 

54

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

51545A

 

IL

 

 

 

 

 

15/MAR/2020

51545A

 

IN

 

 

 

 

 

15/MAR/2014

51545A

 

JP

 

[*****]

 

 

 

15/MAR/2020

51545A

 

KR

 

[*****]

 

 

 

15/MAR/2020

51545A

 

NO

 

 

 

 

 

15/MAR/2020

51545A

 

NZ

 

 

 

 

 

15/MAR/2020

51545A

 

US

 

 

 

[*****]

 

22/MAR/2020

51545A

 

US

 

 

 

 

 

09/APR/2000

51545A

 

WO

 

[*****]

 

 

 

 

51545A

 

ZA

 

 

 

 

 

15/MAR/2020

51545A

 

HK

 

[*****]

 

 

 

15/MAR/2020

51547A

 

DE

 

[*****]

 

 

 

17/DEC/2017

51547A

 

EP

 

[*****]

 

[*****]

 

09/DEC/2018

51547A

 

JP

 

 

 

 

 

09/DEC/2018

51547A

 

US

 

[*****]

 

 

 

17/DEC/2018

51547A

 

US

 

 

 

 

 

07/JAN/1999

51547A

 

WO

 

 

 

 

 

 

51549A

 

WO

 

[*****]

 

 

 

 

51562A

 

US

 

 

 

 

 

03/DEC/1999

51562A

 

WO

 

[*****]

 

 

 

 

51563A

 

US

 

 

 

 

 

03/DEC/1999

51563A

 

WO

 

[*****]

 

 

 

 

51564A

 

WO

 

[*****]

 

 

 

 

51590A

 

DE

 

[*****]

 

 

 

03/APR/2018

51613A

 

DE

 

[*****]

 

 

 

24/JUL/2018

51613A

 

EP

 

[*****]

 

 

 

15/JUL/2019

51613A

 

JP

 

 

 

 

 

15/JUL/2019

51613A

 

NO

 

 

 

 

 

15/JUL/2019

51613A

 

TW

 

 

 

 

 

02/JUL/2014

51613A

 

US

 

[*****]

 

 

 

23/JUL/2019

51613A

 

US

 

 

 

 

 

30/OCT/1999

51613A

 

WO

 

[*****]

 

 

 

 

51614A

 

DE

 

 

 

[*****]

 

22/SEP/2018

51614A

 

EP

 

[*****]

 

[*****]

 

20/AUG/2019

51614A

 

JP

 

 

 

 

 

20/AUG/2019

51614A

 

NO

 

 

 

 

 

20/AUG/2019

51614A

 

US

 

 

 

[*****]

 

21/SEP/2019

51614A

 

US

 

 

 

 

 

09/NOV/1999

51614A

 

WO

 

[*****]

 

 

 

 

51614A

 

AT

 

[*****]

 

[*****]

 

20/AUG/2019

51614A

 

FI

 

[*****]

 

[*****]

 

20/AUG/2019

51614A

 

NL

 

[*****]

 

[*****]

 

20/AUG/2019

51614A

 

LU

 

[*****]

 

[*****]

 

20/AUG/2019

51614A

 

DK

 

[*****]

 

[*****]

 

20/AUG/2019

51614A

 

GB

 

[*****]

 

[*****]

 

20/AUG/2019

51614A

 

CH

 

[*****]

 

[*****]

 

20/AUG/2019

51614A

 

SE

 

[*****]

 

[*****]

 

20/AUG/2019

51614A

 

ES

 

[*****]

 

[*****]

 

20/AUG/2019

51614A

 

PT

 

[*****]

 

[*****]

 

20/AUG/2019

 

55

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

51614A

 

MC

 

[*****]

 

[*****]

 

20/AUG/2019

51614A

 

IT

 

[*****]

 

[*****]

 

20/AUG/2019

51614A

 

IE

 

[*****]

 

[*****]

 

20/AUG/2019

51614A

 

GR

 

[*****]

 

[*****]

 

20/AUG/2019

51614A

 

DE

 

[*****]

 

[*****]

 

20/AUG/2019

51614A

 

FR

 

[*****]

 

[*****]

 

20/AUG/2019

51614A

 

CY

 

[*****]

 

[*****]

 

20/AUG/2019

51614A

 

BE

 

[*****]

 

[*****]

 

20/AUG/2019

51645A

 

AU

 

 

 

 

 

17/NOV/2019

51645A

 

CA

 

 

 

 

 

17/NOV/2019

51645A

 

CN

 

[*****]

 

 

 

A17/NOV/2019

51645A

 

CZ

 

 

 

 

 

17/NOV/2019

51645A

 

DE

 

 

 

[*****]

 

02/DEC/2018

51645A

 

EP

 

[*****]

 

 

 

17/NOV/2019

51645A

 

HK

 

[*****]

 

 

 

17/NOV/2019

51645A

 

IL

 

 

 

 

 

17/NOV/2019

51645A

 

JP

 

 

 

 

 

17/NOV/2019

51645A

 

KR

 

[*****]

 

 

 

17/NOV/2019

51645A

 

NO

 

 

 

 

 

17/NOV/2019

51645A

 

NZ

 

 

 

 

 

17/NOV/2019

51645A

 

SK

 

 

 

 

 

17/NOV/2019

51645A

 

US

 

 

 

[*****]

 

01/DEC/2019

51645A

 

US

 

 

 

 

 

15/JAN/2000

51645A

 

WO

 

[*****]

 

 

 

 

51645A

 

ZA

 

 

 

[*****]

 

17/NOV/2019

51658A

 

JP

 

 

 

 

 

17/SEP/2018

51669A

 

DE

 

 

 

 

 

29/SEP/2019

51669A

 

EP

 

[*****]

 

 

 

28/SEP/2020

51669A

 

US

 

 

 

 

 

29/SEP/2020

51669A

 

US

 

 

 

 

 

08/OCT/2000

51684A

 

WO

 

[*****]

 

 

 

 

51729A

 

DE

 

[*****]

 

 

 

29/SEP/2019

51729A

 

EP

 

[*****]

 

 

 

28/SEP/2020

51729A

 

US

 

 

 

[*****]

 

29/SEP/2020

51729A

 

US

 

 

 

 

 

08/OCT/2000

51729A

 

US

 

 

 

 

 

12/JUL/2022

51734A

 

PE

 

 

 

 

 

19/JUL/2022

51734A

 

AR

 

 

 

 

 

19/JUL/2022

51734A

 

CL

 

 

 

 

 

 

51734A

 

DE

 

 

 

[*****]

 

20/JUL/2021

51734A

 

TW

 

 

 

 

 

19/JUL/2022

51734A

 

US

 

 

 

 

 

19/JUL/2022

51734A

 

UY

 

 

 

 

 

17/JUL/2022

51734A

 

VE

 

 

 

 

 

 

51734A

 

WO

 

[*****]

 

 

 

 

51734B

 

AR

 

 

 

 

 

19/JUL/2022

51734B

 

CL

 

 

 

 

 

 

51734B

 

DE

 

 

 

[*****]

 

20/JUL/2021

51734B

 

TW

 

 

 

 

 

19/JUL/2022

 

56

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

51734B

 

US

 

 

 

 

 

19/JUL/2022

51734B

 

VE

 

 

 

 

 

 

51734B

 

WO

 

[*****]

 

 

 

 

51734B

 

UY

 

 

 

 

 

17/JUL/2022

51734B

 

PE

 

 

 

 

 

19/JUL/2022

51735A

 

US

 

 

 

 

 

08/OCT/2000

51752A

 

DE

 

[*****]

 

 

 

06/AUG/2019

51752A

 

EP

 

[*****]

 

 

 

25/JUL/2020

51752A

 

JP

 

 

 

 

 

25/JUL/2020

51752A

 

US

 

 

 

 

 

04/AUG/2020

51752A

 

US

 

 

 

 

 

16/AUG/2000

51752A

 

WO

 

[*****]

 

 

 

 

51760A

 

AR

 

 

 

 

 

10/AUG/2021

51760A

 

CL

 

 

 

 

 

 

51760A

 

DE

 

[*****]

 

 

 

11/AUG/2020

51760A

 

PH

 

 

 

 

 

10/AUG/2021

51760A

 

TH

 

 

 

 

 

10/AUG/2021

51760A

 

TW

 

 

 

 

 

17/AUG/2016

51760A

 

US

 

 

 

 

 

10/AUG/2021

51760A

 

US

 

 

 

 

 

26/SEP/2001

51760A

 

VE

 

 

 

 

 

 

51760A

 

WO

 

[*****]

 

 

 

 

51760A

 

AU

 

 

 

 

 

23/JUL/2021

51760A

 

BY

 

 

 

 

 

23/JUL/2021

51760A

 

CA

 

 

 

 

 

23/JUL/2021

51760A

 

HR

 

 

 

 

 

 

51760A

 

HU

 

 

 

 

 

23/JUL/2021

51760A

 

IL

 

 

 

 

 

23/JUL/2021

51760A

 

YU

 

 

 

 

 

23/JUL/2021

51760A

 

UA

 

 

 

 

 

23/JUL/2021

51760A

 

KR

 

 

 

 

 

23/JUL/2021

51760A

 

ZA

 

 

 

 

 

23/JUL/2021

51760A

 

SK

 

 

 

 

 

23/JUL/2021

51760A

 

PL

 

 

 

 

 

23/JUL/2021

51760A

 

NO

 

 

 

 

 

23/JUL/2021

51760A

 

NZ

 

 

 

 

 

23/JUL/2021

51760A

 

MX

 

 

 

 

 

23/JUL/2021

51760A

 

JP

 

 

 

 

 

23/JUL/2021

51760A

 

HK

 

 

 

 

 

 

51760A

 

EP

 

[*****]

 

 

 

23/JUL/2021

51760A

 

RU

 

 

 

 

 

23/JUL/2021

51760A

 

EE

 

 

 

 

 

23/JUL/2021

51760A

 

BR

 

 

 

 

 

23/JUL/2021

51760A

 

IN

 

 

 

 

 

23/JUL/2015

51760A

 

CZ

 

 

 

 

 

23/JUL/2021

51760A

 

CN

 

 

 

 

 

23/JUL/2021

51760A

 

CO

 

 

 

 

 

23/JUL/2021

51760A

 

BG

 

 

 

 

 

23/JUL/2021

51761A

 

AU

 

 

 

 

 

23/JUL/2021

 

57

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

51761A

 

BG

 

 

 

 

 

23/JUL/2021

51761A

 

CN

 

 

 

 

 

23/JUL/2021

51761A

 

BR

 

 

 

 

 

23/JUL/2021

51761A

 

BY

 

 

 

 

 

23/JUL/2021

51761A

 

HR

 

 

 

 

 

 

51761A

 

EE

 

 

 

 

 

23/JUL/2021

51761A

 

UA

 

 

 

 

 

23/JUL/2021

51761A

 

KR

 

 

 

 

 

23/JUL/2021

51761A

 

SK

 

 

 

 

 

23/JUL/2021

51761A

 

RU

 

 

 

 

 

23/JUL/2021

51761A

 

PL

 

 

 

 

 

23/JUL/2021

51761A

 

NZ

 

 

 

 

 

23/JUL/2021

51761A

 

MX

 

 

 

 

 

23/JUL/2021

51761A

 

JP

 

 

 

 

 

23/JUL/2021

51761A

 

HU

 

 

 

 

 

23/JUL/2021

51761A

 

YU

 

 

 

 

 

23/JUL/2021

51761A

 

ZA

 

 

 

 

 

23/JUL/2021

51761A

 

IN

 

 

 

 

 

23/JUL/2015

51761A

 

HK

 

 

 

 

 

 

51761A

 

NO

 

 

 

 

 

23/JUL/2021

51761A

 

IL

 

 

 

 

 

23/JUL/2021

51761A

 

CO

 

 

 

 

 

23/JUL/2021

51761A

 

EP

 

[*****]

 

 

 

23/JUL/2021

51761A

 

CZ

 

 

 

 

 

23/JUL/2021

51761A

 

CA

 

 

 

 

 

23/JUL/2021

51761A

 

AR

 

 

 

 

 

10/AUG/2021

51761A

 

CL

 

 

 

 

 

 

51761A

 

DE

 

 

 

[*****]

 

11/AUG/2020

51761A

 

PH

 

 

 

 

 

10/AUG/2021

51761A

 

TH

 

 

 

 

 

10/AUG/2021

51761A

 

TW

 

 

 

 

 

17/AUG/2016

51761A

 

US

 

[*****]

 

 

 

10/AUG/2021

51761A

 

US

 

 

 

 

 

26/SEP/2001

51761A

 

VE

 

 

 

 

 

 

51761A

 

WO

 

[*****]

 

 

 

 

51762A

 

AR

 

 

 

 

 

10/AUG/2021

51762A

 

CL

 

 

 

 

 

 

51762A

 

DE

 

[*****]

 

 

 

11/AUG/2020

51762A

 

TW

 

 

 

 

 

17/AUG/2016

51762A

 

US

 

[*****]

 

 

 

10/AUG/2021

51762A

 

US

 

 

 

 

 

26/SEP/2001

51762A

 

UY

 

 

 

 

 

07/AUG/2021

51762A

 

VE

 

 

 

 

 

 

51762A

 

WO

 

[*****]

 

 

 

 

51762A

 

AU

 

 

 

 

 

23/JUL/2021

51762A

 

BY

 

 

 

 

 

23/JUL/2021

51762A

 

BG

 

 

 

 

 

23/JUL/2021

51762A

 

CO

 

 

 

 

 

23/JUL/2021

51762A

 

CZ

 

 

 

 

 

23/JUL/2021

 

58

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

51762A

 

IN

 

 

 

 

 

23/JUL/2015

51762A

 

JP

 

 

 

 

 

23/JUL/2021

51762A

 

EP

 

[*****]

 

 

 

23/JUL/2021

51762A

 

YU

 

 

 

 

 

23/JUL/2021

51762A

 

PL

 

 

 

 

 

23/JUL/2021

51762A

 

NZ

 

 

 

 

 

23/JUL/2021

51762A

 

MX

 

 

 

 

 

23/JUL/2021

51762A

 

BR

 

 

 

 

 

23/JUL/2021

51762A

 

NO

 

 

 

 

 

23/JUL/2021

51762A

 

HK

 

 

 

 

 

 

51762A

 

RU

 

 

 

 

 

23/JUL/2021

51762A

 

EE

 

 

 

 

 

23/JUL/2021

51762A

 

CA

 

 

 

 

 

23/JUL/2021

51762A

 

IL

 

 

 

 

 

23/JUL/2021

51762A

 

HU

 

 

 

 

 

23/JUL/2021

51762A

 

HR

 

 

 

 

 

 

51762A

 

CN

 

 

 

 

 

23/JUL/2021

51766A

 

AE

 

 

 

 

 

06/SEP/2015

51766A

 

AT

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

AU

 

 

 

 

 

06/SEP/2020

51766A

 

BE

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

BG

 

[*****]

 

 

 

06/SEP/2020

51766A

 

BR

 

[*****]

 

 

 

06/SEP/2020

51766A

 

BY

 

 

 

 

 

06/SEP/2020

51766A

 

CA

 

 

 

 

 

06/SEP/2020

51766A

 

CH

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

CN

 

 

 

 

 

06/SEP/2020

51766A

 

CY

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

CZ

 

 

 

 

 

06/SEP/2020

51766A

 

DE

 

[*****]

 

 

 

09/SEP/2019

51766A

 

DE

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

DE

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

DK

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

EE

 

 

 

 

 

06/SEP/2020

51766A

 

EP

 

[*****]

 

 

 

06/SEP/2020

51766A

 

ES

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

FI

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

FR

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

GB

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

GR

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

HR

 

 

 

 

 

 

51766A

 

HU

 

[*****]

 

 

 

06/SEP/2020

51766A

 

ID

 

[*****]

 

 

 

06/SEP/2020

51766A

 

IE

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

IL

 

 

 

 

 

06/SEP/2020

51766A

 

IN

 

 

 

 

 

06/SEP/2014

51766A

 

IT

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

JP

 

[*****]

 

 

 

06/SEP/2020

51766A

 

KR

 

[*****]

 

 

 

06/SEP/2020

 

59

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

51766A

 

LU

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

MC

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

MX

 

 

 

 

 

06/SEP/2020

51766A

 

NL

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

NO

 

 

 

 

 

06/SEP/2020

51766A

 

NZ

 

 

 

 

 

06/SEP/2020

51766A

 

PL

 

 

 

 

 

06/SEP/2020

51766A

 

PT

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

RU

 

 

 

 

 

06/SEP/2020

51766A

 

SE

 

[*****]

 

[*****]

 

09/SEP/2019

51766A

 

SK

 

 

 

 

 

06/SEP/2020

51766A

 

TW

 

 

 

 

 

28/SEP/2015

51766A

 

UA

 

 

 

 

 

06/SEP/2020

51766A

 

US

 

 

 

 

 

15/SEP/2019

51766A

 

US

 

 

 

 

 

11/SEP/2020

51766A

 

US

 

 

 

 

 

 

51766A

 

WO

 

[*****]

 

 

 

 

51766A

 

YU

 

 

 

 

 

06/SEP/2020

51766A

 

ZA

 

 

 

 

 

06/SEP/2020

51766A

 

HK

 

 

 

 

 

 

51766A

 

US

 

 

 

 

 

11/SEP/2020

51768A

 

EP

 

 

 

 

 

16/JAN/2022

51768A

 

DE

 

[*****]

 

[*****]

 

26/JAN/2021

51768A

 

US

 

 

 

 

 

28/JAN/2022

51768A

 

US

 

 

 

 

 

13/FEB/2002

51768A

 

WO

 

[*****]

 

 

 

 

51769A

 

DE

 

 

 

[*****]

 

06/APR/2021

51769A

 

US

 

 

 

 

 

24/APR/2002

51772A

 

JP

 

 

 

 

 

18/MAR/2017

51780A

 

JP

 

 

 

 

 

15/OCT/2019

51800A

 

DE

 

 

 

[*****]

 

13/JAN/2020

51800A

 

US

 

 

 

 

 

27/JAN/2001

51800A

 

WO

 

[*****]

 

 

 

 

51832A

 

DE

 

 

 

 

 

20/DEC/2022

51834A

 

EP

 

 

 

 

 

05/DEC/2021

51834A

 

AR

 

 

 

 

 

14/DEC/2021

51834A

 

CL

 

 

 

 

 

 

51834A

 

DE

 

[*****]

 

[*****]

 

15/DEC/2020

51834A

 

JO

 

 

 

 

 

02/JUL/2022

51834A

 

PE

 

 

 

 

 

13/DEC/2021

51834A

 

SA

 

 

 

 

 

 

51834A

 

TH

 

 

 

 

 

14/DEC/2021

51834A

 

TW

 

 

 

 

 

07/NOV/2016

51834A

 

US

 

 

 

 

 

13/DEC/2021

51834A

 

US

 

 

 

 

 

28/DEC/2001

51834A

 

UY

 

 

 

 

 

05/DEC/2021

51834A

 

VE

 

 

 

 

 

 

51834A

 

WO

 

[*****]

 

 

 

 

51954A

 

DE

 

[*****]

 

 

 

15/SEP/2020

 

60

--------------------------------------------------------------------------------

 

File number

 

Country C

 

Publication number

 

Grant number

 

Expiry

51954A

 

TW

 

 

 

 

 

14/SEP/2016

51954A

 

US

 

 

 

 

 

14/SEP/2021

51954A

 

US

 

 

 

 

 

27/SEP/2001

51954A

 

WO

 

[*****]

 

 

 

 

51954A

 

EP

 

 

 

 

 

05/SEP/2021

51954A

 

JP

 

 

 

 

 

05/SEP/2021

51954A

 

NO

 

 

 

 

 

05/SEP/2021

52024A

 

DE

 

 

 

 

 

28/MAR/2022

52024A

 

US

 

 

 

 

 

 

52024A

 

WO

 

 

 

 

 

15/NOV/2022

52024A

 

US

 

 

 

 

 

 

52162A

 

DE

 

[*****]

 

 

 

18/JUN/2021

52163A

 

DE

 

[*****]

 

[*****]

 

19/JUN/2021

52163A

 

US

 

 

 

 

 

19/JUN/2022

52163A

 

WO

 

[*****]

 

 

 

 

52164A

 

DE

 

[*****]

 

 

 

11/JUL/2021

52164A

 

US

 

 

 

 

 

11/JUL/2022

52164A

 

US

 

 

 

 

 

18/JUL/2002

52164A

 

WO

 

 

 

 

 

 

52165A

 

AR

 

 

 

 

 

10/JUL/2022

52165A

 

CL

 

 

 

 

 

 

52165A

 

DE

 

 

 

 

 

10/JUL/2021

52165A

 

PE

 

 

 

 

 

10/JUL/2022

52165A

 

TW

 

 

 

 

 

09/JUL/2022

52165A

 

US

 

 

 

 

 

07/OCT/2022

52165A

 

US

 

 

 

 

 

19/JUL/2002

52165A

 

VE

 

 

 

 

 

 

52165A

 

WO

 

[*****]

 

 

 

 

52165A

 

UY

 

 

 

 

 

28/JUN/2022

52207A

 

US

 

 

 

 

 

22/OCT/2002

52231A

 

DE

 

 

 

 

 

03/APR/2023

52231A

 

US

 

 

 

 

 

 

52307A

 

US

 

 

 

 

 

16/JUL/2003

52307A

 

DE

 

 

 

 

 

10/JUL/2022

52308A

 

DE

 

 

 

 

 

13/DEC/2022

52308A

 

US

 

 

 

 

 

12/FEB/2004

52309A

 

DE

 

 

 

 

 

19/FEB/2023

52309A

 

US

 

 

 

 

 

06/MAR/2004

52335A

 

DE

 

 

 

 

 

03/APR/2023

52335A

 

US

 

 

 

 

 

11/APR/2004

53061A

 

DE

 

 

 

 

 

04/FEB/2023

53061A

 

US

 

 

 

 

 

12/FEB/2004

53063A

 

DE

 

 

 

 

 

03/APR/2023

53063A

 

US

 

 

 

 

 

 

53072A

 

DE

 

 

 

 

 

04/FEB/2023

53072A

 

US

 

 

 

 

 

12/FEB/2004

 

61

--------------------------------------------------------------------------------

 

Exhibit 2.1

 

Proof of Concept Study – Deliverables

 

SCOPE

 

•                  Schering AG wants to have delivered data of a [*****] to
[*****] of EP-2104R

•                  This means:

•                  Data on [*****] of EP-2104R in [*****]

•                  Data on imaging [*****] for [*****] of [*****] and [*****] as
well as [*****] in [*****]

 

Imaging topics to be addressed include

•                  Demonstration of [*****] of [*****] and [*****]

•                  Delineation of [*****] and [*****]

•                  Delineation of [*****] (if available from study data)

•                  Detection [*****] (evaluation of [*****], [*****])

•                  [*****]

 

STUDY DETAILS

 

•                  [*****] in [*****] at [*****] up to [*****]; [*****] x
([*****]) = [*****]

•                  MRI of [*****] or [*****] in [*****] at [*****] [*****], and
at [*****] at [*****])

•                  Starting [*****] MRI: start [*****] on [*****] and [*****],
if [*****] considered [*****]

•                  Investigate [*****] in [*****] [*****]

1.               [*****] patients

 

• [*****] with [*****] or [*****]
• in case of [*****] in the [*****], [*****] to [*****]

 

2.             [*****] patients
• [*****] or [*****] of patients should be [*****]

 

[*****] patients
• [*****] or [*****] [*****] or [*****])
•- MR [*****]

 

•                  Evaluation of [*****] and [*****], i.e.

•                  Depiction of [*****] including assessment of
[*****]investigate [*****] of [*****]

•                  Investigate [*****]

•                  Measurement of [*****]

 

62

--------------------------------------------------------------------------------

 

Exhibit 3.1

 

Epix Budget Plan EP-2104R

 

 

 

02

 

03

 

04

 

2003

 

01

 

02

 

03

 

04

 

2004

 

01

 

02

 

03

 

04

 

2005

 

Total

 

Task

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

[*****]

 

 

 

 

 

 

 

 

 

 

 

 

 

[*****]

 

[*****]

 

 

 

 

 

 

 

 

 

 

63

--------------------------------------------------------------------------------